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thesis; carbohydrate metabolism; and others. Many 
medications are absorbed within the liver, where an 
extensive set of enzyme systems are activated for me-
tabolism of these agents. In addition, the liver is im-
portant in immune systems, as it contains a large pool 
of mononuclear phagocytes and natural killer cells. 
Kupffer cells, which are part of the reticuloendothelial 
system, provide an important role in the initiation of 
immunological responses as they act as the first line 
of defense against gut-derived foreign material. The 
bile duct system, including the intra- and extrahepat-
ic bile ducts and the gallbladder, regulates bilirubin 
excretion, cholesterol homeostasis and absorption of 
dietary lipid in the intestine2. 
 
The liver is routinely divided in eight segments, ac-
cording to Couinaud (Fig. 4)3,4. He described eight 
segments: one for the caudate lobe (segment I), three 
on the left (segments II, III and IV) and four on the right 
(segments V, VI, VII and VIII). The caudate lobe receives 
vessels both from the left and right branches of the 
portal vein and hepatic artery, its hepatic veins are 
independent and drain directly into the inferior vena 
cava. Recent studies suggest that the caudate lobe 
could be divided into a left part or Spiegel’s lobe or 
segment I and the right part or segment IX or para-
caval portion5. Identification of Couinaud’s segments 
on cross-sectional imaging as well as during surgery 
is important for determination of the location of in-
trahepatic tumors relative to the intrahepatic vessels, 
for evaluation of respectability and extent of potential 
surgery.  Even though this classification is sometimes 
questioned for its accuracy, it is routinely used in daily 
practice until an improved classification system be-
comes available6.
Many of the disease processes in the liver result in 
profound changes in the hepatic hemodynamics. In 
addition, almost all liver diseases are accompanied by 
damage to the hepatocytes, which can be observed 
as steatosis, atrophy, or cell death2. Liver diseases can 
be categorized as focal, or diffuse; and they can be 
congenital or acquired, including infections, auto-im-
mune diseases, or (nodular) neoplasm’s (primary or 
secondary). Diffuse liver diseases include a wide va-
riety of metabolic (storage) diseases, including accu-
mulation of iron within the liver (hemochromatosis or 
hemosiderosis), accumulation of copper, or fat (non-
alcoholic fatty liver disease (NAFLD)); and hepatitis 
which may be either acute or chronic, associated with 
either an auto-immune etiology or with an infectious 
agent (hepatitis B and C virus are most common)7. 
Several of these disease entities may lead to fibrosis 
and cirrhosis and give rise to various types of hepatic 
nodules. According to an International Working Party, 
liver nodules are characterized by the regenerative, or 
dysplastic nature of the lesion. In addition, the char-
acteristics of the surrounding liver parenchyma are 
considered8. The most important primary liver lesions 
are focal nodular hyperplasia (FNH), hepatocellular 
adenoma (HCA) and hepatocellular carcinoma (HCC), 
including the precursor nodules in the step-wise de-
velopment of HCC: regenerative nodules (RN) and 
dysplastic nodules (DN). 
MR imaging of the hepatobiliary system
An historical perspective
In 2003, Paul Lauterbur and Peter Mansfield were 
awarded the Nobel prize for Medicine for their 
pioneer work in the fundamentals of magnetic 
resonance imaging9. The potential of nuclear mag-
netic resonance (NMR), which was later called mag-
netic resonance imaging (MRI), was already known for 
many decades, since the publication of Walter Ger-
lach and Otto Stern in 1924. In this publication, they 
described the quantum nature of magnetic moment 
of silver atoms, by molecular beam deflection in an 
inhomogeneous magnetic field9,10. In 1952, Bloch and 
Purcell jointly received the Nobel Prize in Physics, for 
their independent description in 1946 of a physico-
chemical phenomenon which was based upon the 
magnetic properties of certain nuclei in the periodic 
system. Their discoveries entailed that nuclei within a 
magnetic field absorbed energy, and re-emitted this 
energy when they returned to their normal state. The 
strength of the magnetic field matched the radiofre-
quency according to the so-called “Larmor” relation-
ship. This was nuclear magnetic resonance, or NMR11,12. 
However, the exact origin of the NMR signal could not 
be determined within the sample, as all experiments 
had been one-dimensional and therefore lacked 
spatial information. In 1973, both Paul Lauterbur and 
Figure 3: Schematic representation of intrahepatic blood flow 
Anatomy of the liver
The liver, located in the upper right abdomen, 
develops very early in embryogenesis. It is of 
endodermal origin, and arises from the hepatic 
diverticulum which is a midline outgrowth form the 
ventral wall of the future duodenum (foregut). The 
connective tissue of the liver on the other hand, is of 
mesenchymal origin. The liver has remarkable poten-
tial for regulation of its size, as is demonstrated in pa-
tients after partial liver surgery1. 
The high level metabolism within the liver is 
directly related to the hepatic blood flow, which 
comes from two main hepatic vessels: the hepatic ar-
tery which originates in the abdominal aorta; and the 
portal vein, which originates within the bowel wall as 
mesenteric vein (Fig. 1, overview of the liver anatomy). 
The hepatic artery accounts for approximately 25% of 
the blood flow to the liver, while the portal vein con-
tributes to the remaining 75% of the hepatic flow2.  
 The metabolic function of the liver is facilitated by this 
dual blood supply. The total blood supply may vary 
considerably, depending on the feeding status and 
amount of exercise. Also, the proportions of blood 
supply divided among hepatic artery and portal vein 
may vary considerably. The inflowing blood is distrib-
uted and flows through the hepatic sinusoids, which 
are aligned in a columnar fashion. These columns of 
hepatocytes, which radiate from a central vein, are 
contained within a three-dimensional hexagonal unit 
(liver lobule) (Fig. 2). The hepatic vein is located in the 
center of the hexagonal liver lobule, for the outflow of 
metabolized blood into the caval vein (Fig. 3)2. 
The liver has an important role in detoxification pro-
cesses, including clearance of bilirubin resulting from 
breakdown of hemoglobin and other hem-contain-
ing substances; lipoprotein metabolism; cholesterol 
homeostasis; amino acid metabolism; protein syn-
For accurate inter-
pretation of MR  
imaging findings  
of hepatic diseases, 
UNDERSTANDING OF 
THE LIVER ANATOMY 
IS OF PARAMOUNT 
IMPORTANCE. 
Figure 1: Overview of the liver anatomy 
Figure 2: Overview of the hexagonal liver lobule, with 
organization in sinusoids; six sets of three tubules surrounding 
the lobule (hepatic artery, portal vein and bile duct); and the 
hepatic vein in the center. 
In this chapter, fundamentals of the liver anatomy 
and fundamentals of MR imaging of the hepatobiliary 
system will be discussed, followed by an overview of 
the research questions that are addressed in this dis-
sertation.
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 outline
Peter Mansfield independently published a method 
for spatial localization of the NMR signals, by means 
of local magnetic field gradients9,13,14. Their discoveries 
laid the foundations of modern MR imaging. 
Modern MR imaging
In today’s daily practice, MR imaging is routinely ap-
plied in patients with a wide variety of abnormalities 
of the hepatobiliary system. MR imaging has evolved 
in a versatile imaging modality that allows adequate 
characterization of intrinsic tissue characteristics, by 
means of several imaging sequences based on differ-
ent T1- and T2-weighting. In addition, multiple vascu-
lar phases can be imaged after intravenous contrast 
administration in a dynamic fashion, allowing charac-
terization of focal or diffuse disease processes15. 
The currently used state-of-the-art MR imaging proto-
col typically consists of T1-weighted sequences with 
in- and opposed-phase (chemical shift) imaging; sin-
gle-shot T2-weighted fast spin-echo (FSE) sequences; 
fat-suppressed T2-weighted sequences and dynamic 
multiphasic gadolinium-enhanced imaging. In addi-
tion, a heavily T2-weighted sequence may be added 
for evaluation of the biliary tree (magnetic resonance 
cholangiopancreatography, MRCP)7. 
Essentially, T1-weighted gradient-echo sequences 
provide information for characterization purposes, 
including information on material with high pro-
tein, fibrotic or fatty components. Fat-suppressed 
T2-weighted sequences are important for detection 
of liver nodules, because most nodules depict high 
signal intensity compared to the surrounding hepatic 
stroma. Dynamic contrast-enhanced multiphasic se-
quences demonstrate the enhancement pattern of 
the lesion, including amount of arterial enhancement, 
distribution of contrast within the lesion, washout 
characteristics and delayed enhancement of fibrotic 
components within or surrounding the lesion. The 
combination of these sequences results in adequate 
diagnosis in most cases, obviating the need for more 
invasive diagnostic strategies including percutaneous 
needle biopsy7.
Aims of the study
The aim of the research projects described in this dis-
sertation was to investigate and improve knowledge 
on MR imaging findings of primary hepatocellular tu-
mors. Emphasis was put on non-invasive diagnostic 
possibilities in young women with focal nodular hy-
perplasia or hepatocellular adenoma and improved 
early diagnosis of developing hepatocellular carcino-
ma in cirrhosis. In addition, the potential of imaging 
on higher field MR imaging systems as well as post-
processing of dynamic gadolinium-enhanced imag-
ing data is assessed for the work-up of hepatobiliary 
diseases.
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In chapter 1, a general introduction is provided, 
with an overview of the anatomy of the liver, funda-
mentals of MR imaging and current state-of-the-art 
MR imaging. In chapter 2, the imaging findings of 
focal nodular hyperplasia are discussed, including 
imaging findings before and after administration 
of two different contrast agents. In chapter 3, 
hepatocellular adenoma is reviewed and discussed, 
with special emphasis on imaging findings on MR 
imaging in correlation with histology findings of 
both liver and lesions. In addition, recent literature 
concerning a potential pathway for development 
of malignancy within hepatocellular adenoma is 
discussed. In chapter 4, hepatocellular carcinoma 
is discussed, with special emphasis on step-wise 
carcinogenesis in cirrhosis, and MR imaging findings 
in relation to the size of the tumor.  In chapter 5, two 
optimization strategies for hepatobiliary imaging on 
higher magnetic field strength are discussed, includ-
ing the application of variable-rate selective excitation 
and black-blood echo-planar imaging. In chapter 6, 
post-processing techniques including generation 
of color-encoded images and time-intensity curves 
are discussed, for improved analysis of multiphasic 
dynamic contrast-enhanced imaging. In chapter 7, a 
general discussion is provided with conclusions and 
recommendations for future research, followed by an 
overview article illustrating the current status of MR 
imaging of primary hepatocellular lesions. In chapter 
8, the findings of this project are summarized.
Outline of 
THE THESIS
This thesis describes the imaging findings of primary 
hepatocellular tumors on magnetic resonance imag-
ing.
chapter2
 MR IMAGING OF FOCAL  
 NODULAR HYPERPLASIA
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Figure 1: State-of-the-art MR imaging of classical FNH; 
signal intensity, enhancement patterns and uptake of 
SPIO. (a) Fat-suppressed T2-weighted fast spin-echo 
(FSE): large, well-circumscribed FNH in the left liver 
lobe, just slightly hyperintense to the liver, with a faint 
hyperintense septa. (b) Black-blood T2-weighted echo 
planar imaging (BBEPI): hyperintense signal intensity, 
with hyperintensity of central scar and septa. 
(c) Single-shot T2-weighted fast spin-echo (SSFSE): 
the lesion is isointense with the liver. (d) Opposed-
phase T1-weighted gradient-echo (GRE): the lesion is 
isointense, with hypointense central scar, septa and 
pseudocapsule composed of compressed vessels. 
(e) Arterial phase gadolinium-enhanced T1-weighted 
GRE: immediate, homogeneous enhancement with 
sparing of central scar and septa. (f) Delayed phase 
gadolinium-enhanced 3D T1-weighted GRE: the signal 
intensity has faded to isointensity with the liver, with 
faint delayed enhancement of central scar, septa 
and pseudocapsule. (g) Post-SPIO fat-suppressed 
T2-weighted fast spin-echo (FSE): the liver and spleen 
have dropped in signal intensity after SPIO. The lesion 
is hyperintense, with slightly improved conspicu-
ity of central scar and septa. (h) Post-SPIO diffusion 
T2-weighted black-blood echo planar imaging (BBEPI): 
better conspicuity of central scar and septa, with high 
signal intensity. (i) Post-SPIO opposed-phase T1-weight-
ed gradient-echo (GRE): high signal of central scar and 
septa, especially when compared to delayed phase 3D 
dynamic gadolinium-enhanced imaging (f).features alone are not diagnostic for FNH and have 
been observed in a number of benign and malignant 
lesions7,8.
Dynamic gadolinium-enhanced MR imaging enables 
evaluation of the hemokinetics of contrast distribu-
tion during the first few minutes after injection. Re-
lated to the hypervascularity of the tumor, during the 
arterial phase of hepatic enhancement, FNH typically 
shows an immediate and intense enhancement, with 
the exception of the central scar, which has delayed 
enhancement caused by the presence of abundant 
fibrous stroma (Fig. 1)9,10. During portal or delayed 
venous phases the hyperintensity of the tumor fades, 
which results in an isointense lesion, with gradual dif-
fusion of the contrast material into the fibrous cen-
tral scar. On delayed phase imaging, the central scar 
shows high signal intensity because of the accumula-
tion of contrast material.
Atypically, FNH may present as a large lesion, which is 
sometimes multiple in localization5. Rare imaging fea-
tures include nonvisualization or nonenhancement of 
the central scar, and pseudocapsular enhancement on 
delayed images9. In these cases it may be difficult to 
differentiate an atypical FNH from other benign and 
malignant hypervascular liver lesions such as hepa-
tocellular adenoma (HCA), hepatocellular carcinoma 
(HCC) and hypervascular metastases11-13.
At our institute, we apply a state-of-the-art compre-
hensive MR imaging, which provides information 
concerning the soft tissue characteristics of the lesion 
besides the vascularity of the lesion at gadolinium-
enhanced multiphasic dynamic imaging. In addition, 
in selected cases specific MR imaging contrast agents 
such as SPIO particles can provide information con-
cerning the primary nature of the lesion14,15.
Previous studies have described imaging features of 
FNH using both non-specific and specific contrast 
agents such as manganodipir16 and superparamag-
netic iron-oxide (SPIO) particles. In a few studies, up-
take of SPIO and imaging characteristics of FNH were 
assessed using conventional MR sequences17-21. To our 
knowledge, none of the previous studies have evalu-
ated lesion characteristics of pathology-proven FNH 
using both dynamic gadolinium-enhanced imaging 
and multiple T1- and T2-weighted sequences after 
gadolinium/SPIO.
The purpose of our prospective study was to image 
a cohort of patients with pathology-proven FNH in 
order to assess which of the characteristics derived 
from the state-of-the-art comprehensive MR imag-
ing of the liver (including T1-weighted imaging, T2-
weighted imaging with short and long TE-values, dy-
namic gadolinium-enhanced, multi-phasic imaging, 
and imaging after SPIO-uptake) were most useful for 
improved detection and characterization of FNH.
MATERIALS AND 
METHODS
Patients
The study was performed in a tertiary referral center 
ABSTRACT
Purpose: To image a cohort of patients with pathol-
ogy-proven focal nodular hyperplasia (FNH) in order 
to assess which of the characteristics on state-of-the-
art magnetic resonance (MR) imaging of the liver are 
most useful for improved detection and characteriza-
tion of FNH.
Materials and Methods: In fourteen patients, patholo-
gy-proven FNH (n=33) were prospectively examined, 
using gadolinium and superparamagneticiron-oxide 
(SPIO) contrast media. All lesions were evaluated for 
signal intensity, fatty infiltration, central scar, mode of 
enhancement with gadolinium and uptake of SPIO. 
Percentages of dynamic contrast-enhancement in ar-
terial, portal and delayed phases were assessed. Con-
trast-to-noise ratio (CNR) before and after administra-
tion of SPIO contrast was calculated. 
Results: Signal intensity of the lesions was low to isoin-
tense on T1-weighted and intermediate to isointense 
on T2-weighted imaging. Fatty infiltration of the le-
sions was present in 6%.  Percentage of enhancement 
in liver and lesion respectively were 110, 115, 95% and 
151, 182, 160% (p<0.001). All lesions showed uptake of 
SPIO with improved conspicuity of central scar and 
septa. The CNR values pre-contrast and post-gadolin-
ium/SPIO were significantly different for T1-weighted 
in- and opposed-phase and black-blood echo planar 
imaging.
Conclusion: Combination of dynamic gadolinium-en-
hanced imaging with T1- and T2-weighted sequences 
after administration of SPIO facilitates comprehensive 
evaluation of FNH. 
INTRODUCTION
Although focal nodular hyperplasia (FNH) of the liver is 
a well-described lesion in the literature, considerable 
diagnosis problems regarding this lesion still remain. 
Given the fact that FNH is the second most common 
benign liver tumor after hemangioma and has a re-
ported prevalence of approximately 1%1, definitive 
distinction between this benign liver lesion and other 
benign and malignant hepatic masses is a common 
dilemma. Since FNH is usually observed in young to 
middle-aged women and most often is asymptomatic, 
the main goal of imaging in these patients is to firmly 
establish the diagnosis in order to avoid unnecessary 
biopsy or surgical resection and to suggest a conser-
vative approach to therapy2,3.
Since morphology and radiological enhancement 
patterns of FNH is strongly determined by its histo-
logical composition, it is important to realize that this 
lesion is divided into two types: classic and non-clas-
sic1. According to one large pathology study, the non-
classic type contains three subtypes (a) teleangiec-
tatic FNH, (b) FNH with cytologic atypia, and (c) mixed 
hyperplastic and adenomatous FNH. More recently, a 
study based on DNA micro-array analysis suggested 
that teleangiectatic FNH had more similarities with 
hepatocellular adenomas than with FNH4. Classic 
FNH is characterized by the presence of (a) abnormal 
nodular architecture, (b) malformed vessels, and (c) 
cholangiolar proliferation. Nonclassic FNH lacks one 
of the following classic features – nodular abnormal 
architecture or malformed vessels – but always shows 
bile duct proliferation.
Typical magnetic resonance (MR) imaging features 
of FNH – that is iso- or hypointensity on T1-weighted 
images, slight hyper- or isointensity on T2-weighted 
images, and a hyperintense central scar on T2-weight-
ed images – are seen in up to 84-100% of these lesions 
(Fig. 1)5,6. However, in our experience these imaging 
Focal nodular 
hyperplasia:
LESION CHARACTER-
ISTICS AT STATE-OF-
THE-ART MR IMAGING
including dynamic gadolinium-enhanced and super-
paramagnetic iron-oxide-uptake sequences in a pro-
spective study.
Türkan Terkivatan, MD, PhD1, Indra C. van den Bos, MD2, Shahid 
M. Hussain, MD, PhD2, 3, Piotr A. Wielopolski, PhD2, Robert A. de 
Man, MD, PhD4, Jan N.M. IJzermans, MD, PhD1
Departments of 1Surgery, 2Radiology, and 4Gastroenterology 
and Hepatology, Erasmus MC, University Medical Center Rot-
terdam, The Netherlands, 3Department of Radiology, Univer-
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The following MR items were assessed qualitatively 
and/or quantitatively: 1) liver surrounding the focal le-
sions (presence or absence of normal parenchyma, 2) 
diffuse and focal fatty infiltration, 3) focal non-steato-
sis, 4) iron deposition); 5) lesion localization according 
to the hepatic segment numbering system of Couin-
aud; 6) number and diameter of lesions; 7) signal in-
tensity of lesions compared with normal parenchyma 
before and after intravenous administration of gado-
linium and SPIO at T1- and T2-weighted images; 8) 
signal intensity characteristics of the lesions at unen-
hanced and contrast-enhanced T1-weighted images 
with regard to the surrounding liver parenchyma; 9) 
homogeneous or heterogeneous appearance; 10) 
presence of fatty infiltration within the lesion (in- and 
opposed-phase); 11) presence of a central scar, 12) 
presence of a pseudocapsule; 13) the uptake of SPIO, 
and 14) the conspicuity of the central scar and septa 
after the uptake of SPIO.
For quantitative image analysis, the signal intensity of 
the lesion and liver parenchyma was measured using 
operator-defined regions of interest (ROI). For the le-
sions, the largest possible region of interest in the le-
sion that excluded fibrotic areas was selected for mea-
surement of signal intensity. For the liver, a region of 
interest that excluded vessels and artifacts was used 
to measure the signal intensity of the liver adjacent to 
the tumor. The ROI’s were placed identically for both 
the unenhanced and contrast-enhanced images.
In dynamic gadolinium-enhanced imaging, enhance-
ment patterns in arterial, portal en delayed phase im-
aging were subjectively evaluated. The lesion-to-liver 
contrast-to-noise ratio (CNR) was calculated as the dif-
ference in signal intensity between the lesion and the 
liver scaled to the standard deviation of background 
noise. The percentage of contrast enhancement was 
calculated for gadolinium-chelates and the SPIO 
agent as follows:[(SIenhanced - SIunenhanced) / SIunenhanced] x 
100, where SI is signal intensity.
Statistical analysis
Statistical parameters (mean, median, standard de-
viation, and range) were calculated using the Statis-
tical Package for the Social Sciences (SPSS) program. 
Significance levels were determined by two-tailed 
Mann-Whitney test analysis. The unit of measure in 
our statistical analysis was number of lesions, rather 
than number of patients. 
RESULTS
Signal intensity of the lesions
At T1-weighted imaging, signal intensity of the le-
sions compared to the surrounding liver parenchyma 
was slightly lower to isointense at both in-phase T1-
weighted GRE (30 of 31 lesions (96.8%)) and opposed-
phase T1-weighted GRE (21 of 31 lesions (67.8%)) im-
ages. The lesions appeared relatively brighter to much 
brighter to the liver at opposed-phase T1-weighted 
GRE in 24.5% (8 of 31 lesions). This was caused by fatty 
infiltration of the liver parenchyma in those cases.
At T2-weighted imaging, the lesions showed an isoin-
tense to slightly higher signal intensity of the lesions 
at SSFSE T2-weighted images with short and long TE 
respectively (18 of 31 lesions (90.4%) and 26 of 29 le-
sions (89.6%)). This implied that the lesion and the 
liver behaved very similar on both sequences, most 
likely because of the solid nature as well as compa-
rable tissue composition.
At fat-suppressed T2-weighted FSE and diffusion T2-
weighted BBEPI, the lesions showed a slightly higher 
to much higher signal intensity in 28 of 30 lesions 
(93.3%) and 30 of 30 lesions (100%), respectively. In 
FSE, fat-suppression and fewer numbers of refocus-
ing pulses per TR than SSFSE, most likely improved 
the liver-to-lesion contrast. In BBEPI, several factors 
improved the liver-to-lesion contrast, including 1) fat-
suppression; 2) less magnetization transfer contrast 
effect than in FSE and SSFSE images due to the lack of 
refocusing pulses; 3) black-blood imaging based on 
the low diffusion-weighted gradient that dephased 
the signal from intrahepatic vessels; and 4) the applica-
tion of the diffusion gradients was applied in all three 
orthogonal directions, and the composite image was 
a sum of three individual images. This improved the 
signal-to-noise ratio (SNR) of BBEPI.
Enhancement after gadolinium
In arterial phase imaging after the administration of 
gadolinium, an intense enhancement was observed 
in 27 of 28 lesions (95%). The enhancement was either 
completely homogeneous in 15 of 28 lesions (53.6%) 
or intensely homogeneous with sparing of septa and 
the central scar in 12 of 28 lesions (42.8%).
In the portal phase, most lesions remained higher or 
slightly higher in signal intensity compared to the sur-
rounding liver parenchyma (18 of 28 lesions (64.2%)). 
The remaining lesions became almost isointense in 9 
of 28 lesions (32.1%).
In the delayed phase, 11 of 28 (39.3%) lesions re-
mained higher in signal intensity, whilst 14 of 28 (50%) 
lesions now showed an almost isointense signal inten-
sity compared to the surrounding liver parenchyma. 
Enhancement of central scar and septa was noted in 
delayed phase imaging.
A quantitative analysis of the enhancement in the 
different phases showed a percentage increase of 
enhancement in liver parenchyma in arterial, portal 
and venous phases respectively of 110, 115 and 95%, 
and in the lesion this was 151, 182 and 160% (p<0.001) 
(Fig. 2). This shows that the lesions are typically hyper-
vascular in the arterial phase, but behave in a similar 
with large experience in hepatobiliary surgery and 
transplantation. Liver pathology reports of percuta-
neous needle biopsies that were performed between 
1990 and 2003 were reviewed for the diagnosis of 
FNH. These data were matched with the hospital 
database to retrieve patients who were managed 
conservatively by observation of the lesion. Fifty-one 
patients had been evaluated for therapy by a hepa-
tobiliary surgeon. In none of these patients a surgical 
treatment was indicated because of the absence of 
complaints. All of these 51 patients were contacted 
to take part in this prospective cohort study with the 
state-of-the-art MR imaging. Of those, 14 replied and 
provided informed consent. The local ethics commit-
tee granted approval for the study.
A total of 33 lesions were detected in 14 patients. The 
patients were all women with a mean age of 45 years 
(range, 30-68 years). Analysis of data was based on 
evaluation of each single lesion. The mean size of all 
lesions was 2.6 cm (range, 0.6-10.0 cm). Twenty-two 
lesions were located in the right lobe and 11 in the left 
lobe. A single lesion was depicted in 7 patients, and 
multiple lesions were present in the other 7 patients 
(2 lesions in 2 patients, 3 in 3 patients, 4 in 1 patient, 
and 9 in 1 patient).
MR imaging technique
The MR examinations were performed using a 1.5T 
unit (Philips Medical Systems, Best, The Netherlands 
or General Electrics, Signa, Milwaukee, WI, USA; iden-
tical scan protocols). A four-channel body-array coil 
with capability of sensitivity encoding (SENSE) was 
used. Scan sequences included single-shot fast spin-
echo (SSFSE) (repetition-time (TR) msec/ echo-time 
(TE) msec 832/80-120; flip-angle 90º) with varying TE 
values (short and long TE, 80 and 120 msec respec-
tively), fat-suppressed T2-weighted fast spin-echo 
(FSE) (3000/80, flip-angle 90º), diffusion T2-weighted 
black-blood echo-planar imaging (BBEPI) (shortest/60, 
flip-angle 90º) and T1-weighted in- and opposed-
phase gradient-echo sequences (shortest/4.6 and 2.3 
respectively, flip-angle 80º). In each patient, a timing 
bolus technique using 2ml of the same contrast agent 
followed by 15ml saline was used to accurately capture 
the arterial phase after the administration of gadolin-
ium. After administration of an intravenous bolus of 
30ml of non-liver specific gadolinium chelate (Magn-
evist [gadopentetate dimeglumine], Schering, Berlin, 
Germany), dynamic imaging with 2D T1-weighted 
gradient-echo sequences in at least 4 phases (pre-
contrast, arterial, portal and delayed phases) was per-
formed. The total dose of administered gadolinium 
was slightly increased in part to compensate for some 
signal loss due to the implementation of the parallel 
imaging. The portal phase was acquired 45 seconds, 
and delayed at least 120 seconds after the acquisition 
of the arterial phase. In addition, a delayed phase 3D 
T1-weighted gradient-echo sequence was performed 
at least 4 minutes after contrast injection, in which the 
evaluation of central scar and septa was done. A slice 
thickness of 7 mm was used in all sequences.
After completion of the gadolinium-enhanced imag-
ing, a SPIO contrast agent (Ferrocarbutan, Schering AG, 
Berlin, Germany) was administered intravenously as a 
bolus of 1.4ml (>60 kg body weight). Ten minutes af-
ter the administration of SPIO imaging was performed 
using fat-suppressed T2-weighted FSE (3000/80, flip-
angle 90º), BBEPI (shortest/60, flip-angle 90º), and 
T1-weighted in- and opposed-phase GRE sequences 
(shortest/4.6 and 2.3 respectively, flip-angle 80º) were 
performed. No adverse reactions were reported dur-
ing the study.
The MR scan sequences, including SSFSE with short 
and long TE values, fat-suppressed T2-weighted FSE, 
diffusion T2-weighted BBEPI and T1-weighted in- and 
opposed-phase GRE sequences were complete for at 
least 29 lesions. In the following sequences, a few le-
sions were too small to visualize: 2 lesions on SSFSE 
sequences with short and long TE values (n=31) and 
2 lesions on T1-weighted in- and opposed-phase GRE 
sequences (n=31). Because of technical problems with 
data acquisition, the following lesions were excluded 
for the following sequences: SSFSE with long TE val-
ues in one patient (2 lesions, n=29), fat-suppressed T2-
weighted FSE sequence in 1 patient (3 lesions, n=30) 
and diffusion T2-weighted BBEPI in 2 patients (with 1 
and 2 lesions, respectively; n=30). The dynamic series 
were available for 28 of 33 lesions after contrast en-
hancement with gadolinium and for 30 lesions after 
enhancement with a SPIO contrast agent. For post-
enhancement evaluation of signal intensities of both 
the liver and the lesion, analysis was based on 30 le-
sions for T1-weighted in- and opposed-phase GRE 
sequences, 27 lesions for fat-suppressed T2-weighted 
FSE, and 23 lesions for BBEPI sequences.
Histologic proof of FNH was obtained in 14 of the 33 
lesions (14 patients). In case of multiple lesions, a per-
cutaneous needle biopsy was performed in the larg-
est one. Nineteen lesions not confirmed at histology 
were at (follow-up) MR imaging identical to the bi-
opsy-pathology-proven FNH. This is a common clini-
cal practice, and it would have been unnecessary and 
unethical to biopsy all the lesions. The appearance of 
the lesions without biopsy remained unchanged at 
imaging during a period of at least 12 months.
Image analysis
All MR imaging exams were transported digitally us-
ing a picture archiving and communication system to 
a viewing station. The analysis of all liver lesions was 
performed by two radiologists in consensus and with 
the knowledge of the diagnosis of FNH.
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as a strong indicator that the lesion is most likely of 
hepatocellular origin. Second, the presence of fatty in-
filtration in a relatively small number of lesions as well 
as in the surrounding liver is important. In our study, 
the lesions demonstrated fatty contents in only 6% of 
all lesions, confirming the fact that accumulation of 
fat inside FNH does occur but it is not a common find-
ing. Other primary liver lesions that contain fat include 
HCA, and HCC. HCA may have fatty contents in up to 
35-77% and HCC in 35%22. Third, the enhancement 
pattern at dynamic gadolinium-enhanced imaging 
is essential in the work-up of focal liver lesions. As 
shown in this study, in the case of FNH, lesions show 
intense enhancement in the early arterial phase, but 
show almost similar enhancement in the later phases; 
the lesions remain slightly more enhanced than the 
surrounding liver. This enhancement pattern is typical 
for primary solid liver lesions, such as FNH, HCA, and 
HCC. Particularly, HCA in which early arterial enhance-
ment is often observed23, but is often less intense 
compared to enhancement patterns observed in 
FNH24. As in FNH, HCA fades to near isointensity with 
the surrounding liver parenchyma in delayed phase 
imaging23,24. HCA, though, does not show any enhanc-
ing central scar and septa. In FNH, central scar and 
septa show high signal intensity at T2-weighted im-
aging, with enhancement in delayed phase imaging. 
Enhancement patterns in small HCC may show almost 
homogeneous enhancement in the arterial phase, but 
will often become heterogeneous (partial washout) or 
even homogeneously lower than the liver (complete 
washout). In addition, HCCs often shows enhanced 
tumor capsule in the delayed phase, and occurs in liv-
ers with parenchymal disease such as fibrosis and cir-
rhotic livers. HCC in non-cirrhotic liver are often single 
lesions with a large size and strong heterogeneous 
enhancement in the arterial phase. Other lesions such 
as hemangiomas and metastases have quite different 
signal intensities and enhancement patterns24. Hem-
angiomas typically enhance in a peripheral nodular 
fashion, with slow centripetal enhancement over 
time, to become and remain isointense with the liver 
in delayed phase imaging. Enhancement patterns in 
metastases may vary according to the origin of the 
malignancy. Colorectal metastases typically demon-
strate ring-like arterial enhancement, with filling of 
the central areas of the lesion over time and washout 
of contrast material in the active peripheral border of 
the lesion24. Fourth, after administration of SPIO, all le-
sions showed uptake of contrast which caused signal 
loss in the lesion, the liver, and spleen on sequences 
with T2*-weighting, such as T2-weighted FSE, SSFSE, 
and BBEPI, and T1-weighted GRE sequences. The sig-
nal loss in the liver was most pronounced, followed by 
Figure 3: 
Contrast-to-noise 
ratio (CNR) before 
and after gado-
linium and su-
perparamagnetic 
iron-oxide (SPIO)-
uptake in in-phase 
T1-weighted GRE, 
showing a sig-
nificant increase in 
CNR after contrast 
enhancement 
(p<0.0005).
Figure 4: 
Contrast-to-
noise ratio (CNR) 
before and after 
gadolinium and 
superparamag-
netic iron-oxide 
(SPIO)-uptake in 
opposed-phase 
T1-weighted GRE, 
showing a signifi-
cant increase in 
CNR after contrast 
enhancement 
(p<0.0005).
Figure 5: 
Contrast-to-
noise ratio (CNR) 
before and after 
gadolinium and 
superparamag-
netic iron-oxide 
(SPIO)-uptake in 
fat-suppressed T2-
weighted FSE (FSE 
fatsat), showing 
a non-significant 
increase in CNR 
after contrast 
enhancement 
(p=0.9).
Figure 6: 
Contrast-to-
noise ratio (CNR) 
before and after 
gadolinium and 
superparamag-
netic iron-oxide 
(SPIO)-uptake in 
diffusion-weight-
ed black-blood 
echo planar 
imaging (BBEPI), 
showing a signifi-
cant increase in 
CNR after contrast 
enhancement 
(p<0.05).
pattern as the surrounding liver parenchyma in the 
portal and delayed phases.
Signal intensity after SPIO-uptake
After administration of SPIO marked decrease in the 
signal intensity of the liver and spleen was observed 
at T2-weighted sequences, which indicated the accu-
mulation of iron particles in the Kupffer cells. When 
compared to the same sequence before and after 
SPIO-uptake, all lesions showed loss of signal intensity. 
This finding, in fact, revealed the presence of Kupffer 
cells within the lesions and hence their hepatocellular 
origin. The lesions showed a marked uptake in 17 of 
30 lesions (56.7%) and slight, but certainly present up-
take in 13 of 30 lesions (43.3%). Conspicuity of specific 
lesion characteristics such as presence of a central 
scar and septa had improved in 90% (27 of 29) of the 
lesions.
A qualitative, subjective evaluation of signal intensity 
of the lesion compared to the surrounding liver paren-
chyma was repeated. At T1-weighted imaging, signal 
intensity was slightly higher to isointense at in-phase 
T1-weighted GRE (23 of 30 lesions (76.7%)) and slightly 
higher to much higher at opposed-phase T1-weight-
ed GRE (30 lesions, 100%). This can be explained based 
on improved T1-weighting and less susceptibility arti-
facts due to relatively shorter TE value. At T2-weighted 
imaging, signal intensity of the lesions was slightly to 
much higher at both fat-suppressed T2-weighted 
FSE and diffusion T2-weighted BBEPI (26 of 27 lesions 
(96.3%) and 22 of 23 lesions (95.7%)).
Contrast-to-noise ratio before and after SPIO-
uptake
Based on the measurements of signal intensity of 
lesion and surrounding liver parenchyma, CNR val-
ues of the lesions before and after SPIO-uptake 
were calculated. These values were as follows: T1- 
weighted in-phase -2.8 and 6.95 (p<0.0005), 
T1-weighted opposed-phase -0.44 and 1.65 
(p<0.0005), fat-suppressed T2-weighted FSE 
6.45 and 16.4 (p=0.9) and BBEPI 5.64 and 
9.25 (p<0.05) (Figure 3). The values for T1-
weighted in- and opposed-phase and BBEPI 
were significantly different. High CNR values 
in BBEPI demonstrated a more pronounced 
uptake in the liver parenchyma compared 
to the lesion, with sensitive detection 
through susceptibility (T2*) effects of iron 
particles in SPIO.
Miscellaneous findings
The liver parenchyma surrounding the le-
sions was normal in magnitude, shape and 
contour in 12 out of 14 cases (85.7%). Diffuse 
fatty infiltration of the liver was present in 3 
out of 14 cases (21.4%), and focal fatty infiltration in 4 
out of 14 cases (28.6%). Focal non-steatosis was seen 
in 2 of 14 cases (14.3%). Fatty infiltration within the le-
sion was noted in 2 of 33 lesions (6.1%). Visibility of a 
central scar and pseudocapsule varied between 3 and 
15% of the lesions for different sequences, but was 
best in post-gadolinium sequences. Low detection 
rate of these characteristics can be explained by the 
relatively large amount of small lesions in this study. 
DISCUSSION
In this study, a cohort of patients with pathology-
proven FNH were examined to assess which of the 
characteristics derived from the state-of-the-art MR 
imaging of the liver are most useful for improved de-
tection and characterization of FNH. The results of our 
study indicated that 1) the signal intensity of FNH was 
only slightly different from the surrounding liver on 
pre-contrast T1- and T2-weighted images; 2) chemical 
shift imaging showed fatty infiltration in a minority of 
FNH (6%) whereas the surrounding liver showed focal 
or diffuse fatty infiltration in up to 50% of the cases; 
3) almost all lesions showed intense homogeneous 
enhancement (with or without intra-tumoral septal 
sparing) in the arterial phase after the administration 
of gadolinium; 4) the lesions faded almost to isoin-
tensity on the delayed phase; 5) the central scar and 
septa were visible only in a minority of patients; 6) all 
lesions showed uptake of SPIO with improved conspi-
cuity of the central scar and septa; 7) most sensitive 
sequences to detect the SPIO-uptake were in- and 
opposed-phase T1-weighted GRE and diffusion T2-
weighted BBEPI.  
The results of our study indicate that the following 
characteristics are significant for the diagnosis of FNH. 
First, the similarity of the signal intensity with the sur-
rounding (non-cirrhotic) liver should be considered 
Figure 2: Percentage of enhancement of liver parenchyma and the lesion in 
arterial, portal and venous phases (p<0.0001). ((t0; pre-contrast phase, t1; arte-
rial phase, t2; portal phase, t3; venous phase)
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vascular embolization treatment. At our institution, an 
asymptomatic single HCA of less than 5 cm in di-
ameter or multiple HCA with variable diameters are 
subject to intensive follow-up with imaging and labo-
ratory tests because of the risk of hemorrhage and 
malignancy. Whereas a single HCA larger than 5 cm or 
HCA with signs of malignancy at imaging (increasing 
size, changing density of signal intensity, changing en-
hancement, washout of contrast, enhancing fibrous 
tumor capsule) often will need surgical removal or at 
least biopsy. It is also important to know that HCA can 
present with intrahepatic or intraperitoneal hemor-
rhage that can be life threatening and may need in-
tervention, including surgery or embolization.
Several studies have described imaging characteris-
tics of focal liver lesions after administration of both 
specific and non-specific liver contrast agents. As has 
been described by Kim et al20, Ba-Ssalamah19 and Pre-
cetti et al17, use of ferumoxide contrast agents may aid 
in better delineation of central scar and septa in FNH. 
Also, Paley et al18 have shown a significant uptake of 
SPIO in pathology-proven FNH at T2-weighted imag-
ing compared to other focal liver lesions. Recently, 
Scharitzer et al16 have described the improved ac-
curacy for differentiation between surgical and non-
surgical liver lesions with mangafodipir-enhanced 
imaging. Few studies have evaluated the combined 
use of both gadolinium- and SPIO-enhanced imaging 
for focal liver lesions19,21. Ba-Ssalamah et al describe the 
imaging results of several focal liver lesions in separate 
imaging sessions for specific and non-specific contrast 
agents19. In addition to this study, we combine the use 
of dynamic gadolinium-enhanced imaging with T1- 
and T2-weighted imaging after administration of SPIO 
in one imaging session, to illustrate imaging findings 
of FNH using modern state-of-the-art MR sequences.
Our study has a limitation because of the relatively 
small cohort of patients. Only patients with an FNH 
lesion that was confirmed by percutaneous needle 
biopsy were included because histological proof is 
still considered to be the gold standard for diagno-
sis. However, since the introduction of state-of-the-
art MR imaging at our department in 1999, FNH has 
been diagnosed non-invasively. Diagnosis of FNH is 
confirmed with at least one follow-up MR imaging 
examination at 6-12 months. Consequently, the small 
amount of patients that are included in this cohort 
were diagnosed with a needle biopsy before the avail-
ability of MR imaging or during analysis elsewhere be-
fore being admitted to our clinic.
In conclusion, our study indicates that combination 
of dynamic gadolinium-enhanced imaging with T1- 
and T2-weighted imaging after administration of SPIO 
facilitates detection and characterization of FNH. It is 
shown that: 1) signal intensity of FNH prior to contrast 
differs only slightly from the surrounding liver; 2) ac-
cumulation of fat is present in a minority of FNH; 3) 
enhancement of FNH is intense homogeneous in ar-
terial phase imaging with fading to near isointensity 
in delayed phase imaging; 4) uptake of SPIO in FNH is 
pronounced with improved conspicuity of the central 
scar and septa. Most sensitive sequences to detect the 
SPIO-uptake are in- and opposed-phase T1-weighted 
GRE and diffusion T2-weighted BBEPI.
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differentiation between FNH and HCA26.
Distinction between FNH and HCA is very important: 
1) follow-up in pregnancy or use of oral anticoncep-
tive medication; 2) risk for hemorrhage and malig-
nancy; and 3) assessment of need of surgical or endo-
Figure 7: Improved conspicuity of central scar and septa after SPIO-uptake
(a and b). Axial fat-suppressed T2-weighted fast spin echo (FSE) and axial T2-weighted black-
blood (based on low diffusion gradients) echo planar imaging (BBEPI): images prior to SPIO-
uptake show a slightly hyperintense lesion without any recognizable central scar. (c and d). 
Axial fat-suppressed T2-weighted FSE and T2-weighted diffusion BBEPI: the same images after 
SPIO-uptake show an improved visibility of the central scar, mainly due to loss of signal within 
the solid parts of the tumor.  
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 MR IMAGING OF HEPATO- 
 CELLULAR ADENOMA
chapter3.1
 hepatocellular adenoma,  
 a review of imaging 
 findings
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(FNH). Mitosis in HCAs are absent or few. In contrast 
to most HCC, the normal reticulin pattern is well pre-
served10. Despite earlier reports, Kupffer cells are pres-
ent in liver cell adenomas11. These Kupffer cells are 
reduced in number and perhaps also less functional, 
which explains the diminished uptake of technetium-
99m sulfur colloid. In a recent study, fat within HCA 
was observed in up to 70% of the cases12. Large tor-
tuous arteries and dilated, thin-walled veins are often 
present, with large veins draining the lesions, which 
denotes the hypervascular nature of HCA. In addition, 
HCAs lack a true, fibrous, tumor capsule, which is a 
characteristic sign of larger HCC13. Therefore, hemor-
rhage may spread into the liver or abdominal cavity. 
Histologically, there is no difference among the ad-
enomas arising as single lesions, multiple lesions (2-6 
lesions), and liver adenomatosis (>10 
lesions)9,10,14. Previously, some reports 
suggested that liver adenomatosis 
occurred in a different population 
and the changes in size of these ad-
enomas did not depend on OC use15. 
Recent reports as well as our own experience contra-
dict this. Therefore, it is likely that “hepatocellular ad-
enomas” and “liver adenomatosis” are two manifesta-
tions of the same underlying disease.  
Lesions formerly known as “teleangiectatic focal 
nodular hyperplasia (TFNH)” are now considered to 
be a variant of HCA, since a recent study16 showed 
the molecular profile is much closer to the profile of 
hepatocellular adenomas than typical FNH. However, 
more recently, Bioulac and colleagues have illustrated 
molecular patterns and morphologic features of TFNH 
which suggest that these lesions do in fact show simi-
larities with HCA and should therefore be treated in 
the same way, but probably be regarded as a separate 
entity17. 
Pathogenesis of HCA and transformation into 
HCC
The exact pathogenesis of HCA is not known. Based 
on a detailed pathologic analysis of various types of 
lesions that occur in patients with liver adenomatosis, 
the following sequence of events was hypothesized: 
focus  group of foci  nodule  micro-adenoma 
 adenoma14.  Malignant transformation of HCA into 
HCC has been described in the literature by several 
groups18-22. Most authors have reported transforma-
tion of an existing HCA into HCC. Gordon and col-
leagues, however, reported a case of HCC after com-
plete regression of HCA at the 
same anatomic location18. At 
this point in time, it is not quite 
clear if all HCAs eventually can 
transform into HCCs. Also, the 
exact characteristics of HCAs 
that eventually may undergo 
malignant transformation are 
not well known. Currently, 
most authors consider increase 
in size of the lesion at imaging, 
increased serum alfa-fetopro-
tein, and suspicious findings at 
fine-needle-aspiration-biopsy 
(for histological criteria of HCA 
versus HCC, please see text 
below) as signs of malignant 
transformation of HCA. 
In this context, Tao recently 
published remarkable findings 
of his study based on 1673 pa-
tients who had undergone a 
fine-needle-aspiration-biopsy 
of liver mass or masses between 
1976 and 199020. In this study, 
99 of 1973 (5.9%) patients were 
diagnosed with HCC20. Among 
them, three patients were long-
term (> 10 years) OC users. Another 9 of 1673 (0.54%) 
were diagnosed with HCA. Two of these 9 patients (OC 
use: 8 and 10 years respectively) showed foci of liver 
cell dysplasia (LCD) within HCA at histological analy-
sis. LCD was defined as a) cytoplasmic and nuclear 
enlargement, b) nuclear pleomorphism as well as 
prominent nuclei, c) hyperchromasia and multinucle-
ation. The cytological features strikingly mimic HCC. 
Therefore, the author suggested that LCD should be 
considered the missing link between HCA and HCC20. 
In addition, the author also suggested that HCA is not 
pre-malignant and may undergo reversible change 
Figure 1: Gross and histology features of he-
patocellular adenomas (HCA) in three different 
patients.  (a) Photograph of part of a resected 
specimen shows a large yellow adenoma in a 
non-cirrhotic liver. Note the sharp demarcation 
between the adenoma and the liver without 
any tumor capsule (open arrow). Central part 
of the lesion shows signs of an old hemor-
rhage (*).  (b) Photomicrograph (hematoxylin 
and eosin (H&E) stain, original magnification 
40x) of a relatively small adenoma with high 
fatty content. Note that the lesion is otherwise 
similar to the surrounding liver. (c) Photomi-
crograph (H&E stain, original magnification 
200x) of an adenoma shows almost normal 
hepatocyte with increased cellularity and 
normal cytoplasm-to-nuclear ratio. Note that 
most plates are not thicker than two cells and 
the sinusoids are slit-like and variable in shape.  
ABSTRACT
The purpose of this paper is to describe the most 
recent concepts and pertinent findings of hepatocel-
lular adenomas, including clinical presentation, gross 
pathology and histology, pathogenesis and transfor-
mation into hepatocellular carcinoma, and imaging 
findings at ultrasound,  computed tomography, and 
magnetic resonance (MR) imaging.
INTRODUCTION
Before the introduction of oral contraceptives (OC) in 
the 1960s, hepatocellular adenoma (HCA) was a rare 
hepatic tumor1. In fact, only two cases of HCA were 
found in a review of 50.000 autopsies performed dur-
ing the 36 years before 19542. During the late 1960s, 
Edmondson and colleagues observed a sudden in-
crease in presented patients with HCA. In their study, 
a significant difference between cases and matched 
controls in mean months of OC use was found: 73.4 as 
compared to 36.2 (p<0.001)3. In 1979, a more extensive 
epidemiological survey was performed in 79 women 
with HCA and 220 matched controls, which also con-
firmed a relationship between OC use and HCA4. In 
addition, this study showed that in women who had 
never used OC or used them for less than 24 months, 
HCA developed at an annual rate of about 1.0-1.3 per 
million, whereas long-term users of OC had an esti-
mated annual incidence of HCA of 3.4 per 100,000 
which is 25-fold higher4. It should be noted that these 
figures are based on OC with much higher hormonal 
levels compared to new generation OC’s. Later stud-
ies suggest that modern OC’s are safer with less ten-
dency to developing HCA5. Non-OC-related causes of 
HCA include glycogen storage diseases or hormonal 
stimulation from other sources, for instance anabolic 
steroid use by body builders, gynecological tumors, 
and pregnancy. Rarely, HCA is reported in men6,7, 
probably related to use of anabolic steroids or based 
on abnormal stimulus from an endogenous source. It 
is important to note that HCA may present with po-
tentially life-threatening hemorrhage, and some HCA 
may develop or present with a hepatocellular carci-
noma (HCC)4. 
On ultrasound (US) and computed tomography (CT), 
distinction of HCA from other hepatic abnormalities 
may be difficult because these modalities, unlike MR 
imaging, lack information concerning tissue charac-
teristics of the lesions. Currently, CT is increasingly ap-
plied for assessment of liver lesions. However, it should 
be kept in mind that in case of a mono-phasic CT or 
incorrect timing of the arterial phase, HCA can easily 
be misdiagnosed, exposing patients to unnecessary 
delay in diagnosis and proper management. Familiar-
ity with clinical presentation, pathology and imaging 
findings of HCA, particularly at state-of-the-art MR 
imaging, facilitates distinction from other hepatic le-
sions and ensures proper treatment8. The purpose 
of this paper is to describe the most recent concepts 
and pertinent findings of hepatocellular adenomas, 
including the clinical presentation, gross pathology 
and histology, pathogenesis and transformation into 
hepatocellular carcinoma (HCC), and imaging findings 
at US, CT, and MR imaging. 
Gross pathology and histology
In 1995, the International Working Party classified HCA 
as neoplastic lesions, composed of hepatocytes which 
show histological characteristics of abnormal growth 
caused by presumed or pathology-proven genetic 
alteration9. Hepatic adenomas are well-circumscribed 
solitary lesions, often with hemorrhage and/or ne-
crosis, in a majority of cases (Fig. 1). At histology, HCA 
solely consists of liver cells, arranged in plates that are 
not thicker than two to three cells. The plates are ar-
ranged in sheets and cords, devoid of lobular pattern 
due to absence of portal areas, and separated by slit-
like sinusoids lined by epithelium. Lack of bile ductules 
facilitates distinction from focal nodular hyperplasia 
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In our experience, relatively small HCAs without hem-
orrhage and necrosis are often asymptomatic, discov-
ered as incidental findings at cross-sectional imaging, 
and are more likely to appear as homogenous lesions, 
particularly at CT and MR imaging. 
Ultrasound 
HCAs without abundant necrosis, hemorrhage or 
malignant degeneration, will most likely have a ho-
mogenous appearance with somewhat variable 
echogenicity, which depends on the structural com-
position of the lesions as well as the surrounding 
liver (Fig. 4). Mathieu and colleagues described the 
US appearance in 27 HCAs as follows: 11 of 27 (41%) 
hypoechoic, 8 of 27 (30%) hyperechoic, 6 of 27 (22%) 
isoechoic, and 2 of 27 (7%) with mixed echogenicity32. 
In another study, five patients underwent US: 4 of 5 
(80%) lesions had mixed echogenicity and in 1 of 5 
(20%) the lesion was clearly hypoechoic32. The sensi-
tivity and specificity of US for HCA is not well-known. 
In general, the sensitivity of US for liver lesions is about 
50%33, 34. In liver adenomatosis, using US, fewer lesions 
were detected than using CT or MRI, and most of the 
lesions were somewhat heterogeneous but predomi-
nantly hypoechoic23. Echogenicity of liver lesions in 
general and of HCAs in particular depends on two 
main factors: 1) architecture of the lesions, and par-
ticularly solid versus non-solid components as well as 
the number of interfaces that influence sound trans-
mission, etc.); 2) architecture of the surrounding liver 
(normal parenchyma versus parenchyma with diffuse 
(depositional) disease). Therefore, HCA with abundant 
fat, fibrosis, or hemorrhage will appear as echogenic 
lesions compared to the surrounding liver. However, 
HCAs within fatty liver are likely to appear hypoechoic 
compared to the surrounding liver tissue.   
According to Mathieu et al, at US, HCAs and FNHs are 
indistinguishable with all echo-structural patterns ob-
served in both types of lesions32. Based on Doppler, 
several authors25,35 have demonstrated a continuous 
(venous) wave form in a majority of HCAs as opposed 
to the pulsatile wave within malignant tumors like 
HCC. In these studies, relatively larger HCAs (mean di-
ameter > 5 cm) were examined. In smaller lesions with 
small vessels, it may be technically difficult to visualize 
reproducible Doppler signal findings.  In our experi-
ence with various imaging modalities for hepatic im-
aging, it is often challenging - if not impossible - to 
diagnose HCA at US with confidence33.
Several developments, including tissue 
harmonics, contrast harmonics, real-
time spatial compound imaging, adap-
tive real-time image processing, pan-
oramic and three-dimensional imaging, 
and real-time reformatting, have con-
solidated the role of US in the current 
clinical practice33. For hepatic imaging 
and in particular for diagnosis of primary 
liver lesions, though, the (fundamental) 
limitations of ultrasound remain. These 
include operator-dependency with 
low reproducibility, lack of overview of 
the anatomy, lack of (technical) ability 
to change the intrinsic tissue contrast. 
Contrast agents facilitate the character-
ization of solitary known liver lesions as 
has been described by several authors 
before26,36,37. A limitation of this exami-
nation however, is that surveying the 
entire liver after contrast administration 
is not possible, which is virtually always an important 
aspect of a liver study. Multiple liver lesions may be 
present, including multiple lesions of different benign 
and malignant histologies. These limitations result in 
low sensitivity and specificity of US for liver abnormal-
ities. In many centers, the clinical and surgical decision 
making does not take place based on the US of the 
liver alone33.
Computed Tomography
At CT, HCA without complications are likely to be 
isodense with the surrounding liver on unenhanced 
CT, and become visible in the arterial phase with a ho-
mogenous blush of contrast enhancement, and then 
fade to isodensity on the portal or delayed phase (Fig. 
5a and b). Typically, on unenhanced CT scans hepatic 
adenomas are usually well circumscribed lesions that 
are predominantly isodense or slightly hyperdense if 
uncomplicated and relatively small (< 5 cm). Larger 
and more complicated HCAs may display a variety of 
density patterns, including a low attenuation if they 
Figure 4: Ultrasound (US) appearance 
of three hepatocellular adenomas (HCA) 
from two different patients. (a) Oblique-
axial section through the left lateral lobe 
of the liver with a large HCA which is 
isoechoic to the surrounding liver, with 
some mass effect. (b) Longitudinal section 
shows two small hypoechoic HCAs in a 
hyperechoic fatty liver. (c) Oblique-sagit-
tal section through the right liver shows 
a small echogenic (fatty) HCA (arrow).
after withdrawal of OC, whereas LCD is an irreversible, 
pre-malignant change and will eventually progress to 
HCC (HCA-LCD-HCC sequence) (Fig. 2). 
The concept of Tao20 can explain some of the issues 
regarding the malignant transformation of HCA, in-
cluding 1) HCA-LCD-HCC sequence has two impor-
tant similarities with the previously described step-
wise carcinogenesis of HCC in cirrhotic liver13, 23 in the 
sense that LCD plays a crucial role in both pathways, 
and LCD in HCA is histologically identical to LCD in 
dysplastic nodules in cirrhosis; 2) why not all HCAs 
undergo malignant transformation; and 3) why HCC 
can occur at the same anatomic location even after 
complete regression of an HCA as described by Gor-
don and colleagues18.
The distinction between HCA and well-differentiated 
HCC at times may be impossible at histology10. The fol-
lowing findings may indicate HCC: a) liver-cell plates 
more than three cells thickness; b) decreased nuclear/
cytoplasm ratio; c) prominent nucleoli; d) mitosis; e) 
loss of reticulin pattern; f) absence of Kupffer cells; g) 
presence of vascular invasion; and h) stainable alfa-
fetoprotein. However, none of these features can be 
relied upon with certainty as some may rarely be seen 
in HCA and others are common in well-differentiated 
HCC10. For pathologists, the most helpful, perhaps, are 
the thickness of the cell plates, amount of reticulin, and 
vascular invasion. This is one of the important reasons 
why a US-guided biopsy of a primary liver lesion with 
suspicion of malignancy may not be the solution, and 
either follow-up with (MR) imaging or even resection 
of the lesion may be preferred to biopsy depending 
on the level of suspicion. 
IMAGING OF HCA
At imaging, hepatocellular adenomas (HCAs) may ap-
pear heterogeneous reflecting the histological nature, 
the complex anatomy and composition of the lesions, 
and the mode of presentation at the time of the diag-
nosis (Fig. 3). Heterogeneity is most likely associated 
with relatively larger lesions containing hemorrhage, 
necrosis, fibrosis and malignant transformation. Pa-
tients with such lesions are more likely to be symp-
tomatic with higher chance of getting an imaging 
examination. This may explain the fact that in most 
publications based on imaging HCAs are large (> 5 
cm) and complex in nature24-31. Some authors there-
fore consider “heterogeneity” as the hallmark of HCAs 
at imaging. 
Figure 2: HCA-HCC sequence. Drawing illustrates recently discovered various steps in hepatocellular adenoma (HCA) and he-
patocellular carcinoma (HCC) sequence. After the use of oral contraceptives (OC) for a certain period, the liver shows altered 
shape and enlargement with the development of one or more HCA. This step is considered to be reversible if OC use is discon-
tinued. Therefore, most recently HCA is not considered as a pre-malignant lesion. During this phase, fatty infiltration within the 
lesion(s) as well as in the liver may concur and coexist. With the continuous use of OC (probably longer than three years), liver cell 
dysplasia (LCD) develops within HCA. HCA with foci of LCD is considered as a pre-malignant lesion. The areas with LCD gradu-
ally transform into foci of HCC. Eventually, the foci of HCC coalesce to form a large HCC. After the development of LCD, the se-
quence of events is thought to be irreversible. Therefore, HCC may also develop at the location of a HCA, even if that particular 
HCA has regressed or disappeared at imaging. In addition to OC, other (genetic) factors play a role in the HCA-HCC sequence.
Figure 3: Many faces of hepatocellular adenomas.  I) A non-fatty single lesion in a non-fatty liver: the lesion appears 
very similar to the surrounding liver. II) Multiple HCAs within a fatty liver. III) Fatty HCA and small HCAs associated with in-
tra- and extra-hepatic hematomas.  IV) Hepatocellular carcinomas (HCC) may arise from HCAs or at the same anatomic lo-
cation after regression of HCA. Note the confluent nodules of HCC contained within a thick fibrous tumor capsule.
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minimum, mainly due to concerns about radiation 
hazard. The issue of radiation is even more important 
in relatively young and otherwise healthy patients 
with an incidental liver lesion, such as HCA, that needs 
characterization or follow-up. One fundamental limi-
tation of CT remains the lack of the ability to alter the 
intrinsic soft tissue contrast, which is useful to assess 
diffuse and focal liver abnormalities. Evaluation of liver 
abnormalities at CT is based on two basic parameters: 
attenuation differences and differential enhancement.
Magnetic Resonance Imaging
At MR imaging, these HCAs often have the following 
characteristics: a) almost isointense or slightly hy-
perintense to the surrounding liver on T1-weighted 
in-phase gradient-echo images (indicating the he-
patocellular nature of the lesions), b) compared to in-
phase images, they may become relatively hyperin-
tense to the liver (due to decreased signal of the fatty 
liver) or hypointense as well as heterogeneous to the 
liver (due to decreased signal within the fatty lesion) 
on the T1-weighted opposed-phase images, c) slight-
ly hyperintense or hypointense on fat-suppressed T2-
weighted images (depending mainly on whether HCA 
is surrounded by fatty liver or the lesion itself contains 
abundant fat or fibrosis, respectively), d) faint homog-
enous enhancement (blush) in the arterial phase, and 
e) isointense in the delayed phase without washout 
or capsular enhancement (Fig. 5c-f and Fig. 6). In one 
study of 51 pathology-proven lesions30, HCA has the 
following characteristics: on T1-weighted spin-echo 
images, 30 of 51 (59%) were hyperintense, 17 of 51 
(33%) isointense, and 4 of 51 (8%) hypointense to the 
liver; and on T2-weighted spin-echo images, 24 of 51 
(47%) were hyperintense, 20 of 51 (39%) isointense, 2 
of 51 (4%) hypointense to the liver. In two studies from 
1994 and 1995, up to 87% of HCA showed homog-
enous enhancement on the gadolinium-enhanced 
gradient-echo images in the arterial phase30,31. In one 
study of 31 lesions, 26% showed fatty infiltration and 
39% signs of hemorrhage at pathologic analysis31. MR 
imaging was able to detect fat in 63% and hemorrhage 
in 83% of the cases31. These data were mainly based 
on T1-weighted spin-echo sequence without fat-sup-
pression. Chemical shift imaging, which is more sensi-
tive for fatty infiltration, was not applied. A complete 
or partial pseudocapsule – comprised of compressed 
surrounding liver tissue or vessels - presenting as a rim 
Figure 6: 41-year old female with a 
fatty HCA. (a) Axial fat-suppressed 
T2-weighted TSE image: adenoma is 
predominantly isointense to the liver. 
(b) Axial in- (IP) and opposed-phase 
(OP) T1-weighted gradient-echo: 
large parts of the adenoma shows 
decrease in signal on opposed-phase 
due to more (**) or less (*) fatty 
infiltration. (c) Axial arterial phase (ART) 
gadolinium-enhanced three-dimen-
sional gradient-echo: adenoma shows 
moderately intense and homogeneous 
enhancement. (d) Coronal delayed 
phase (DEL) gradient-echo with high 
spatial resolution shows the adenoma 
as an exophytic lesion with a large 
intra-tumoral vessel. (e) Photomicro-
graph (H&E, original magnification 
200x) shows typical mono-nuclear 
appearance of the hepatocytes with 
fatty infiltration. (f) Photograph of the 
resected specimen confirms that large 
parts of the tumor contain fat and 
appear yellowish (fatty part). Note the 
striking MR-pathology correlation.
contain fat, relatively high density if hemorrhagic, 
or fluid density if necrotic. In cases of recent hem-
orrhage, HCA is often obscured by the hematoma 
which appears heterogeneous with predominantly 
high attenuation values. In HCAs, calcification is pres-
ent in 5-15 % of cases10. On CT scans obtained after 
IV contrast injection, hepatic adenomas usually show 
early homogeneous enhancement during the arterial 
dominance phase. On portal venous phase and de-
layed CT scans hepatic adenomas exhibit attenuation 
nearly identical to that of normal liver parenchyma27,32. 
In one study, all 44 adenomas (100%) showed homog-
enous enhancement in the arterial phase27. In another 
study, 22 of 27 (81%) HCAs showed enhancement in 
the arterial phase at CT. In the portal phase at CT, a 
minority (39%) of the lesions may be more enhanced 
than the surrounding liver, whereas in the delayed 
phase very few lesions (6%) may still be enhanced 
more than the liver27. As homogenous enhancement 
in the arterial phase plays an important role for diag-
nosis, proper timing strategy to obtain this phase may 
be crucial at CT.
The broad availability of CT as well as the recent de-
velopment and implementation of the faster multi-
row detector machines, make this modality an excel-
lent tool for detection and characterization of focal 
liver lesions. Current CT scanners can obtain simul-
taneous multiple acquisitions per each gantry rota-
tion. With the current multidetector CT, fast data ac-
quisition over a large anatomic area (entire body with 
isometric voxels) is possible in less than 30 seconds. 
The isometric nature of the data facilitates high qual-
ity reconstructions of mainly the vascular and bony 
structures in any desirable anatomic orientation33. The 
shorter scan times also allow the capture of distinct 
phases, including the unenhanced phase, the arterial 
phase, the portal phase, and the venous phase. These 
phases provide important information concerning 
the enhancement patterns and hence the possibil-
ity of characterization of focal liver lesions. In clinical 
practice though, the number of phases that are usu-
ally acquired with CT are limited and often kept to a 
Figure 5: 31-year old female 
with typical HCA within a fatty 
liver. (a) Axial unenhanced CT 
(unenh CT) shows no lesion. (b) 
Axial enhanced CT shows HCA 
with a homogenous blush in 
the arterial (ART) phase (arrow), 
fading to isodensity in the 
portal (POR) phase. (c) Axial in- 
(IP) and opposed-phase (OP) 
T1-weighted gradient-echo 
shows no lesion on IP whereas 
a hyperintense lesion (arrow) 
appears on the OP due to de-
creased signal in the fatty liver.  
(d) Axial fat-suppressed single-
shot black-blood T2-weighted 
echo planar imaging (BBEPI) 
shows the lesion (arrow) with 
faintly higher signal than the 
liver. Spleen (*).  (e) Axial gado-
linium-enhanced T1-weighted 
gradient-echo image in the 
arterial phase (ART) shows a 
homogenous blush of HCA 
(solid arrow). Note the intense 
enhancement of the aorta 
(open arrow) and the spleen 
(*).  (f) Axial gradient-echo im-
age in the delayed phase (DEL) 
shows no washout of contrast 
(i.e. homogenous enhance-
ment) and the lesion is slightly 
more enhanced than the liver 
(arrow). Spleen (*). The find-
ings at MR imaging are more 
specific for HCA than on CT.
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presence or absence of contrast-uptake and enhance-
ment patterns using either non-specific or liver-spe-
cific contrast media. Because MR imaging lacks the 
hazards of ionizing radiation, most centers perform a 
multi-phasic gadolinium-enhanced examination as a 
standard part of their work-up 
of liver diseases. So unlike CT, 
many centers have been rou-
tinely employing a dynamic 
multi-phasic (often three or 
more phases) gadolinium-
enhanced imaging protocol 
as the standard MR imaging 
investigation in patients with 
suspected liver disease for 
more than a decade38-41. Dy-
namic gadolinium-enhanced 
imaging is considered es-
sential in detection and char-
acterization of liver lesions. 
Therefore, for most body MR 
radiologists, the enhance-
ment patterns of various focal 
liver lesions (as well as their 
signal intensity characteristics 
on T2- and T1-weighted se-
quences) are well known for 
many years.
Multiple adenomas
Multiple HCAs are often surrounded by a fatty liver 
with altered shape and size of the segments of the 
liver. At US, such lesions will most likely be hypoechoic 
due to the increased echogenicity of the fatty liver, 
Figure 9: 29-year old female with multiple 
adenomas in a fatty liver. (a)  Axial SSTSE shows 
a lesion (arrow) that is slightly lower in signal 
intensity compared to the surrounding liver 
due to the higher signal of the fatty liver.  Fat-
suppressed turbo spin-echo (TSE-fatsat) shows 
the lesion (arrow) that is slightly hyperintense 
to the liver due to the fat suppression pulse. 
(b) Axial in- (IP) and opposed-phase (OP) T1-
weighted gradient-echo: the liver shows marked 
decrease in signal due to fatty infiltration. The 
adenomas (arrows) remain unchanged in signal 
and hence appear bright.  (c) Axial gadolinium-
enhanced arterial phase (ART) gradient-echo: 
the larger adenoma shows moderately 
intense and homogeneous enhancement 
(arrow). The smaller lesion is not well visible.
Figure 10: 43-year old female with 
multiple hepatocellular adenomas: 
MR imaging before and 6 months 
after withdrawal of oral contracep-
tives (OC). a) Axial fat-suppressed 
T2-weighted turbo spin-echo (pre-
SPIO T2-fatsat) shows at least two 
lesions with high signal intensity: a 
large (solid arrow) and a small lesion 
(open arrow). In addition, two areas 
with low signal intensity (*) are visible 
in an abnormally bright liver.  (b) 
Axial fat-suppressed T2-weighted 
turbo spin-echo after uptake of 
super-paramagnetic iron-oxide 
(post-SPIO T2-fatsat) into Kupffer cells 
shows signal loss with somewhat 
heterogeneous appearance of the 
largest lesion (solid arrow). This 
reflects variable distribution of 
Kupffer cells across this lesion. In addi-
tion, smaller lesions (*) show a more 
homogenous decrease in signal. 
The presence of Kupffer cells proves 
that the lesions are of hepatocel-
lular origin, and hence excludes multiple metastases.  (c) Axial gadolinium-enhanced gradient-echo in the arterial phase shows intense 
homogenous enhancement of all lesions, including the smaller lesion that was visible on T2 (open arrow) and additional lesions not visible 
on T2 (solid arrowheads).  (d)  Axial gadolinium-enhanced gradient-echo in the arterial phase (ART) (6 months after withdrawal of OC) 
shows decrease in size and intensity of enhancement of all lesions and confirms the diagnosis of OC-dependent multiple adenomas.
of low signal intensity at T1-
weighted images and a high 
signal intensity at T2-weight-
ed images, may be seen in 
some cases. In contrast, the 
true fibrous tumor capsule of 
HCC has a low signal intensity 
on both T1- and T2-weighted 
sequences13.
The current state-of-the-art 
MR imaging provides a more 
comprehensive and accurate 
work-up of focal and diffuse 
liver disease33,34. This is based 
on the unique properties of 
MR imaging that comprise a 
combination of high intrin-
sic soft tissue contrast of the 
liver and liver lesions, vari-
ous distinctly different tissue 
characteristics at imaging 
and high sensitivity for the 
Figure 7: 28-year old female with multiple 
hepatocellular adenomas (HCAs) in a fatty 
liver. (a) Axial unenhanced CT shows at least 
three large lesions that are hyperdense (ar-
rows) to the surrounding hypodense enlarged 
liver due to severe fatty infiltration. Note also 
the large thickness of the subcutaneous fat 
that indicates obesity.  (b) Axial enhanced 
CT in the arterial phase shows HCAs with 
a homogenous blush. (c) Axial enhanced 
CT in the portal phase shows HCAs that 
remain hyperdense due to the fatty liver.
Figure 8: 39-year old female with 
small hepatocellular adenomas 
(HCAs) who underwent resection for 
a large HCA in the left liver: CT versus 
MR imaging. (a) Axial unenhanced 
computed tomography (unenh CT) 
shows lesion one lesion (arrow) that is 
hypodense to the liver. Probably due 
to partial volume effects, the density 
(Hounsefield value) was greater than 
zero, which fail to show fatty content 
of the lesion.  (b) Axial enhanced CT 
in the arterial (ART) phase shows HCA 
with little or no enhancement. Based 
on these findings, CT was inconclusive 
about the nature of the lesions. (c) Axial 
T2-weighted SSTSE (SSTSE) shows a 
slightly hyperintense lesion (solid arrow) 
and a more faintly hyperintense small 
lesion (open arrow).  (d) Axial in- (IP) 
and opposed-phase (OP) T1-weighted 
gradient-echo shows the larger lesion 
with more (solid arrow) and less (open 
arrow) loss in signal on OP based on 
the differences in fatty content. Note a 
prominent liver vein coming from the 
area of the lesion (arrowhead). (e) Axial 
gadolinium-enhanced T1-weighted 
gradient-echo image in the arterial 
phase (ART) shows a homogenous 
blush of the larger (solid arrow) and the 
smaller (open arrow) lesion.  (f) Axial 
gradient-echo image in the delayed 
phase (DEL) shows washout of contrast 
(i.e. lesions become less enhanced 
than the liver). No capsular enhance-
ment is visible. Based on CT findings 
as well as MRI findings on T2-weighted sequence and the enhancement pattern, hypervascular metastases cannot be excluded. 
Although, the findings on the chemical shift imaging (IP and OP) exclude this possibility and the lesions can safely be characterized 
as small fat-containing hepatocellular adenomas. Note a prominent liver vein coming from the area of the lesion (arrowhead).
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fat-suppressed T2-weighted sequences, the signal in-
tensity may increase from lower to higher than the liv-
er depending on the amount of liver steatosis (see Fig. 
9). The use of super-paramagnetic iron-oxide (SPIO) 
contrast media for MR imaging as well as follow-up 
with imaging after stopping the oral contraceptives 
are additional possibilities to confirm the primary and 
benign nature of the lesions (Fig. 10). Specific contrast 
media such as SPIO are targeted at the Kupffer cells. 
These contrast media can be used to 
demonstrate the hepatocellular ori-
gin of the lesions. The Kupffer cells 
show uptake of SPIO and this lowers 
the signal intensity of the lesions as 
well as the surrounding liver on T2- 
and T2*-weighted images (see Fig. 
10a-b). In our experience, dynamic 
gadolinium-enhanced MR imaging 
in the arterial phase is more sensitive and specific 
than T2-weighted sequences after SPIO-uptake (see 
Fig. 10).
Large (complicated) adenomas
Larger HCAs as well as HCAs complicated with hem-
orrhage and malignant degeneration may appear 
heterogeneous on all imaging modalities. The hetero-
geneity of the lesions may be caused by several fac-
tors, including 1) the presence of hemorrhage, 2) the 
presence of necrosis or fibrosis, and 3) pre-malignant 
(LCD) or malignant (HCC) changes. Large hematomas, 
which have non-specific appearance on US and CT 
but can easily be recognized as typical bright fluid 
collections on T1-weighted MR images, can compress 
the surrounding liver tissue and conceal the under-
lying HCA as the cause of bleeding. After resolution 
of the hematoma or embolization of the tumor ves-
sels, the HCAs may become evident (Fig. 11 and 12). 
“Adenoma-like” HCC may be discovered at imaging in 
female patients with long-term OC-use (Fig. 13). Such 
lesions may cause difficulty in making the correct di-
agnosis at US, US-guided biopsy, CT, preoperatively. 
And even after resection of the tumor, it may be dif-
ficult to distinguish between 
HCA and HCC at histopathol-
ogy because of overlapping 
features. In this context, the 
ability of the state-of-the-art 
MR imaging for tissue charac-
terization in vivo and distinc-
tion between HCA and HCC is 
unparalleled33.  
DIFFERENTIAL 
DIAGNOSIS
A number of lesions form the differential diagnosis for 
HCA. These include FNH, HCC in a non-cirrhotic liver, 
fatty or hemorrhagic HCC, focal steatosis, angiomyoli-
poma, and hypervascular metastases. 
Most FNHs have distinct pathologic and imaging fea-
tures and cause little to no difficulty in distinguishing 
from HCAs42. Particularly, classical FNH is composed of 
small nodules of normal hepatocytes surrounded by 
a network of capillaries and septa42. Larger septa and 
the central scar form a spoke-wheel configuration that 
is a typical feature of FNH. The signal intensity of FNHs 
on T1- and T2-weighted sequences may overlap with 
Figure 13: “Adenoma-like” hepatocellular carcinoma (HCC) in a healthy 30-years-old 
female with long-term (> 5 years) oral contraceptive use (negative viral serology and 
normal alfa-fetoprotein): MRI-pathology correlation. (a) Axial in- (IP) and opposed-phase 
(OP) imaging shows an isointense lesion (HCC) to the liver. On OP a low signal intensity 
tumor capsule surrounds the lesion (open arrow).  (b)  Axial gadolinium-enhanced gradi-
ent-echo in the arterial phase (ART) shows enhancement of a nodule (*) as well as the 
remaining lesion (**). In addition, a small subcapsular lesion is also enhanced (arrowhead). 
Axial gadolinium-enhanced gradient-echo in delayed phase (DEL) shows some washout 
of contrast and enhancement of a thick tumor capsule (open arrow). (c) At ultrasound-
guided biopsy (before referral to our hospital), the lesion was characterized as “most likely 
an adenoma”. Because of the controversial results of imaging, biopsy, and the large size 
of the lesion (>10 cm) with concern of malignancy, a surgical resection was performed 
of the largest lesion. At histology, the lesion contained hepatocyte-like cells of variable 
size. The nuclei were variable in size as well. Proliferative activity was low (solid arrow).  
The presence and the distribution of vessels varied. The exact nature of the lesion was 
difficult to determine. At gross pathology, tumor was composed of several confluent 
nodules (*), and the entire lesion was completely surrounded by a thick fibrous capsule 
(open arrow). To determine the exact nature of the lesion, the pathology material was 
sent to three authoritative pathologists in Europe: two of them characterized the lesion as 
“well-differentiated HCC with low malignant potential” and according to the third it was 
an “adenoma”. Based on MR imaging and our own pathologic analysis, we considered the 
lesion as HCC, which might have originated from an adenoma. The smaller lesion could 
not be found at surgery and did not change on several follow-up MR imaging exams.
and therefore may mimic a wide variety of lesions, 
including liver metastases. At CT, multiple HCAs may 
appear hyperdense on the unenhanced as well as en-
hanced scans because of the low density of the fatty 
liver. In such cases, the enhancement of the lesions 
may be difficult to appreciate (Fig. 7). Multiple HCAs 
may also be found in non-fatty livers. If these lesions 
are relatively small, and their fatty content cannot be 
detected with certainty, they may mimic hypovascular 
liver metastases particularly at CT (Fig. 8a-b). At MR im-
aging, very small liver lesions within fatty or non-fatty 
liver can be characterized with much higher accuracy 
because of the high intrinsic soft tissue contrast based 
on the T2 characteristics and chemical shift imaging, 
and the ability to visualize enhancement patterns on 
the routine gadolinium-enhanced dynamic imaging, 
(Figs. 8c-f and 9). It should be pointed out here that 
the signal intensity of HCA on non-fat-suppressed T2-
weighted MR imaging can be high if the lesions con-
tain abundant fat. Conversely, on similar sequences 
the signal intensity of HCA may be lower than the liver 
if the liver is steatotic (see Figs. 8 and 9). Whereas, on 
Figure 11: 24-year old female with 
ruptured adenoma: US, CT, and DSA. (a) 
US shows a large fluid collection with-
out a distinct solid lesion or cause of 
the abnormality. Debris within the col-
lection (*) as well as the acute history 
suggest a large hematoma. (b) Axial 
CT in the portal phase confirms the 
findings of US. No distinct solid lesion is 
visible. (c) Selective digital subtraction 
angiography (DSA) prior to emboliza-
tion shows hypertrophic right hepatic 
artery with typical numerous tortuous 
(corkscrew) arteries and several areas 
with blush suggesting multiple adeno-
mas around the hematoma. (d) DSA af-
ter embolization (with gelatin sponge 
particles and after placement of a coil) 
shows no evidence of adenomas.
Figure 12: 24-year old female with 
ruptured adenoma (same patient as in 
Fig. 11): MR imaging before and after 
embolization. (a) Fat-suppressed T2-
weighted turbo spin-echo (T2 fatsat) 
shows a large fluid collection with a 
stalk-like extension (arrow).  (b) Axial 
in-phase T1-weighted gradient-echo 
(T1 in-phase) shows the fluid collection 
with high signal; the signal intensity 
is compatible with a large hematoma 
(high signal is caused by methemoglo-
bin). (c) Axial gadolinium-enhanced 
T1-weighted gradient-echo in the arte-
rial phase (ART) shows homogeneous 
enhancement around the stalk-like 
extension indicating the location 
of the ruptured adenoma. (d) Axial 
gadolinium-enhanced T1-weighted 
gradient-echo in the arterial phase 
(ART) (3-months after embolization) 
shows residual or recurrent adenomas 
surrounding the hematoma that has 
decreased in size (solid arrows). Note 
also an additional adenoma in the 
left side of the liver (open arrow).
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computed tomography and state-of-the-art MR im-
aging. MR imaging provides the most comprehensive 
and non-invasive imaging work-up of patients with 
suspected hepatocellular adenomas.
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Figure 14: 70-year old female with 
hepatocellular carcinoma (HCC) in a 
non-cirrhotic liver: MRI-pathology cor-
relation. (a)  Axial gadolinium-enhanced 
gradient-echo in the arterial phase 
(ART) shows somewhat heterogeneous 
enhancement of the lesion. Axial 
gadolinium-enhanced gradient-echo in 
delayed phase (DEL) shows enhance-
ment of a thick tumor capsule (solid 
arrows). (b) At gross pathology (PATH), 
the lesion was encapsulated by a thick 
fibrous capsule (solid arrows) and the 
liver was clearly non-cirrhotic, which 
confirmed the findings at MR imaging.
Figure 15: 36-year old male with diffuse hemorrhagic and fatty HCC mimicking an 
adenoma or an angiomyolipoma on CT. (a) Axial unenhanced CT shows a low density 
lesion (arrow) with evidence of fat. Therefore, the lesion was characterized as either an 
adenoma or an angiomyolipoma and MRI was requested to confirm one of these two 
entities.  b) Axial in-phase (IP) image shows a very bright lesion compatible with hemor-
rhage (arrow). On opposed-phase (OP), the lesion shows strong loss of signal in some 
parts (compatible with fatty contents) and retaining the rim of high signal (open arrow). 
In addition, atrophy of segment IV (IV) was noted in combination with several regenera-
tive nodules and irregular contours of the liver, strongly suggesting cirrhosis. (c) Axial 
gadolinium-enhanced gradient-echo in the arterial image (ART) shows an enhancing 
nodule within the hematoma (arrowhead) as well as diffuse heterogeneous enhance-
ment of almost the entire segment VI (*). On the delayed phase (DEL), washout of 
contrast with irregular enhancement along the portal vein (open arrows) is visible. These 
findings are compatible with a diffuse HCC with portal invasion and a hemorrhage. Pro-
spectively, at CT the signs for cirrhosis were not appreciated and therefore HCC was not 
considered as a possibility. In retrospect, portal vein thrombosis was also present on CT.
383
he
pa
to
ce
llu
la
r a
de
no
m
aR
EV
IE
W
 O
F 
IM
AG
IN
G
 F
IN
D
IN
G
S
chapter3.2
 hepatocellular adenoma  
 and the surrounding liver
 CE, Meyers WC, Baker ME. Hepatic adenoma: MR 
 characteristics and correlation with pathologic 
 findings. AJR Am J Roentgenol 1994; 163:113-116.
30. Arrive L, Flejou JF, Vilgrain V, et al. Hepatic adeno- 
 ma: MR findings in 51 pathology-proven le- 
 sions. Radiology 1994; 193:507-512.
31. Chung KY, Mayo-Smith WW, Saini S, Rahmouni A, 
 Golli M, Mathieu D. Hepatocellular adenoma: MR 
 imaging features with pathologic correlation. AJR 
 Am J Roentgenol 1995; 165:303-308.
32. Mathieu D, Bruneton JN, Drouillard J, Pointreau CC, 
 Vasile N. Hepatic adenomas and focal nodular hy- 
 perplasia: dynamic CT study. Radiology 1986; 
 160:53-58.
33. Hussain SM, Semelka RC. Hepatic imaging: com- 
 parison of modalities. Radiol Clin North Am 2005; 
 43:929-947, ix.
34. Hussain SM, Semelka RC. Liver masses. Magn Re- 
 son Imaging Clin N Am 2005; 13:255-275.
35. Bartolozzi C, Lencioni R, Paolicchi A, Moretti M, 
 Armillotta N, Pinto F. Differentiation of hepatocel- 
 lular adenoma and focal nodular hyperplasia of 
 the liver: comparison of power Doppler imaging 
 and conventional color Doppler sonography. Eur 
 Radiol 1997; 7:1410-1415
36. Bartolotta TV, Midiri M, Quaia E, et al. Benign fo- 
 cal liver lesions: spectrum of findings on Sono- 
 Vue-enhanced pulse-inversion ultrasonography. 
 Eur Radiol 2005; 15:1643-1649.
37. Klein D, Jenett M, Gassel HJ, Sandstede J, Hahn D. 
 Quantitative dynamic contrast-enhanced sonog- 
 raphy of hepatic tumors. Eur Radiol 2004; 14:1082- 
 1091.
38. Mahfouz AE, Hamm B, Taupitz M, Wolf KJ. Hyper- 
 vascular liver lesions: differentiation of focal nodu- 
 lar hyperplasia from malignant tumors with dy- 
 namic gadolinium-enhanced MR imaging. Radiol- 
 ogy 1993; 186:133-138.
39. McFarland EG, Mayo-Smith WW, Saini S, Hahn PF, 
 Goldberg MA, Lee MJ. Hepatic hemangiomas 
 and malignant tumors: improved differentiation 
 with heavily T2-weighted conventional spin-echo 
 MR imaging. Radiology 1994; 193:43-47.
40. Mitchell DG, Saini S, Weinreb J, et al. Hepatic me- 
 tastases and cavernous hemangiomas: distinction 
 with standard- and triple-dose gadoteridol-en- 
 hanced MR imaging. Radiology 1994; 193:49-57.
41. Semelka RC, Martin DR, Balci C, Lance T. Focal 
 liver lesions: comparison of dual-phase CT and 
 multisequence multiplanar MR imaging including 
 dynamic gadolinium enhancement. J Magn Re- 
 son Imaging 2001; 13:397-401.
42. Hussain SM, Terkivatan T, Zondervan PE, et al. Fo- 
 cal nodular hyperplasia: findings at state-of-the- 
 art MR imaging, US, CT, and pathologic analysis. 
 Radiographics 2004; 24:3-17; discussion 18-19.
43. Attal P, Vilgrain V, Brancatelli G, et al. Telangiectatic 
 focal nodular hyperplasia: US, CT, and MR imaging 
 findings with pathologic correlation in 13 
 cases. Radiology 2003; 228:465-472.
403
he
pa
to
ce
llu
la
r a
de
no
m
aH
EP
AT
O
CE
LL
U
LA
R 
AD
EN
O
M
A 
AN
D
 T
H
E 
SU
RR
O
U
N
D
IN
G
 L
IV
ER
413
he
pa
to
ce
llu
la
r a
de
no
m
aa
de
no
m
aH
EP
AT
O
CE
LL
U
LA
R 
AD
EN
O
M
A 
AN
D
 T
H
E 
SU
RR
O
U
N
D
IN
G
 L
IV
ER
MR imaging should be considered as primary tool for 
detection and characterization to avoid radiation ex-
posure11.
 The spectrum of imaging features of HCA lesions has 
been described before. In one study, enhancement 
patterns were evaluated at multiphasic helical CT10. 
Several studies addressed the MR imaging findings12-
14, including enhancement patterns after specific hep-
atobiliary and non-specific contrast administration15-17. 
In one study, imaging and pathologic findings in liver 
adenomatosis were described18. 
To our knowledge, none of the previous imaging 
studies have described the spectrum of HCA findings 
in relation to findings within the surrounding liver 
parenchyma. We hypothesized that tissue changes 
in both liver parenchyma and HCA might be inter-
related, due to similar effects of the causative agent 
(most frequently OC). Therefore, careful analysis of 
size, morphology and signal intensity of liver paren-
chyma in case of HCA could possibly provide further 
understanding in characterization and classification 
of these lesions. In this study, we combined the spec-
trum of imaging findings of pathology-proven HCA 
with morphology and characteristics of the liver pa-
renchyma, at modern MR imaging. To the best of our 
knowledge, this has not been reported before.
The purpose of our study therefore, was to evaluate 
the spectrum of imaging findings of both hepato-
cellular adenoma (HCA) and the surrounding liver at 
state-of-the-art MR imaging.
MATERIALS AND
METHODS
Patients
The study was performed in a large university referral 
hospital for hepatobiliary diseases. Permission of the 
institutional review board (IRB) was not required giv-
en the retrospective nature of the study. The hospital 
archive and pathology registration were searched for 
patients with pathology-proven HCA that underwent 
MR imaging in January 2000 – December 2005. A total 
of fourteen patients were identified, all female, with a 
mean age of 39 years (range 21-52 years) (Table 1). One 
patient was diagnosed with teleangiectatic adenoma 
and was excluded, since recent literature suggests this 
is a different entity19,20. A total of 53 lesions were identi-
fied, with a mean size of 2.45 cm (range 0.8-11 cm).
MR imaging protocol
All MR examinations were performed on a 1.5T unit 
(Philips Medical Systems, Best, The Netherlands or 
General Electrics, Signa, Milwaukee, Wisconsin, USA; 
using identical scan protocols). A four-channel body-
array coil with capability of parallel imaging was used. 
Scan sequences included single-shot fast spin-echo 
(repetition-time msec/ echo-time msec 832/90-120; 
flip-angle 90º), fat-suppressed T2-weighted fast spin-
echo (FSE) (3000/80, flip-angle 90º), diffusion T2-
weighted black-blood echo-planar imaging (BBEPI) 
(shortest/60, flip-angle 90º) and 2D or 3D T1-weight-
ed in- and opposed-phase gradient-echo sequences 
(shortest/4.6 and 2.3 respectively, flip-angle 80º). Af-
ter intravenous administration of a gadolinium-che-
late (28 ml; Magnevist [gadopentetate dimeglumine], 
Schering, Berlin, Germany) at 3 ml/sec using a power 
injector, dynamic imaging with either 2D T1-weighted 
gradient-echo (GRE) (Philips) or 3D T1-weighted fat-
suppressed GRE (General Electrics) sequences in at 
least 4 phases (precontrast, arterial, portal and de-
layed phases) was performed. In each patient, a tim-
ing bolus technique using 2ml of the same contrast 
agent followed by 15ml saline was used to accurately 
capture the arterial phase. The high injection rate of 3 
ml/sec was used to compensate for some signal loss 
due to implementation of parallel imaging. The portal 
phase was acquired approximately at 45 seconds, and 
the delayed phase at least 120 seconds after the ac-
quisition of the arterial phase. A slice thickness of 7mm 
was used in most sequences, except the T1-weighted 
fat-suppressed GRE sequence, in which 4mm slices 
were acquired.
Image analysis
All MR imaging exams were transferred to a picture 
archiving and communication system (PACS) viewing 
station. Evaluation was performed of each single le-
sion. Assessment of the lesions was based on quali-
tative and quantitative parameters. Analysis of all 
lesions was performed by two radiologists with ex-
perience in hepatobiliary imaging in consensus. All 
evaluations were categorized and documented using 
standardized data sheets. 
  Mean age 39 (range 21-52)
  Use of oral contraception 10/13
  Storage disease 1/13
  Amount of lesions 1 2/13 (15.4)
  1-10 7/13 (53.8)
  >10 4/13 (30.8)*
   Surgical resection 9/13
   Percutaneous biopsy 4/13
Table 1: Patient characteristics. 
Data are the number of patients. Data in parenthesis are percentages. 
* Of these four patients, only one patient did not use oral 
contraception.
ABSTRACT
Purpose: To evaluate the spectrum of imaging find-
ings of both hepatocellular adenoma (HCA) and the 
surrounding liver at state-of-the-art MR imaging.
Materials and Methods: MR images of 13 patients (all 
female, mean age 39 years (range 21-52)) with pa-
thology-proven HCA (n=51) were retrospectively as-
sessed for morphologic features of liver and lesions. 
Signal intensity (SI) was determined with calculation 
of contrast-to-noise ratios (CNR). Quantitative analysis 
with percentage enhancement in arterial, portal and 
delayed phases of dynamic multiphasic contrast-en-
hanced imaging was calculated. Histology sections 
were retrieved for analysis.
Results: The mean lesion size was 2.45 cm (range 0.8-
11 cm). Lesion SI was predominantly hyperintense on 
fat-suppressed T2-weighted sequences and isoin-
tense on in-phase T1-weighted GRE, with drop in SI 
on opposed-phase T1-weighted GRE indicating intra-
tumoral fatty infiltration in >70%. Percentages of en-
hancement in liver and lesion respectively was 37, 107 
and 95%; and 120, 151 and 133% (p<0.001). The liver 
showed abnormal segmental shape and size (100%), 
with steatosis (77%). Transient arterial patchy hetero-
geneous enhancement was observed in a diffuse or 
segmental distribution within the liver (92%). Paren-
chymal MRI findings correlated with histopathology 
findings that comprised large portal tracts, inflamma-
tory infiltration and subtle fibrosis.
Conclusion: The results of our study indicate that in 
patients with HCA, both lesions as well as the sur-
rounding liver parenchyma show similar soft tissue 
and vascular abnormalities. 
INTRODUCTION
Hepatocellular adenoma (HCA) is rare1, but the inci-
dence has increased since the introduction of oral 
contraception (OC)2. Detection is important, not only 
because of associated risk of potentially life-threaten-
ing hemorrhage, but also because malignant transfor-
mation may occur3,4. Therefore, although the growth 
pattern is relatively benign, the International Working 
Party classified HCA as neoplastic5. 
Most frequently, HCA occurs in young women, strong-
ly associated with use of OC. Also, HCA has been re-
ported in use of anabolic steroids or in glycogen stor-
age disease1. As has been described by Flejou and 
colleagues (1984), hepatic adenomatosis (more than 
ten adenomas, no association with use of OC) may 
represent a different entity from isolated adenoma6. 
However, no pathologic differentiation can be found 
between isolated adenoma and adenomas in case of 
presumed hepatic adenomatosis7 and therefore, pre-
sumably, both entities are representations of the same 
ongoing disease process8. 
At imaging, HCA may have a heterogeneous appear-
ance, which causes difficulty for diagnosis using ul-
trasound (US) or computed tomography (CT). At US, 
echogenicity of focal liver lesions varies considerably, 
and fewer lesions are detected compared to CT and 
magnetic resonance (MR) imaging9. Although current 
multislice CT scanners are promising for analysis of 
dynamic enhancement patterns10, often, MR imaging 
is performed additionally for further characterization. 
The unique ability of MR imaging to detect intrinsic 
cellular characteristics combined with dynamic con-
trast-enhanced imaging renders it a superior tech-
nique for diagnosis of focal liver lesions1. Especially in 
work-up of focal liver lesions in young fertile women, 
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Pathologic analysis of the sur-
rounding liver
Histopathology sections of select-
ed study patients were retrieved 
and reviewed for abnormalities 
in adjacent liver parenchyma by 
an experienced hepatobiliary pa-
thologist. Histology material was 
available in 10 patients. Qualita-
tive analysis of the following char-
acteristics was performed: 1) fatty 
infiltration; 2) aspect and size of 
vessels; 3) presence of inflamma-
tory cells; 4) presence and thick-
ness of liver plates; 5) variation 
in size of hepatocytes; 6) aspect 
of cytoplasm and size of nucleus 
versus cytoplasm; 7) presence of fibrosis (scaled ac-
cording to the Metavir classification (F0=no fibrosis; 
F1=portal fibrosis without septa; F2=portal fibrosis 
with septa; F3=septal fibrosis without cirrhosis; and 
F4=cirrhosis); 8) presence of hemorrhagic compo-
nents.
Statistical analysis
Statistical parameters (mean, median, standard devia-
tion and range) were calculated using the Statistical 
Package for Social Sciences (SPSS) program. The unit 
of measure was number of lesions, rather than num-
ber of patients. Significance levels were determined 
by the Wilcoxon signed rank test, since some data did 
not have a fully symmetric distribution. A p-value of 
less than 0.05 was considered statistically significant. 
 
RESULTS
Lesion analysis
Imaging findings of hepatocellular adenoma (HCA) 
that were most frequently observed included: 1) isoin-
tensity with surrounding liver on conventional T1- and 
single-shot T2-weighted se-
quences; 2) decrease in sig-
nal intensity of the lesion on 
opposed-phase T1-weighted 
GRE, indicating intratumoral 
fat; 3) hyperintensity on fat-
suppressed T2-weighted FSE; 
4) homogeneous enhance-
ment on arterial phase gado-
linium-enhanced imaging and 5) fading to isointen-
sity with surrounding liver in delayed phase imaging 
(Fig. 1). Detailed findings are described below.
Signal intensity of HCA
Qualitative imaging findings are described in detail 
in Table 2. On T1-weighted imaging, most lesions ap-
peared isointense to the liver on in-phase T1-weight-
ed GRE (82.4%). On opposed-phase T1-weighted GRE, 
within the majority lesions (78%), areas of decreased 
signal intensity were observed indicating intratumor-
al fat. On the other hand, signal intensity of the overall 
lesion compared to the liver was predominantly hy-
  
T1-in phase
(n=53)
T1-op phase
(n=53)
SSFE
(n=53)
T2FSE fatsat
(n=52)
BBEPI
(n=48)
  Markedly hyperintense 1 (2) 17 (33.3) 0 10 (19.6) 28 (54.9)
  Slightly hyperintense 1 (2) 16 (31.4) 21 (41.2) 32 (62.5) 13 (25.5)
  Isointense 42 (82.4) 13 (25.5) 27 (52.9) 6 (11.8) 2 (3.9)
  Slightly hypointense 6 (11.8) 2 (3.9) 2 (3.9) 1 (2) 1 (2)
  Markedly hypointense 1 (2) 3 (5.9) 1 (2) 1 (2) 2 (3.9)
   Not performed - - - 1 (2) 5 (9.8)
Table 2: Signal intensity of hepatocellular adenoma compared to the surrounding 
liver parenchyma.
In-phase T1-weighted gradient-echo (T1-in phase), opposed-phase T1-weighted gradient-echo
(T1-opp phase), single-shot T2-weighted fast spin-echo (SSFSE), fat-suppressed T2-weighted 
fast spin-echo (T2-FSE), diffusion-weighted black-blood echo-planar imaging (BBEPI). 
N: number of included patients. Data are the number of lesions. Data in parenthesis are 
percentage of lesions classified in these categories.
Figure 3: Contrast-to-noise ratio 
(CNR) of T2-weighted sequences, 
showing an increase in CNR of 
single-shot T2-weighted fast spin-
echo (SSFSE) to fat-suppressed 
T2-weighted fast spin-echo (T2-FSE) 
to diffusion-weighted black-blood 
echo-planar imaging (BBEPI). (SSFSE 
from FSE fatsat and BBEPI p<0.0001 
and BBEPI from FSE fatsat p<0.05).
Qualitative assessment
Qualitative assessment of the following characteristics 
was performed: 1) visual assessment of liver size with 
segmental distribution (according to hepatic segment 
numbering system of Couinaud) categorized accord-
ing to enlargement of right or left liver lobe or total 
enlargement; 2) signs of steatosis or cirrhosis (includ-
ing undulating liver surface, hypertrophy of segment 
1, atrophy of segment 4, enlargement of the peri-por-
tal spaces and/or signs of portal hypertension such 
as splenomegaly or presence of collaterals); 3) total 
amount and localization of lesions; 
4) presence of pseudo-capsule (de-
fined as thin capsule composed of 
compressed vessels, slightly hyper-
intense on T2-weighted and slightly 
hypointense on T1-weighted se-
quences), true capsule (thicker, low 
signal intensity on both T1-weight-
ed and T2-weighted sequences), 
intratumoral fat or hemorrhage; 5) 
signal intensity; 6) enhancement 
patterns at dynamic gadolinium-
enhanced imaging. 
Quantitative analysis
For quantitative analysis purposes, 
signal intensity measurements were 
performed using operator-defined 
regions-of-interest (ROI). For lesions, 
the largest possible ROI was se-
lected that excluded hemorrhagic 
areas. For adjacent liver, ROI exclud-
ing vessels and artefacts was used. 
The lesion-to-liver contrast-to-noise 
ratio (CNR) was calculated as differ-
ence in signal intensity (SI) between 
lesion and liver scaled to standard deviation (SD) of 
background noise [(SIlesion-SIliver)/SDnoise]. In dynamic 
gadolinium-enhanced imaging, ROI measurements 
were performed identically in arterial, portal and de-
layed phases. Definition of arterial phase consisted 
of enhancement of hepatic artery and aorta, slight 
enhancement of portal vein, no enhancement of 
hepatic veins and (almost) no enhancement of liver 
parenchyma. Percentages of contrast enhancement 
were calculated as follows: [(SIenhanced - SIunenhanced) / SI-
unenhanced] x 100. Because of artefacts in the lesion area, 
the following lesions were 
excluded: 1 lesion for fat-sup-
pressed T2-weighted FSE and 
2 lesions for T2-weighted BBE-
PI. Because of technical prob-
lems with data acquisition, 3 
other lesions were excluded 
in T2-weighted BBEPI. 
Figure 1: MR imaging findings 
of classic hepatocellular ad-
enoma. (a) Transverse in-phase 
T1-weighted gradient-echo 
shows isointensity of the 
lesion (arrow). (b) Transverse 
opposed-phase T1-weighted 
gradient-echo shows marked 
decrease in signal intensity of 
the lesion, indicating marked 
fatty infiltration (arrow). (c) 
Transverse fat-suppressed 
T2-weighted fast spin-echo 
shows isointensity of the lesion 
(arrow). (d) Transverse arterial 
phase gadolinium-enhanced 
T1-weighted gradient-echo 
shows intense homogeneous 
enhancement of the lesion 
(arrow). (e) Transverse delayed 
phase gadolinium-enhanced 
T1-weighted gradient-echo 
shows the lesion has become 
isointense with the surrounding 
liver (arrow). (f) Photomicro-
graph (hematoxylin and eosin 
(HE) stain, original magnification 
x100) shows accumulation of fat 
within the lesion (*).
Figure 2: Contrast-to-noise ratio 
(CNR) of in-phase T1-weighted gradi-
ent-echo (T1 in-phase) and opposed-
phase T1-weighted gradient-echo (T1 
opp-phase), showing a statistically 
significant increase (p<0.001).
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Dynamic multiphasic gadolinium-enhanced imaging 
of HCA
Quantification of enhancement patterns by means of 
ROI measurements showed percentage increase of 
enhancement in liver parenchyma in arterial, portal 
and venous phases respectively of 37, 107 and 95%; 
in the lesion this was 120, 151 and 133 % (p<0.0001) 
(Fig. 5). This illustrates that HCA shows immediate, in-
tense enhancement in the arterial phase after contrast 
administration, but behaves like the surrounding liver 
tissue in delayed phase imaging.
Secondary characteristics of HCA
A thin pseudocapsule was observed in 15 of 51 le-
sions (29.4%), with mildly higher signal intensity at 
T2-weighted images, isointense to slightly lower sig-
nal intensity at T1-weighted images and enhancing in 
delayed phases after gadolinium (Fig. 6). Intratumoral 
fat was was observed in 40 of 51 lesions (78.4%), dif-
fusely present in 3 lesions (5.9%), heterogeneous in 3 
lesions (5.9%) and focal in 34 lesions (66.7%). Hemor-
rhage associated with the lesion was observed in 6 of 
51 lesions (11.8%). This was diffusely present in 1 lesion 
(2%) and focal in 5 lesions (9.8%). In 1 lesion, the 
hemorrhage extended beyond the lesion, but 
remained intrahepatic (Fig. 6). 
Liver analysis
Most frequently observed findings at MR im-
aging and pathological analysis of the liver 
include: 1) moderate to marked fatty infiltra-
tion of the entire liver with MR-pathology corre-
lation; 2) inhomogeneous arterial enhancement 
of the liver; 3) changes in segmental shape and 
size and 4) vessel malformation, inflammatory in-
filtration and subtle periportal fibrotic changes 
at histology (Fig. 7, 8 and 9). Detailed findings are 
described below.
Liver morphology at MR imaging
Visual assessment of size and shape of the liver was 
performed in 10 patients. The remaining 3 patients 
either underwent partial hepatic surgery previously 
(n=2) or had diffuse hepatic abnormalities because 
of storage disease (n=1). In all 10 patients, abnormal 
segmental size and shape was observed. In 6 of 10 
patients, an enlarged left liver lobe was observed, in 
which the liver partially encircled the spleen in some 
cases (Fig 7a, b). In 3 of 10 patients, an abnormal size 
of the right liver lobe was present (Fig 7c, d). The as-
pect of the liver in these cases, with fatty infiltration, 
enlargement of Couinaud’s segment 6 and 7, in com-
bination with enlargement of segments 5 and 8 made 
co-existence of a Riedel’s lobe less likely. In one pa-
Figure 6: Hepatocellular adenoma with recent hemorrhage 
and a thin pseudocapsule. (a) Transverse in-phase T1-
weighted gradient-echo shows a round area with high signal 
intensity in the left liver lobe (bl), with an adjacent moon-
shaped hepatocellular adenoma (ha) which has isointense 
signal intensity. The HA is surrounded by a thin, hypointense 
pseudocapsule (arrow). (b) Transverse fat-suppressed 
T2-weighted fast spin-echo shows heterogeneous signal 
intensity of this area (bl), consisting of a layered area of low 
signal intensity, an area of higher signal intensity, surrounded 
by a hypointense rim; consistent with an hemorrhage of 
older and more recent date. The hepatocellular adenoma 
(ha) has a slightly hyperintense pseudocapsule (arrow). (c) 
Transverse arterial phase gadolinium-enhanced T1-weighted 
gradient-echo shows the hepatocellular adenoma enhances 
early in the arterial phase (arrow). (d) Transverse delayed 
phase gadolinium-enhanced T1-weighted gradient-echo 
shows the adenoma (ha) has become near isointense with 
the surrounding liver, with delayed enhancement of the 
pseudocapsule (arrow). (e) Macroscopic evaluation of the 
resected adenoma, shows a large lesion, consisting of blood 
(bl) surrounded by a rim of fibrosis (f), and a moon-shaped 
adenoma (ha) which is surrounded by a thin pseudocapsule 
(arrow), confirming the MR findings. (f) Photomicrograph 
(hematoxylin and eosin (HE) stain, original magnification 
x100) shows a transition of a focus of hepatocellular adeno-
ma (ha) into an area of fibrosis (f) and blood (bl), surrounded 
by an inflammatory infiltrate (*). 
perintense (64.7%) due to liver steatosis (Table 
2). On fat-suppressed T2-weighted FSE, most 
lesions (82.1%) were slightly to markedly hyper-
intense (Table 2). 
The quantitative measurements confirmed 
these data. CNR was calculated: for T1-weight-
ed sequences: in-phase T1-weighted GRE -0.5 
and opposed-phase T1-weighted GRE 5.24 
(p<0.0001) (Fig. 2). For T2-weighted sequences 
CNR was: single-shot T2-weighted FSE (SSFSE) 
2.51, fat-suppressed T2-weighted FSE (FSE fatsat) 
5.68 and diffusion-weighted BBEPI 6.6 (Fig. 3). 
These values were significantly different (SSFSE 
from FSE fatsat and BBEPI p<0.0001 and BBEPI 
from FSE fatsat p<0.05)).
Figure 4: Large hepatocellular adenoma, with central 
fibrous tissue. (a) Transverse in-phase T1-weighted gradient-
echo shows slight hyperintensity of a large adenoma, with 
an amorphous area of lower signal intensity in the center 
(arrow). (b) Transverse fat-suppressed T2-weighted fast spin-
echo shows slight hyperintensity of the lesion, with slight 
hypointensity of the centrally oriented structure (arrow). (c) 
Transverse arterial phase gadolinium-enhanced T1-weighted 
gradient-echo shows heterogeneous enhancement of the 
lesion. The central area does not enhance and remains low 
in signal intensity (arrow). (d) Transverse delayed phase 
gadolinium-enhanced fat-suppressed three-dimensional 
T1-weighted gradient-echo shows near isointensity of the le-
sion compared to the liver, with slightly increased enhance-
ment of the central structure (arrow). (e) Macroscopic image 
of the resected adenoma confirms a central amorphous 
area, with signs of fibrosis and recent hemorrhage (arrow). 
(f) Photomicrograph (iron staining, original magnification 
x200) shows enhancement of iron-containing macrophages 
(blue, arrow) and deposition of erythrocytes indicating more 
recent hemorrhage (open arrow).
Figure 5: Percent-
age increase of 
enhancement of 
liver parenchyma and 
the lesion in arterial, 
portal and venous 
phases (p<0.001).
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fading to near isointensity in delayed phase imaging. 
The surrounding liver parenchyma shows co-existing 
abnormalities, including 1) changed segmental dis-
tribution; 2) steatosis and 3) inhomogeneous arterial 
enhancement. These findings confirm our hypothesis 
that an interrelation exists between the tissue chang-
es in both lesions and liver parenchyma in patients 
with HCA. 
These findings are clinically relevant. In our study, 
intratumoral fat was observed in >70% of HCA, 
in correspondence with a recent study in which 
accumulation of fat was described in 35-77%20. 
In contrast, fatty components are observed in 
only a minority of FNH20. On T2-weighted se-
quences, including single-shot T2-weighted FSE, 
fat-suppressed T2-weighted FSE and diffusion-
weighted BBEPI, the lesions appeared increas-
ingly hyperintense. The difference in liver-to-le-
sion contrast of fat-suppressed T2-weighted FSE 
and BBEPI compared to single-shot T2-weighted 
FSE most likely resulted from the fat suppression 
technique with fewer refocusing pulses. Also, in 
comparing single-shot FSE, fat-suppressed FSE and 
BBEPI, magnetic transfer of contrast (MTC) effects de-
crease, which result in improved detection of lesions 
with increased signal intensity compared to the liver, 
since MTC effects lower the liver-to-lesions contrast 
due to saturation of macromolecules21. In considering 
the observed enhancement pattern of HCA, early ho-
mogeneous enhancement was observed in the arte-
Figure 8: Liver abnormalities in hepatocellular adenoma. 
(a) Transverse in-phase T1-weighted gradient-echo shows 
isointensity of the lesions. (b) Transverse opposed-phase 
T1-weighted gradient-echo shows marked decrease in signal 
intensity of the entire liver parenchyma, indicating extensive 
steatosis. Note a hyperintense signal intensity of three 
lesions compared to the surrounding liver (arrows). (c) Trans-
verse fat-suppressed T2-weighted fast spin-echo shows faint 
hyperintensity of the lesions (arrows). (d) Transverse arterial 
phase gadolinium-enhanced T1-weighted gradient-echo 
shows intense homogeneous enhancement of the lesions 
(arrows). (e) Transverse delayed phase gadolinium-enhanced 
three-dimensional T1-weighted gradient-echo shows the 
lesions remain slightly hyperintense compared to the liver 
(arrows) (f) Photomicrograph (hematoxylin and eosin (HE) 
stain, original magnification x100) shows extensive fatty 
infiltration within the hepatocytes, inflammatory infiltration 
(arrow) around the vessels consisting of small-cell lympho-
cytes and scattered macrophages. Note a large periportal 
vessel (*), aligned next to a bile duct (B).
Figure 9: Patchy arterial 
enhancement of the liver in case 
of hepatocellular adenoma 
(the same patient as figure 7). 
(a) Transverse arterial phase gado-
linium-enhanced T1-weighted 
gradient-echo shows patchy 
enhancement of the liver (left 
liver lobe, arrow). Note two 
intensely enhancing lesions in the 
right liver lobe (open arrow). (b) 
Transverse delayed phase gado-
linium-enhanced T1-weighted 
gradient-echo shows the patchy 
enhancement has become near 
isointense. 
tient, total liver enlargement was observed (Fig 7e, f). 
Whilst some segments showed enlargement, at the 
same time, other segment seemed atrophic, even 
with an empty gallbladder fossa at times. Assessment 
of size was performed only visually because the small 
group size would potentially result in unreliable data 
measurements. No signs of cirrhosis were present. 
Signal intensity and dynamic gadolinium-enhanced 
imaging of the liver 
Liver steatosis was observed in 10 of 13 patients (77%), 
graded as marked in 4 of 13 patients (30.8%) and fo-
cal in 6 patients (46.2%) (Fig. 8). In the arterial phase 
of dynamic gadolinium-enhanced imaging, abnormal 
enhancement of the liver parenchyma was observed 
in 12 of 13 patients (92.3%), which consisted of tran-
sient, diffuse or segmental, patchy, heterogeneous 
enhancement of the liver parenchyma (Fig 9). The en-
hancement became homogeneous in the portal and 
delayed phase in all patients. The inhomogeneous 
arterial enhancement is most likely explained by a 
combination of fatty infiltration and vascular malfor-
mation with shunting. 
MR-histopathology correlation of the liver pa-
renchyma
MR imaging findings of the liver parenchyma 
were confirmed at histopathology, which 
showed extensive steatosis of the hepatic stro-
ma in 2 of 10 patients (20%) and moderate ste-
atosis in 7 of 10 patients (70%). Vascular anatomy 
could be assessed in 9 patients, 8 of whom (89%) 
showed abnormally wide portal veins with peri-
portal vessel formation. An inflammatory infil-
trate was observed in 9 of 10 patients, consisting 
of lymphocytes and scattered macrophages (Fig 
8). Arrangement of hepatocytes in layered plates 
was organized in 6 of 10 patients and mildly chaotic in 
2 of 10 patients. Size of the hepatocytes was enlarged 
in 2 of 10 patients, mainly due to presence of exten-
sive large vacuolar fatty infiltration in those cases. The 
size of nuclei and cytoplasm was mildly disturbed 
in one patient, who also had extensive fatty infiltra-
tion. Fibrosis could be assessed in 9 patients, and was 
scaled as F0 in 5 patients, F1 in 3 patients and F2 in 
one patient. 
DISCUSSION
The results of our study show that in patients with 
hepatocellular adenomas (HCA), both lesions as well 
as the surrounding liver parenchyma show similar soft 
tissue and vascular abnormalities. Specific results of 
our study indicate that in patients with HCA, the le-
sions show the following characteristics: 1) accumula-
tion of fat is present in >70% of HCA; 2) signal intensity 
of HCA is predominantly hyperintense on T2-weight-
ed fat-suppressed sequences with high CNR, facilitat-
ing the detection of multiple lesions; 3) enhancement 
of HCA is early and intense in the arterial phase with 
Figure 7: Abnormalities in segmental size and shape in 
three patients with hepatocellular adenoma. (a) Patient 
A; Coronal single-shot T2-weighted fast spin-echo shows 
an abnormally shaped and enlarged left liver lobe (*). (b) 
Patient A; Transverse in-phase T1-weighted gradient-echo 
shows a large left liver lobe, which extends beyond the 
spleen (s) and even partially encircles it (arrow). Note the 
adenoma (a), which is isointense to slightly hypointense 
to the surrounding liver. (c) Patient B; Coronal single-shot 
T2-weighted fast spin-echo shows an enlarged right liver 
lobe, which extends well beyond the right kidney (arrow). 
(d) Patient B; Transverse opposed-phase T1-weighted gradi-
ent-echo shows concavity of the left liver lobe, located in 
Couinaud’s segment 3 (arrow). Note an inhomogeneous 
low signal intensity of the liver, indicating steatosis (in-phase 
T1-weighted gradient-echo not shown). (e) Patient C; 
Coronal single-shot T2-weighted fast spin-echo shows an 
entirely enlarged liver, with abnormal shape and dominant 
Couinaud’s segment 8 (right liver lobe). (f) Patient C; 
Transverse single-shot T2-weighted fast spin-echo shows a 
slight bulging of the left liver lobe (*). Note the hyperintense 
adenoma in the right liver lobe.
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rial phase with fading to isointensity in the delayed 
phase. Other primary liver lesions such as focal nodu-
lar hyperplasia (FNH) and hepatocellular carcinoma 
(HCC) show quite different enhancement patterns. 
FNH enhances more intensely in the arterial phase, 
with delayed enhancement of central scar and septa. 
Large (>5 cm) HCC shows heterogeneous enhance-
ment, with delayed phase washout and capsule en-
hancement. Hemangioma, enhances in a peripheral 
nodular way, to become and remain isointense with 
the liver in delayed phase imaging1. Distinction of 
HCA from FNH in case of multiple primary liver lesions 
in (young) female patients is important, since diagno-
sis of HCA has direct therapeutic consequences. Oral 
contraceptives should be stopped and, more impor-
tantly, pregnancy may be contraindicated in case of 
multiple or larger lesions. In some cases, partial liver 
resection or even liver transplantation is considered22. 
Considering the reported liver abnormalities, previ-
ously, the assessment of abnormalities in liver archi-
tecture has mainly served for evaluation purposes in 
liver cirrhosis. A multitude of abnormalities have been 
described in cirrhosis, including altered volume ratios 
of right-, left and caudate liver lobe23 representing 
both atrophic and hypertrophic reactions, resulting 
from changes in perfusion pattern. In our study, mor-
phologic changes with abnormal segmental shape 
and size were observed in all patients, although path-
ological analysis showed only slight fibrotic changes 
in a few cases. Also, areas of patchy enhancement in 
the arterial phase were observed, most likely related 
to vascular alterations and inflammatory infiltration at 
histology, which has also been described in acute or 
chronic hepatitis24,25. These findings suggest diffuse 
alterations in the liver as part of the ongoing disease 
process in case of HCA, most likely related to oral con-
traception use, coexistence of overweight, pre-exist-
ing liver steatosis and genetic risk factors; but this is 
yet to be defined. 
There are several limitations to our study, including 1) 
relatively small amount of included patients, 2) cre-
ation of an inclusion bias in considering only pathol-
ogy-proven HCA; 3) the retrospective study design 
and 4) absence of a control group of normal liver pa-
renchyma of matched patients that did not use OC 
for the analyses of histology sections. In our opinion, 
the small amount of included patients results directly 
from the ability of MR imaging to differentiate and 
characterize focal liver lesions in a highly accurate way. 
Although percutaneous needle biopsy is still consid-
ered the golden standard, in many centers, diagnostic 
confidence in MR imaging diagnosis has improved at 
such rate that histological proof is not routinely ob-
tained in all cases. Only larger HA (>5 cm), or lesions 
with signs suspect for HCC at imaging will need sur-
gical resection or at least percutaneous biopsy. Even 
though the analysis of liver sections in case of HCA 
is limited, we think the results of this study warrants 
further evaluation of the exact extent and underlying 
pathogenesis of the abnormalities in hepatic stroma 
in case of HCA. This may include further prospective 
studies with more extensive pathologic evaluation of 
the liver, combined with data after intake of oral con-
traceptives have been stopped.
In conclusion, our findings indicate that in patients 
with HCA, abnormalities are observed in both lesions 
and liver; 1) HCA shows intratumoral fat in >70%, hy-
perintense signal intensity on T2-weighted fat-sup-
pressed sequences and early arterial enhancement; 
2) the surrounding liver parenchyma shows changed 
segmental distribution; steatosis and inhomogeneous 
patchy arterial enhancement. These results indicate 
that in patients with HCA, both lesions as well as sur-
rounding liver parenchyma show similar soft tissue 
and vascular abnormalities. 
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mulations of fat on chemical-shift imaging and iron 
on T2*-weighted sequences. Current high spatial and 
temporal resolution of fat-suppressed three-dimen-
sional T1-weighted sequences with thin sections al-
lows superior dynamic contrast-enhanced scanning 
which enables detection of neovascularity in an early 
stage14, without radiation exposure. Tissue specific 
contrast agents, such as super-paramagnetic iron-ox-
ide particles (SPIO), are specifically targeted at Kupffer 
cells and should mainly serve to determine the pri-
mary versus secondary nature of a liver lesion non-
invasively15,16. In addition, diffusion information and 
spectroscopy may facilitate diagnostics in the future17. 
These characteristics make MR imaging an ideal imag-
ing modality for detection and differentiation of focal 
liver lesions. 
Several studies have described the characteristics 
of different cirrhotic nodules at MR imaging. In one 
study, published by Sadek and colleagues in 1995, it 
was demonstrated that lesions with a nodule-within-
a-nodule appearance on T2-weighted images have 
potential for rapid growth18. To our knowledge how-
ever, serial state-of-the-art MR imaging findings of de-
veloping HCC have not been demonstrated in detail 
before. 
The purpose of this paper therefore was to evaluate 
and illustrate the imaging findings of step-wise carci-
nogenesis of hepatocellular carcinoma in cirrhosis at 
sequential state-of-the-art MR imaging.
MATERIALS AND 
METHODS
MR imaging reports of all patients who had under-
gone MR imaging of the liver between January 2000 
and December 2004 were reviewed to identify pa-
tients with sequential exams in the setting of cirrhosis 
or fibrosis. MR imaging data were cross-referenced 
with pathology and laboratory reports from the same 
period. Patients were included if: 1) they had under-
gone sequential MR imaging examinations; 2) they 
had evidence of a suspected lesion or area within pa-
thology-proven cirrhotic or fibrotic liver that showed 
changes over time; and 3) MRI findings could be cor-
related to either AFP or pathology findings. 
Only three patients from a total of 320 patients ful-
filled the inclusion criteria. These patients were all 
male with a range in age of 42 to 59 years (mean 52 
years). A total of 19 (10, 5, 4 respectively) MR examina-
tions were performed in a mean period of 24 months 
(range 14-33).
All examinations were performed at 1.5T (Philips 
Medical Systems, Best, The Netherlands or General 
Electrics, Signa, Milwaukee, Wis; with identical scan 
protocols) using a body-array coil. The standard MR 
imaging protocol in our institution includes single-
shot fast spin-echo (repetition-time msec/ echo-time 
msec 832/90-120; flip-angle 90º), fat-suppressed T2-
weighted fast spin-echo (3000/80, flip-angle 90º), and 
T1-weighted in- and opposed-phase gradient-echo 
Figure 1: In the step-wise transition of RN-DN-HCC, increase in size, increasing cellularity and increasing neovascularity surrounding the
nodules are observed. Enhancement patterns on dynamic gadolinium-enhanced images show increasing arterial enhancement, which
may overlap with previous or next stages in the carcinogenesis.
ABSTRACT
Purpose: To demonstrate imaging findings of step-
wise carcinogenesis of hepatocellular carcinoma 
(HCC) in cirrhosis at serial state-of-the-art MR imaging 
exams.
Material and Methods: In a retrospective search of 
the hospital archives, three patients were identified 
in which developing HCC was observed in serial MR 
examinations, with histopathology or alpha-foeto-
protein (AFP) correlation. Image findings were as-
sessed for signal intensity of the lesions at multiple 
sequences, including dynamic gadolinium-enhanced 
imaging. 
Results: Initial findings in patient A showed a small 
nodule with fatty infiltration, which developed in HCC 
in follow-up MR imaging, comprised of low-grade 
dysplastic nodule (DN), high-grade DN and eventually 
classic HCC. In patient B, increased signal intensity on 
T2-weighted images in a single DN among numerous 
regenerative nodules was the only initial sign. Follow-
up MR imaging showed further increase in signal in-
tensity and increased neovascularity, which suggested 
focal HCC in a high-grade DN. Patient C demonstrated 
gradually increasing neovascularity as only initial sign, 
with development of classic HCC over time.
Conclusion: MR imaging provides insight in various 
pathways of step-wise carcinogenesis of developing 
hepatocellular carcinoma in cirrhosis. This may further 
explain the genetic heterogeneity, and may facilitate 
early detection and better selection of patients for fol-
low-up. 
INTRODUCTION
In cirrhotic livers, HCC typically develops in a step-
wise fashion, which has been described by Sakamoto 
and colleagues in 19911. According to their findings, 
the step-wise carcinogenesis of HCC is based on in-
creasing cellularity and size of the liver lesion. In 1995, 
an International Working Party of Gastroenterology 
proposed a terminology in which dysplastic features 
of the hepatic nodule is expressed2. The currently ac-
cepted nomenclature in step-wise carcinogenesis of 
HCC is regenerative nodule (RN) – low grade dysplas-
tic nodule (DN I)) – high grade dysplastic nodule (DN 
II) – small HCC – large HCC (see Fig. 1)3. 
Early detection of HCC in patients with cirrhosis is im-
portant in improving patient outcome and decision 
making in therapeutic strategies. Observation of the 
patient, regular blood serum analysis of liver function 
and tumor antigens such as alpha-fetoprotein (AFP) 
and follow-up imaging examinations are indicated for 
correct and timely decision-making4. Although AFP 
is not specific for HCC, and can give false-positive re-
sults in hepatitis, fibrosis, and cirrhosis5, it is useful in 
monitoring the disease process in combination with 
imaging results. Currently, treatment of HCC includes 
liver transplantation, segmental liver resection, percu-
taneous minimal invasive therapies, such as radiofre-
quency ablation (RFA), stereotactic radiation therapy6, 
transarterial (chemo)-embolization procedures and 
gene or immune therapies7. 
Accurate detection of small HCC in cirrhosis and dis-
tinction from other hepatocellular nodules may be 
challenging using ultrasound and CT8. Although he-
lical multi-phasic CT is promising for evaluation of 
neo-vasculature in patients with clinically suspect 
disease9,10, it may create diagnostic dilemmas due to 
presence of hemodynamic changes because of portal 
hypertension and extensive structural abnormalities11. 
For early detection of HCC, MR imaging is potentially 
more promising8,12. 
State-of-the-art MR allows better visualization of 
intrinsic contrast characteristics of liver tissue13. Ad-
equate information can be provided on both accu-
Step-wise  
carcinogenesis of 
HEPATOCELLULAR 
CARCINOMA 
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MR imaging findings at 15 months after the initial 
exam: the nodule had increased in size to 15 mm, and 
now showed a clear hypointense signal intensity on 
both in-phase and opposed-phase T1-weighted GRE 
(see Fig. 5a), and subtle hyperintensity on fat-sup-
pressed T2-weighted FSE (see Fig. 5b). At gadolinium-
enhanced imaging, intense arterial phase enhance-
ment was noted in a small nodule within the lesion 
(see Fig. 5c) (nodule-within-a-nodule), with washout 
in the delayed phase (see Fig. 5d). This was compat-
ible with DN II, now with a focus of HCC. Serum AFP 
had risen to 39 µg/ml (see Fig. 2). Meanwhile, the 
patient showed poor compliance with the advice to 
reduce alcohol intake, regular visits to our outpatient 
clinic and regular follow-up MR imaging. Therefore, 
follow-up MRI imaging was only performed after 9 
months. 
MR imaging findings at 25 months after the initial 
exam: the lesion had tripled in size (3 cm). Signal in-
tensity was low on in-phase T1-weighted GRE (see 
Fig. 6a), and markedly hyperintense on fat-suppressed 
T2-weighted FSE (see Fig. 6b). gadolinium-enhanced 
imaging showed intense, homogeneous enhance-
ment in the arterial phase with washout and capsule 
enhancement in the delayed phase (see Fig. 6c-d), 
compatible with a large (>2 cm) HCC. Serum AFP had 
risen to 107 µg/ml (see Fig. 
2). 
Based on the presence of 
a single lesion and pre-
served liver functions, the 
liver tumor board of the 
hospital recommended 
partial liver resection to 
our patient who refused 
to undergo surgical treat-
ment for his condition. Alternatively, to achieve local 
control of the disease and to prevent local dissemi-
nation, ultrasound guided radiofrequency ablation 
therapy was applied. Serum AFP lowered to 33µg/ml 
(see Fig. 2). Currently, follow-up MR examinations are 
performed every 3 months.
Patient B
A 59-year old man with chronic hepatitis B infection 
since 1981 and pathology-proven cirrhosis (Metavir 
F4) since 1992 showed slightly increased liver trans-
aminases as well as AFP (10-15 µg/ml). These values, 
though, had been stable since several years. Routine 
follow-up ultrasound examinations were performed 
every 6 to 12 months since 1987, which showed a 
macro-nodular, inhomogeneous liver. The first MR im-
aging was performed in November 2000 because of 
complaints of pain in the right upper abdomen. 
Initial MR imaging findings (not shown): an impres-
sive macro-nodular liver parenchyma was observed 
with multiple nodular structures. Subcapsular in the 
left liver lobe, a larger nodule was observed with 
slightly higher signal intensity at T2-weighted images 
compared to the surrounding nodules, which was 
considered a possible DN. Apart from this lesion, over 
time, several other areas showed subtle changes in 
Figure 3: Initial MR examination 
in patient A, a 54-year old man 
with hepatitis C – related liver 
fibrosis. (a) In-phase T1-weighted 
gradient-echo shows no lesion 
(b) Transverse opposed-phase T1-
weighted gradient-echo shows 
a small area with decreased 
signal (arrow), most likely within 
a regenerative or low-dysplastic 
nodule. (c) Transverse fat-sup-
pressed T2-weighted fast 
spin-echo shows no abnormali-
ties. (d) Transverse arterial phase 
gadolinium-enhanced fat-sup-
pressed three-dimensional T1-
weighted gradient-echo shows 
slight hypointensity (arrow), most 
likely due to a combination of 
less enhancement and effect 
of the fat suppression pulse.
(shortest/4.6 and 2.3 respectively, flip-angle 80º) se-
quences. Dynamic contrast-enhanced exams were 
performed either with two-dimensional T1-weighted 
gradient-echo (126/shortest, flip angle 90º) or three-
dimensional T1-weighted fat-suppressed gradient-
echo (shortest/shortest, flip angle 15º), in at least 4 
phases using 0.1 mmol/kg of non-liver specific gad-
olinium-chelate (Magnevist [gadopentetate-dime-
glumine], Schering, Berlin, Germany). The MR imag-
ing exams were transported digitally using a picture 
archiving and communication system to a viewing 
station. Analysis of the liver lesions was performed 
by two radiologists in consensus for the following 
items: 1) detection of focal liver lesions, 2) signal in-
tensity at various T1- and T2-weighted sequences, 3) 
characterization of enhancement patterns at dynamic 
gadolinium-enhanced imaging, and 4) description of 
morphology of both liver and lesion in combination 
with growth pattern of the lesion.
RESULTS
Patient A
A 54-year old man with chronic hepatitis C infection 
since 1974 and long-term alcoholism was referred to 
our department for follow-up MR imaging. At physical 
examination no abnormalities were observed. Patho-
logical evaluation of a percutaneous needle biopsy 
in 2000 showed liver fibrosis without septa (Metavir 
F319). Ultrasound imaging revealed a small (5 mm) 
hypoechogenic nodule in the left liver lobe, which 
was subsequently evaluated with CT. This confirmed 
a small hypodense nodule without any enhancement 
in the arterial and portovenous phases after contrast 
administration. For further characterization and evalu-
ation, the patient was referred for MR imaging. In the 
following section, the findings at various follow-up 
MR imaging exams will be described and correlated 
to the AFP level (see Fig. 2).
Initial MR imaging findings: On in-phase T1-weight-
ed gradient-echo (GRE) (see Fig. 3a), no lesions were 
detected, whereas on opposed-phase GRE (see Fig. 
3b), a small area of 7 mm in diameter was visible with 
decreased signal intensity compared to the surround-
ing liver, indicating a fat-containing area, most likely 
within a nodule. Fat-suppressed T2-weighted fast 
spin-echo (FSE) showed no abnormalities (see Fig. 
3c). In the arterial phase of gadolinium-enhanced T1-
weighted gradient-echo (GRE) (see Fig. 3d), slightly 
less intense enhancement was noted, most likely due 
to a combination of less enhancement and focal ac-
cumulation of fat. These findings were interpreted as 
a local area with fat infiltration or a RN/DN I with fatty 
infiltration. Follow-up MRI imaging was recommend-
ed in 6 months. AFP was 14 µg/ml (normal range < 7 
µg/ml) (see Fig. 2). Because of poor patient compli-
ance, the follow-up MR imaging was performed only 
after one year. 
MR imaging findings at 12 months after the initial 
exam: on in-phase T1-weighted GRE still no nodule 
was visible (not shown). Opposed-phase T1-weighted 
GRE (see Fig. 4a) showed an increase in size (10 mm). 
Fat-suppressed T2-weighted FSE now demonstrated 
a subtle hyperintensity in the area (see Fig. 4b). In 
arterial phase gadolinium-enhanced T1-weighted 
GRE, the nodule was now 
isointense with the liver, 
possibly because of increas-
ing enhancement of the 
lesion (see Fig. 4c). In the 
delayed phase of the same 
sequence, the nodule was 
slightly hypointense (see 
Fig. 4d), most likely due to 
a combination of local accumulation of fat and some 
washout. Serum AFP was about twice as high at 26µg/
ml (see Fig. 2). The lesion was classified as possible DN 
II without clear evidence of HCC.
Figure 2:  Alpha-fetoprotein (AFP) 
level (range < 7 µg/ml) relative to 
performed MRI exams in patient A; 
(a) initial MRI (see Fig. 3); (b) MRI at 
12 months after initial exam (see 
Fig. 4);  (c) MRI at 15 months after 
initial exam (Fig. 5); (d) MRI at 25 
months after initial exam (Fig. 6); 
(e) radiofrequency ablation (RFA).
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signal intensity of the nodules over time, which was 
interpreted as multiple RN with high risk of dysplastic 
transformation, for which short-term follow-up exam-
inations were advised and performed. Mainly based 
on the MR imaging findings and expected high risk 
of malignant transformation, the liver tumor board 
decided on admission to the national liver-transplant 
waiting list.
The last MR examination, performed 2 months prior 
to liver transplantation, showed the above described 
multiple nodular structures, slightly hyperintense on 
opposed-phase T1-weighted GRE (see Fig. 7a) and 
slightly hypointense on T2-weighted imaging (see Fig. 
7b). The dominant, subcapsular nodule now showed a 
heterogeneous high signal intensity in fat-suppressed 
T2-weighted FSE (see Fig. 7b), which had increased 
slightly compared to the previous exam (not shown). 
At gadolinium-enhanced arterial phase imaging, sub-
tle nodular enhancement was now observed in the 
periphery of the lesion (see Fig. 7c) whilst the remain-
der of the nodule enhanced in a fashion similar to the 
other nodules, although better visible in the delayed 
phase (see Fig. 7d). 
Because of this new finding, this DN was now clas-
sified as possibly having a small focus of HCC. After 
liver transplantation, macroscopic examination of 
the explant liver specimen confirmed the diffusely 
macronodular liver parenchyma, with the dominant 
nodule subcapsular in left liver lobe (see Fig. 7e). Pho-
tomicrograph (original magnification x100) showed 
a transition of almost normal appearing hepatocytes 
into a focus of HCC, in which crowding of small nu-
clei and small cell dysplasia in combination with more 
than three-cells thick plates and very small vessels was 
observed (see Fig 7f).
Patient C
A 42-year old man with a chronic hepatitis B infection 
since 1985 and pathology-proven cirrhosis (Metavir 
F4) in 1997 was referred to our department for diag-
nostic imaging. Clinical examination showed no ab-
normalities. Liver function 
was normal; AFP was 44 
µg/ml and stable at this 
level since 3 years. Initial 
routine ultrasound exami-
nation showed a small in-
homogeneous liver with 
irregular borders. Detec-
tion of lesions was techni-
cally unreliable, for which patient was referred for MR 
imaging in 2003. 
Initial MR imaging findings: both T1-weighted and 
T2-weighted images (see Fig. 8a) did not show any 
distinct nodules. Dynamic imaging in the arterial 
phase revealed a small area (7 mm) with increased 
arterial enhancement (see Fig. 8b). In delayed phase 
Figure 6:  MR imaging find-
ings at 25 months after the 
initial exam in patient A. (a) 
Transverse in-phase T1-weighted 
gradient-echo shows the nodule 
has tripled in size (3 cm). (b) 
Transverse fat-suppressed T2-
weighted fast spin-echo shows 
a clear, markedly high signal 
intensity. (c) Transverse arterial 
phase gadolinium-enhanced fat-
suppressed three-dimensional 
T1-weighted gradient-echo 
shows clear intense enhance-
ment of the entire lesion. (d) 
Transverse delayed phase gado-
linium-enhanced fat-suppressed 
three-dimensional T1-weighted 
gradient-echo shows washout of 
contrast material and capsule-en-
hancement. The combination of 
the findings is compatible with a 
classic hepatocellular carcinoma.
Figure 4:  MR imaging findings 
at 12 months after initial exam 
in patient A. (a) Transverse 
opposed-phase T1-weighted 
gradient-echo shows increase 
in size of the nodule (arrow). (b) 
Transverse fat-suppressed T2-
weighted fast spin-echo shows a 
subtle increase in signal intensity 
(arrow). (c) Transverse arterial 
phase gadolinium-enhanced fat-
suppressed three-dimensional 
T1-weighted gradient-echo 
shows near isointensity of the 
nodule, indicating increas-
ing arterial enhancement. (d) 
Transverse delayed phase gado-
linium-enhanced fat-suppressed 
three-dimensional T1-weighted 
gradient-echo shows the nodule 
appears hypointense compared 
to the liver (arrow), probably 
due to a combination of some 
washout and fatty content.
Figure 5:  MR imaging findings 
at 15 months after the initial 
exam in patient A. (a) Transverse 
opposed-phase T1-weighted 
gradient-echo shows the nodule 
has further increased in size 
(arrow). (b) Transverse fat-sup-
pressed T2-weighted fast spin-
echo shows a larger area with 
subtle increase in signal intensity 
(arrow). (c) Transverse arterial 
phase gadolinium-enhanced 
fat-suppressed three-dimen-
sional T1-weighted gradient-
echo shows a smaller enhancing 
nodule (arrow) within the larger
nodule (nodule-within-a-nodule 
appearance). (d) Transverse 
delayed phase gadolinium-
enhanced fat-suppressed 
three-dimensional T1-weighted 
gradient-echo shows the nodule 
becomes much more hypoin-
tense, due to clear washout 
of contrast material (arrow). 
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Fig. 9c) and subtle washout in the delayed phase (see 
Fig. 9d), suspicious for a small HCC. AFP was stable at 
44 µg/ml. Based on these MR imaging findings, long-
standing liver disease and clinical condition, the pa-
tient was placed on the national waiting list for liver 
transplantation. 
MR imaging at 9 months after the initial exam: the le-
sion had doubled in size (9 to 23 mm), with identical 
signal intensity on T1- and T2-weighted images. In ar-
terial phase gadolinium-enhanced T1-weighted GRE 
an intense enhancement was observed in the arte-
rial phase (see Fig. 10a), with washout in the delayed 
phase. In addition, a second lesion was observed 
in the left liver lobe, with similar characteristics and 
strong, homogenous enhancement in the arterial 
phase of dynamic imaging (see Fig. 10b), suspicious 
for a second localization of HCC. AFP had risen to 56 
µg/ml.
MR imaging at 13 months after the initial exam: both 
lesions had further increased in size (not shown). Be-
cause of a rapidly growing HCC and taking a waiting-
list for liver transplantation into consideration, patient 
underwent a living-related liver-transplantation 4 
months after the last MR examination, at which both 
lesions were proved to be a HCC. Macroscopic evalu-
ation of the cirrhotic liver confirmed the two lesions, 
which had both increased in size. (see Fig 10c). Micro-
scopic evaluation confirmed the diagnosis of HCC (see 
Fig. 10d). Specific endothelial staining (CD34) showed 
striking vascularity within the tumor (see Fig 10e).
DISCUSSION
This paper describes detailed imaging findings of 
developing hepatocellular carcinoma in cirrhosis at 
sequential MR imaging in three patients. State-of-
the-art MR imaging displayed a spectrum of findings 
in the initial detection of developing HCC, including 
1) localized fatty infiltra-
tion within a developing 
dysplastic nodule that 
gradually evolved into 
HCC in combination with 
a slowly increasing AFP; 2) 
development of a focus 
of pathology-proven HCC 
with high signal intensity 
at T2-weighted imaging 
in a dysplastic nodule; 3) 
prominent neovasculature 
as the initial sign of developing, fast growing HCC, 
confirmed pathologically after liver explantation. 
These findings provide evidence in support of the 
proposed step-wise carcinogenesis in HCC in vivo. 
Such findings are clinically significant and can be used 
for early detection of HCC, which may allow improved 
patient selection for close follow-up MR imaging. Also, 
the heterogeneity of MR imaging findings suggests 
that development of HCC may consist of a number of 
different genetic pathways, eventually leading to the 
Figure 9:  MR imaging find-
ings at 3 months after the 
initial exam in patient C. (a) 
Transverse opposed-phase T1-
weighted gradient-echo shows 
a hypointense nodule (arrow). 
(b) Transverse fat-suppressed 
T2-weighted fast spin-echo shows 
subtle increase in signal intensity 
(arrow). (c) Transverse arterial 
phase gadolinium-enhanced 
two-dimensional T1-weighted 
gradient-echo shows intense, 
increased enhancement of the 
nodule (arrow). (d) Transverse por-
tal phase gadolinium-enhanced 
two-dimensional T1-weighted 
gradient-echo shows subtle 
washout of contrast material in at 
least a part of the nodule (arrow).
imaging, no washout of contrast medium was visible. 
This small enhancing area, in the absence of other 
findings such as high signal intensity in T2-weighted 
images or washout was interpreted as a possible vas-
cular shunt, or an early enhancing lesion. Follow-up 
MR was recommended to exclude the possibility of a 
developing small HCC.
MR imaging at 3 months after the initial exam: the 
enhancing area had increased in size (14 mm), and 
now showed a nodular configuration. Signal intensity 
was low on opposed-phase T1-weighted GRE (see Fig. 
9a) and high on fat-suppressed T2-weighted FSE (see 
Fig. 9b). Dynamic gadolinium-enhanced T1-weighted 
GRE showed an intense arterial enhancement (see 
Figure 7:  MR imaging findings in patient B, a 59-year 
old man with hepatitis B – related liver cirrhosis. (a) 
Transverse opposed-phase T1-weighted gradient-echo 
shows a frankly macronodular liver with multiple nodular 
structures. In the left lobe, a slightly larger and eccentric 
subcapsular nodule is present, with slightly lower 
signal intensity (arrow). (b) Transverse fat-suppressed 
T2-weighted fast spin-echo shows subtle hyperinten-
sity within the dominant nodule (arrow). (c) Transverse 
arterial phase gadolinium-enhanced two-dimensional 
T1-weighted gradient-echo shows a subtle focus of 
enhancement within the nodule (arrow). (d) Transverse 
delayed phase gadolinium-enhanced two-dimensional 
T1-weighted gradient-echo shows that the nodule is 
surrounded by prominent septal enhancement (arrow). 
(e) Explant liver specimen with cross sections at two 
levels shows impressive macronodular cirrhosis, with the 
dominant nodule subcapsular in the left liver lobe (arrow) 
confirming the MRI findings. (f) Photomicrograph (hema-
toxylin and eosin (HE) stain, original magnification x100) 
shows a detailed view from an area within the dominant 
nodule with clear transition between almost normal 
appearing hepatocytes (L) into a focus of hepa-
tocellular carcinoma (T), which is characterized 
by 1) crowding of small nuclei; 2) small cell 
dysplasia in combination with more than three-
cells thick plates and 3) very small vessels.
Figure 8:  MR imaging findings 
in patient C, a 42-year old man 
with hepatitis B – related liver 
cirrhosis. (a) Transverse fat-sup-
pressed T2-weighted fast spin-
echo shows no abnormalities. (b 
Transverse arterial phase gado-
linium-enhanced two-dimen-
sional T1-weighted gradient-echo 
shows a small, early enhancing 
area in the right liver lobe (arrow).
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findings suggest that MR imaging should be regarded 
as primary imaging tool in the work-up and follow-up 
of patients with liver cirrhosis at high risk for develop-
ment of HCC. Currently, clinical surveillance for early 
detection of HCC is typically performed by follow-up 
clinical examinations, monitoring of serum liver func-
tions and ultrasound examination every six months, 
as recommended by the European Association for the 
Study of the Liver (EASL, 2000)4. Ultrasound is con-
sidered an inexpensive and accessible modality, but 
the reported sensitivity and specificity for detection 
of focal lesions in the liver is low8 and there is signifi-
cant interobserver variability. Multi-detector (MD) CT 
is improving rapidly for detection purposes of espe-
cially larger (> 1cm) lesions23-25 when compared to 
contrast-enhanced MR imaging. However, when ana-
lyzing comparative studies for CT and dynamic con-
trast-enhanced MR imaging using a non-liver specific 
contrast agent only, higher sensitivities are reported 
for MR imaging12,23. Understanding of the step-wise 
carcinogenesis in HCC at MR imaging and applying 
it at follow-up MR imaging every three to six months 
in identified high-risk patients, may aid in timely di-
agnosis of developing HCC and therapeutic measures 
in an early stage. Third, in analyzing the image char-
acteristics of developing HCC in the three presented 
patients, we observed a difference in presentation of 
the malignancy which may possibly reflect the poly-
genic predisposition for carcinogenesis in cirrhosis 
which has been described by several authors26-28. This 
observation may warrant further study for correlation 
of MR imaging findings to the genetic changes found 
in HCC.
Previously, several studies have described the imag-
ing features of step-wise carcinogenesis of HCC at MR 
imaging16,29-34. In 1995, Sadek and colleagues evaluated 
the imaging findings and growth rate of lesions that 
presented with a nodule-within-a-nodule appearance 
with high signal intensity on T2-weighted images18. 
More recently, Taouli and colleagues have described 
imaging findings and enhancement patterns of cir-
rhotic nodules and HCC in several patients35. Yeong 
and colleagues described imaging features of cirrhot-
ic nodules, with emphasis on enhancement patterns 
of RN, DN and HCC respectively, which show a gradual 
change of normal, portovenous- to early arterial en-
hancement32. The findings on individual MRI exams in 
our study confirm the observations of these previous 
investigators. In addition to these studies, however, 
our study clearly demonstrates the serial changes in 
various cirrhotic nodules, which eventually lead to full 
blown HCC. To our knowledge, this is the first descrip-
tion of findings in developing HCC on serial state-of-
the-art MR imaging. 
Our study is limited by the small amount of presented 
patients. However, this also reflects the situation in the 
clinical practice, in which: 1) MRI is often not applied 
as the primary exam and follow-up is performed with 
various imaging modalities which do not provide re-
liable correlation; 2) at our hospital, early detected 
HCC lesions are often treated as soon as possible; 3) 
pathological analysis of lesions may sometimes not 
be possible due to location and size of the lesion; 4) 
detection of HCC at MR imaging in very early stages of 
development may be hampered by unfamiliarity with 
imaging features and characteristics of developing 
HCC. More studies are needed with a larger number 
of patients for better understanding and identifica-
tion of additional characteristics of developing HCC 
at MR imaging.
In conclusion, state-of-the-art MR imaging provides 
insight in various pathways of step-wise carcinogen-
esis of developing hepatocellular carcinoma in cir-
rhosis, which may facilitate early detection, improve 
patient outcome, provide better identification of pa-
tients for follow-up and further explain the genetic 
heterogeneity of hepatocellular carcinoma. 
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tient compliance allowed detailed MR documentation 
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ed with steadily increasing AFP. In patient B, develop-
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plantation was offered at an early stage, because of 
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inent neovasculature as an initial find-
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with identical characteristics had de-
veloped in the contralateral liver lobe. 
Both lesions were proved to be a HCC 
after pathological examination of the 
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The findings of our study may have a 
number of implications in consider-
ing clinical management of cirrhosis 
and HCC. First, although the incidence of HCC has 
increased in recent years, potentially curative surgical 
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well. (b) Transverse arterial phase gadolinium-
enhanced two-dimensional T1-weighted gradi-
ent-echo shows that in addition, a second nodule 
has appeared (arrow) with striking similarity in 
appearance and enhancement (other sequences 
not shown). (c) Explant liver specimen (8 months 
later) shows a cirrhotic liver and confirms the two 
lesions observed at MR imaging which have fur-
ther increased in size. Note also a satellite nodule 
in approximity of the larger nodule (open arrow). 
(d) Photomicrograph (hematoxylin and eosin 
(HE) stain, original maginification x100) shows 
hepatocellular carcinoma within a cirrhotic liver. 
(e) Photomicrograph (stained with endothelial 
marker CD34, x100) shows numerous arterial 
vessels with stained endothelial linings indicating 
extensive neovascularity inside the tumor.
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1) intrinsic soft tissue contrast; 2) different intracellular 
components, including accumulation of iron and fat; 
and 3) enhancement patterns on dynamic gadolini-
um-enhanced imaging; which renders MR imaging a 
superior technique for detection and characterization 
of primary liver tumors6,10. 
During the recent years, faster MR imaging protocols 
have become available which have further improved 
confident diagnosis of focal liver lesions1. In such 
protocols, sequences have been developed which 
make use of multiple refocusing pulses and/or par-
allel imaging11. Application of multiple refocusing 
pulses however, may result in increased magnetic-
transfer-contrast (MTC) effects, which may alter signal 
behavior of lesions and lower lesion-to-liver contrast. 
Particularly on (fast spin-echo (FSE)) T2-weighted se-
quences, which are important for characterization of 
cirrhotic nodules, malignant lesions may not present 
with the characteristic high signal intensity11. Parallel 
imaging techniques have enabled faster acquisition 
of T1-weighted dynamic contrast-enhanced images, 
with improved visualization of distinct enhancement 
phases and -patterns. This provided improved visual-
ization of particularly smaller nodules. 
Eventually, these sequences may have influenced the 
assessment of classical MR imaging findings in cir-
rhotic nodules. Classically, the MR imaging features of 
HCC included high signal intensity on (conventional) 
T2-weighted sequences12,13, arterial enhancement, and 
washout with capsular enhancement in the delayed 
phase6,13. However, based on our own experience as 
well as observations of others13, MR imaging features 
of especially smaller HCC may be more variable on 
currently used T2-weighted FSE and dynamic gado-
linium-enhanced sequences. 
To further evaluate these observations, we designed 
a single-center retrospective study to systematically 
assess MR imaging findings of histologically proven 
HCC, based on current MR imaging sequences. To the 
best of our knowledge, this has not been reported 
before. 
The purpose of this study therefore, was to assess the 
relationship between lesion size and MR imaging find-
ings of pathology-proven hepatocellular carcinoma. 
MATERIALS & 
METHODS
Patient population
The institutional review board (IRB) granted permis-
sion for this retrospective cohort study, which was 
performed in a large university referral hospital for 
hepatobiliary diseases. The hospital archive system 
and pathology registration were searched for patients 
with pathology-proven HCC following surgical partial 
liver resection or liver transplantation; and preopera-
tive MR imaging in January 1999 – December 2004. A 
total of 37 patients was identified, with 47 pathology-
proven HCC. The patient group (Table 1) consisted of 
11 female and 27 male patients, with a mean age of 
50.8 years (range 23-76 years). 
MR imaging technique
All MR examinations were performed on a 1.5T unit 
(Philips Medical Systems, Best, The Netherlands or 
General Electrics, Signa, Milwaukee, Wisconsin, USA; 
using identical scan protocols). A four-channel body-
array coil with capability of parallel imaging was 
used. Scan sequences included single-shot fast spin-
echo (SSFSE) (repetition-time (TR) msec/ echo-time 
(TE) msec 832/80; flip-angle 90º), respiratory-gated 
fat-suppressed T2-weighted fast spin-echo (FSE) 
(3000/80, flip-angle 90º), and T1-weighted in- and op-
posed-phase gradient-echo sequences (shortest/4.6 
and 2.3 respectively, flip-angle 90º). After intravenous 
administration of a gadolinium-chelate (28 ml; Magn-
evist [gadopentetate dimeglumine], Schering, Berlin, 
Germany) at 3 ml/sec using a power injector, dynamic 
imaging with either 2D T1-weighted gradient-echo 
(GRE) (Philips) or 3D T1-weighted fat-suppressed GRE 
(General Electrics) sequences in at least 4 phases 
(precontrast, arterial, portal and delayed phases) was 
performed. In each patient, a timing bolus technique 
using 2ml of the same contrast agent followed by 
15ml saline was used to accurately capture the arterial 
phase. The high injection rate was used to compen-
sate for some signal loss due to implementation of 
parallel imaging. The portal phase was acquired ap-
proximately at 45 seconds, and the delayed phase at 
least 120 seconds after the acquisition of the arterial 
phase. A slice thickness of 7mm was used in most se-
quences, except the T1-weighted fat-suppressed GRE 
sequence, in which 4mm slices were acquired.
Image analysis
All MR imaging exams were transferred to a picture 
archiving and communication system (PACS) viewing 
Table 1
Underlying liver disease, expressed in number of patients compared 
to the total group (37 patients). Data in parenthesis are percentages.
Multiple etiologies existed in 9 patients: *2 with co-existing hepatitis
C, **6 with co-existing hepatitis B, and † 1 with chronic alcohol
abuse.
  Hepatitis B infection 14/37* (41%)
  Hepatitis C infection 10/37** (27%)
  Chronic alcohol abuse 1/37† (3%)
  Biliary atresia 1/37 (3%)
  Non-cirrhotic liver disease 11/37 (30%)ABSTRACT
Purpose: To assess the relationship between lesion 
size and MR imaging findings of pathology-proven 
hepatocellular carcinoma (HCC). 
Materials and Methods: In a retrospective, single-
center study, a cohort of 37 consecutive patients 
was identified between 1999-2005, that underwent 
both pre-operative MR imaging and surgical resec-
tion of HCC. A total of 47 lesions (mean size 6.85 cm 
(range 1-25 cm)) was assessed both qualitatively and 
quantitatively for signal intensity (SI), enhancement 
patterns and secondary morphologic features. In-
terobserver rating for the qualitative assessment, per-
centages of enhancement and contrast-to-noise-ratio 
(CNR) were determined. Lesions were assessed for com-
binations of T2-weighted signal, arterial and delayed 
phase enhancement patterns. Regression analysis 
was used to assess relations between MR imaging 
findings and tumor size.
Results: On fat-suppressed T2-weighted fast spin- 
echo, smaller lesions had significantly lower SI com-
pared to larger lesions, which were more frequently 
hyperintense (p<0.05). In the arterial phase, smaller 
lesions showed significantly higher percentage en-
hancement compared to larger lesions (p<0.05). In 
the delayed phase, smaller lesions showed less pro-
nounced washout (qualitative assessment, p<0.05). 
Heterogeneity of the lesions, including fatty infiltra-
tion, internal nodules or mosaic pattern, was ob-
served significantly more frequently in larger lesions 
(p<0.001). The classic combination of high T2-weight-
ed signal, strong arterial enhancement and delayed 
phase washout was present in 23/44 lesions (52%).  
Conclusion: Smaller HCC often showed lower signal 
intensity on T2-weighted, more intense arterial en-
hancement, and less pronounced delayed washout 
compared to larger HCC. Therefore, small liver lesions 
in the setting of liver cirrhosis need to be evaluated 
with caution.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common 
primary hepatocellular malignancy1. The incidence is 
highest in patients with hepatitis B or C related cirrho-
sis and cirrhosis related to alcohol abuse, metabolic 
liver diseases and others2-4. In cirrhosis, HCC develops 
in a step-wise fashion5. In this sequence, a regenera-
tive nodule (RN) develops in low grade dysplastic 
nodule (DN I)) – high grade dysplastic nodule (DN II) 
– small HCC – large HCC, respectively6. Although HCC 
in a non-cirrhotic liver develops in a de-novo fashion, 
histologically, it is indistinguishable from HCC occur-
ring in cirrhosis6.
In many centers, state-of-the-art MR imaging is re-
garded the modality of choice for diagnostic work-up 
of primary liver tumors7,8. Even though multiphasic 
multidetector computed tomography (CT) is an excel-
lent modality for imaging of hepatic vasculature and 
assessment of neovasculature surrounding suspect 
liver nodules, characterization of especially smaller le-
sions remains challenging9. 
Current routinely used MR imaging protocols con-
tain a combination of breath-hold T2-weighted se-
quences, chemical shift imaging, and multi-phasic 
gadolinium-enhanced T1-weighted imaging. This 
provides consistent and reproducible information on 
MR imaging of 
hepatocellular 
carcinoma:
RELATIONSHIP 
BETWEEN LESION 
SIZE AND IMAGING 
FINDINGS, 
Indra C. van den Bos, MD1, Shahid M. Hussain, MD, PhD1,2, Roy 
S. Dwarkasing, MD1, Wim C.J. Hop, Msc, PhD3,  Pieter E. Zonder-
van, MD4,  Robert A. de Man, MD, PhD5, Jan N.M. IJzermans, MD, 
PhD6, Craig W. Walker, MD2, Gabriel P. Krestin, MD, PhD1
Departments of 1Radiology, 3Epidemiology and Biostatistics, 
4Pathologie, 5Gastroenterology and Hepatology and 6Surgery, 
Erasmus MC, University Medical Center Rotterdam, The Neth-
erlands; 2Department of Radiology, University of Nebraska 
Medical Center, Omaha, NE, USA
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including signal intensity and dynamic enhancement 
patterns
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aging, expressed as signal intensity of the lesion com-
pared to the surrounding liver (graded as: 1=markedly 
lower, 2=slightly lower, 3=similar to liver, 4=slightly 
higher, 5=markedly higher); 3) presence of capsule; 
4) fatty infiltration, hemorrhage or central scar within 
the lesion; 5) presence of heterogeneity within lesion, 
defined as multiple nodular structures or mosaic pat-
tern with varying signal intensity. 
For an assessment of different combinations of T2-
weighted signal intensity, arterial enhancement and 
delayed phase washout, four different types of en-
hancement were determined based on presence or 
absence of arterial phase enhancement and delayed 
phase washout, namely: I -strong arterial enhance-
ment with minimal delayed phase washout; II - strong 
arterial enhancement with clear delayed phase wash-
out; III - slight, heterogeneous arterial enhancement 
with clear delayed phase washout, and IV – slight, 
heterogeneous arterial enhancement with minimal 
delayed phase washout.
Quantitative assessment
The quantitative assessment included measurements 
of signal intensity, using operator-defined regions-of-
interest (ROI). For the lesions, the largest possible ROI 
was selected that excluded areas of intra-tumoral fat 
or hemorrhage. For the liver adjacent to the tumor, 
a ROI that excluded vessels and artifacts was used. 
CNR was calculated as difference in signal intensity 
between lesion and liver, scaled to SD of background 
noise. In dynamic gadolinium-enhanced imaging, 
measurements using ROI were 
performed identically in arteri-
al, portal and delayed phases. 
Definition of the arterial phase 
consisted of enhancement of 
hepatic artery and aorta; no 
enhancement of hepatic veins 
and (almost) no enhance-
ment of the liver parenchyma. 
Percentages of contrast en-
hancement were calculated 
as follows: [(SIenhanced - SI-
unenhanced) / SIunenhanced] 
x 100 (SI=signal intensity). 
Correlation between tumor 
size and MR imaging findings 
was assessed for all itinerar-
ies described. Smaller lesions 
are considered <2 cm, whilst 
larger lesions are considered 
>2 cm, in consensus with the 
guidelines of the International 
Working Party for hepatocellu-
lar nodules14. 
Statistical analysis
Statistical parameters (mean, median, standard devia-
tion and range) were calculated using the Statistical 
Package for Social Sciences (SPSS 11.0) program. To 
assess the interobserver agreement for the qualitative 
analysis, к statistic for multiple observers was calculat-
ed. A к value of less than 0.200 indicated positive but 
poor agreement; 0.210 - 0.400, fair agreement; 0.410 
– 0.600, moderate agreement; 0.610 – 0.800, good 
agreement; and greater than 0.810, excellent agree-
ment. Data were analyzed taking account of intra- and 
inter-patient differences, using mixed model ANOVA 
(SAS PROC MIXED; version 8.2, SAS Institute Inc., Cary, 
NC, USA). Tumor size was logarithmically transformed 
to reduce the influence of outlying observations. A 
p-value of less than 0.05 was considered statistically 
significant.
RESULTS
The mean size of all assessed lesions was 6.85 cm 
(range 1-25). The interobserver agreement for the 
qualitative assessment, expressed as к score, was 0.68 
(good) for in-phase T1-weighted GRE, 0.78 (good) for 
fat-suppressed T2-weighted FSE, 0.89 (excellent) for 
arterial phase T1-weighted GRE and 0.86 (excellent) 
for delayed phase T1-weighted GRE respectively. The 
consensus reading was used for the correlation be-
tween signal intensity and tumor size.  
Figure 3: Subjective signal intensity of HCC on fat-suppressed T2w FSE, in relation to tumor size, 
showing a significant increase for larger lesions (p<0.05) (graded as: 1=markedly hypointense, 
2=slightly hypointense, 3=isointense, 4=slightly hyperintense, 5=markedly hyperintense).
station. Evaluation was performed on basis of of each 
single lesion. Assessment of the lesions was based on 
qualitative and quantitative parameters. Only lesions 
with a diameter >10mm were included to ensure re-
producible measurement of data in the quantitative 
analysis. Primary lesions were assessed only, therefore, 
all satellite lesions in close proximity to the main tu-
mor were excluded from the study. The four most 
important MR sequences for diagnosis were evalu-
ated, including: 1) T1-weighted in-phase GRE, 2) fat-
suppressed (fatsat) T2-weighted FSE, 3) arterial-phase 
– and 4) delayed phase after contrast administration. 
In three patients, fatsat T2-weighted FSE was not 
performed because of technical reasons. All MR im-
ages were qualitatively assessed by two readers with 
experience in hepatobiliary imaging (3 and 6 years 
respectively). These observers first evaluated the MR 
images independently, then a consensus reading was 
performed of all MR examinations. The quantitative 
assessment was performed by one reader. All evalu-
ations were categorized and documented by using 
standardized data sheets. 
 
Qualitative assessment
The qualitative assessment included the following 
characteristics of both liver and lesions: 1) signal in-
tensity of the lesion compared to the liver, assessed vi-
sually (graded as: 1=markedly hypointense, 2=slightly 
hypointense, 3=isointense, 4=slightly hyperintense, 
5=markedly hyperintense); 2) visual interpretation of 
enhancement at dynamic gadolinium-enhanced im-
Figure 1: Extensive cirrhotic changes in 54-year female with chronic 
hepatitis B infection and a 2-cm HCC (arrows), with low T2-weighted 
signal, marked arterial enhancement and minimal washout (Type I 
enhancement). (a) In-phase T1-weighted GRE, showing the lesion in the 
right liver lobe, with slightly higher signal intensity (SI) compared to the 
surrounding liver, surrounded by a hypointense tumor capsule. Note 
multiple regenerative nodules within the entire liver. (b) Fat-suppressed 
T2-weighted FSE, showing isointensity of the lesion. (c) Arterial phase 
T1-weighted GRE, showing marked arterial enhancement of the lesion. 
(d) Delayed phase T1-weighted GRE, showing only slight hypointensity 
of the lesion, with enhancement of the tumor capsule. (e) Macroscropic 
correlation after liver explantation, illustrating multiple internal nodules 
within the lesion, and a surrounding fibrous tumor capsule. (f)  Photomi-
crograph (hematoxylin and eosin (HE) stain, original magnification x10), 
showing a focus of HCC surrounded by multiple regenerative nodules.
Figure 2: 52-year old male, with chronic 
hepatitis B infection, moderate fibrosis 
and 4-cm HCC, with high T2w signal, slight 
heterogeneous arterial enhancement 
and marked delayed washout (Type III 
enhancement). (a) In-phase T1-weighted 
GRE, showing hypointensity of the tumor 
in the right liver lobe. (b) Fat-suppressed 
T2-weighted FSE, showing heterogeneous 
hyperintensity of the lesion. (c) Macroscopic 
correlation after surgical resection of the 
tumor, illustrating multiple nodules within 
the lesion and a fibrous tumor capsule. 
(d) Arterial-phase T1-weighted GRE after 
gadolinium, showing minimal patchy 
arterial enhancement. (e) Delayed-phase 
T1-weighted GRE after gadolinium, showing 
hypointensity of the lesion accompanied by 
enhancement of a tumor capsule. (f) Pho-
tomicrograph (hematoxylin and eosin (HE) 
stain, original magnification x20, illustrating 
multiple vessels and chaotic organization 
of hepatocytes with dysplastic nuclei.
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tumors, in 2 patients with cirrhosis (Fig. 5), and 1 pa-
tient with a non-cirrhotic liver. Heterogeneity within 
the tumor, with internal nodules was observed more 
significantly more often in larger lesions (p<0.001), in 
the assessment of fat-suppressed T2-weighted FSE. 
Combined diagnostic imaging sequences
The classic combination of high T2-weighted signal 
intensity, arterial enhancement and delayed phase 
washout (type II enhancement) (Fig. 6) as determined 
in the qualitative assessment was observed in 23 of 44 
lesions (52%). The remaining 21 lesions have different 
combinations of MR imaging findings, including pres-
ence or absence of high T2-weighted signal intensity, 
in combination with three types of enhancement (I, II 
and III) The comparison of these six groups shows a 
steady increase in tumor size (Fig. 7). Groups I, II an III 
with high T2-weighted signal occurred in 3/44 lesions 
(7%), 23/44 (53%), and 6/44 (14%) respectively. Groups 
I, II and III with low T2-weighted signal occurred in 
7/44 (16%), 1/44 (2%) and 4/44 (9%), respectively. 
DISCUSSION
The results of this study indicate that a relationship ex-
ists between tumor size of hepatocellular carcinoma 
and MR imaging findings. The most important find-
ings of our study include: 1) the classic combination of 
high T2-weighted signal, strong arterial enhancement 
and delayed washout is not present in all lesions; 2) 
smaller HCC have tendency for hypo- or 
isointensity on fat-suppressed T2-weighted 
sequences; 3) smaller HCC show more pro-
nounced arterial enhancement compared 
to larger HCC; 4) smaller HCC show less pro-
nounced washout in the delayed phase; 5) 
smaller lesions more frequently show an 
enhancing tumor capsule than previously 
reported in literature, based on enhance-
ment in the delayed phase after contrast 
administration.  
These findings are clinically relevant for a 
number of reasons. First, the classical combination 
of high signal intensity on T2-weighted sequences 
and arterial enhancement was not present in all 
evaluated patients on currently used state-of-the-art 
MR imaging. Isointensity or hypointensity of small 
HCC may pose diagnostic challenges. In case of a 
Figure 6: 69-year old male, with cirrhosis based on 
prolonged alcohol abuse, and a 4-cm large HCC in 
the right liver lobe, with classical appearance (high 
T2 signal, strong arterial enhancement and clear 
delayed washout (Type II enhancement). (a) in-phase 
T1-weighted GRE, showing slight hyperintensity of the 
lesion. (b) fat-suppressed T2-weighted FSE, showing 
slight hyperintensity of the lesion. (c) Arterial phase 
T1-weighted GRE, showing marked arterial enhance-
ment of the lesion; (d) Delayed phase T1-weighted 
GRE, illustrating washout of contrast within the 
lesion, accompanied by capsular enhancement.
Figure 7: Different combinations of the three most important 
sequences (T2-weighted signal intensity, arterial enhancement 
and delayed phase washout), in relation to tumor size. Groups I, 
II and III (x-axis, enhancement patterns) represent the follow-
ing: I – strong arterial enhancement with minimal delayed 
phase washout; II – strong arterial enhancement with marked 
delayed phase washout; and III – slight, heterogeneous arterial 
enhancement with marked delayed phase washout. Note that 
in these groups, tumor size increases from groups I to III.
Signal intensity
On in-phase T1-weighted GRE, the subjective, graded 
qualitative analysis showed no relation with tumor 
size; although a tendency for higher signal intensity 
was observed in smaller lesions (Fig. 1a). CNR did not 
vary significantly. 
On fat-suppressed T2-weighted FSE (FS-FSE), the sub-
jective, graded qualitative analysis showed a signifi-
cantly lower signal intensity for smaller 
lesions (p<0.05) (see Fig. 1b, 2b, 3). CNR 
assessments showed a tendency for 
higher CNR in larger lesions, which did 
not reach statistical significance (p=0.10, 
in which for each doubling of the tumor, 
CNR increased 1.4 (95% CI –0.3 - +3.1)).  
Dynamic enhancement
In the arterial phase, the subjective 
analysis showed a higher SI for small 
lesions, which approached statistical 
significance (p=0.052, in which for each 
doubling of the tumor size, the graded 
outcome increased 0.24, 95% CI 0.04 
– 0.44) (Fig. 1c, 2c). The quantitative 
analysis showed a significantly higher 
percentage increased enhancement of 
HCC compared to the surrounding liver 
in smaller lesions (p<0.05) (Fig. 4). 
In the delayed phase, the subjective 
analysis illustrated a significantly lower 
SI for larger lesions (p<0.05) (Fig. 1d, 2d, 4). The quanti-
tative analysis showed a persistent increased percent-
age enhancement of HCC versus liver, which did not 
reach statistical significance.  
Morphologic tumor characteristics
A capsule was present in 79% of HCC (37 of 47 lesions) 
for the assessments based on delayed phase imaging 
after gadolinium. On T1-weighted  imaging, a hypoin-
tense capsule was observed in 25/37 lesions (68%); 
and on T2-weighted  imaging this was observed in 
21/36 lesions (58%). There was no correlation between 
presence or absence of a tumor capsule and tumor 
size.  Fatty infiltration occurred significantly more of-
ten in larger HCC (p<0.001). Hemorrhage occurred in 6 
cases, without clear association with size of the tumor. 
A central scar was observed in 3 patients with larger 
Figure 4: Arterial-phase percentage increased ehancement of HCC compared to the 
liver, showing a significantly higher percentage enhancement in smaller HCC (p<0.05).
Figure 5: 74-year old male, with chronic hepatitis C infection, incom-
plete septal cirrhosis and a 9-cm HCC with a central scar, with low 
T2-weighted signal, marked arterial enhancement and marked delayed 
phase washout (type II enhancement). (a) In-phase T1-weighted GRE, 
showing hypointensity of the lesion. (b) Fat-suppressed T2-weighted 
FSE, showing only slight hyperintensity of the lesion compared to the 
surrounding liver, and with a slightly hyperintense central scar (arrow). 
(c) Arterial-phase fat-suppressed 3D T1-weighted GRE after gadolinium, 
showing classic heterogeneous arterial enhancement of the lesion, 
with sparing of the central scar. (d) Delayed-phase fat-suppressed 3D 
T1-weighted GRE after gadolinium, showing hypointensity of the lesion 
with delayed capsule enhancement. (e) Macroscopic correlation after 
surgical resection, illustrating multiple tumor nodules, central scar and 
a fibrous tumor capsule. (f) Photomicrograph (hematoxylin and eosin 
(HE) stain, original magnification x10) of the tumor, showing atypi-
cal hepatocytes with multiple nuclei, variation in size of the nuclei and 
multiple nuclei within one cell. Note fibrous scar tissue in the center.
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signal intensity in the delayed phase after contrast ad-
ministration did not follow the visually observed sig-
nal intensity which demonstrated more pronounced 
washout in larger lesions. This may be related to a 
combination of the following: 1) dual-input blood 
supply of the liver, based on inflow from both the he-
patic artery and the portal vein, resulting in an overall 
higher signal intensity of the lesion compared to the 
liver; and 2) the ROI measurements which were per-
formed included a measurement of the entire lesion 
that excluded areas of intra-tumoral fatty infiltration 
or hemorrhage, including therefore areas with differ-
ent washout characteristics.
Previously, the imaging findings of HCC have been de-
scribed by several authors who evaluated the imag-
ing findings of smaller lesions as well5,12,21-23. Yamashita 
and colleagues evaluated the histological subtypes 
and differentiation degree of HCC in correlation with 
dynamics enhancement patterns, illustrating a corre-
lation between degree and pattern of enhancement 
with tumor differentiation and internal architecture24. 
More recently, several studies addressed the imaging 
findings of HCC using liver specific contrast agents25-27 
In one study, the imaging findings of HCC were de-
scribed in a multicenter study, to describe the most 
common imaging findings of these lesions13. In this 
study, a cut-off was described for 1.5-cm large le-
sions. In our report, no significant cut-off value was 
observed in the statistical analysis, most likely related 
to the fact that signal behavior of HCC changes only 
gradually as the tumor increases in size. In addition to 
this study, we evaluated the imaging findings of HCC 
with a wide range in diameter in a single-center study, 
specifically aiming at the evaluation of the spectrum 
of MR imaging findings in relation to the size of the 
lesion. 
Our study is limited by the following factors. First, the 
retrospective nature of the study may have resulted in 
an inclusion bias of studied subjects. However, in our 
opinion, the retrospective study design would suffi-
ciently answer the defined research question. In ad-
dition, the applied MR imaging protocol we routinely 
apply in our institution was kept relatively constant 
over the years; therefore this did not result in exten-
sive variation in signal intensity or imaging findings. 
Second, the inclusion of both patients with and with-
out cirrhotic liver disease was based on the fact that 
larger HCC in fact have comparable imaging findings 
compared to HCC occurring in non-cirrhotic liver. The 
fact that HCC in non-cirrhotic liver is discovered only 
when lesions are much larger most likely depends on 
the metabolic function of the underlying liver, which 
is preserved for a much longer time in non-cirrhosis 
compared to cirrhosis. The assumption that imaging 
findings are in fact similar in HCC occurring in absence 
or presence of cirrhosis was confirmed by our study 
results, which did not show any significant differenc-
es. Finally, the small sample size may have resulted in 
biased study results.
In conclusion, our study indicates that the imaging 
features of HCC on MR imaging are related to tumor 
size. Smaller lesions often showed lower SI on T2-
weighted, more intense arterial enhancement, slight 
delayed washout whereas larger lesions were pre-
dominantly hyperintense on T2-weighted with less 
intense, heterogeneous arterial enhancement, and 
more pronounced delayed washout. Therefore, small 
liver lesions in the setting of liver cirrhosis need to be 
evaluated with caution.
 
REFERENCES
1. Hussain SM, Semelka RC. Liver masses. Magn Re- 
 son Imaging Clin N Am 2005; 13:255-275.
2. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepa- 
 tocellular carcinoma in cirrhosis: incidence and 
 risk factors. Gastroenterology 2004; 127:S35-50.
3. El-Serag HB. Hepatocellular carcinoma: recent 
 trends in the United States. Gastroenterology 
 2004; 127:S27-34.
4. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. 
 The continuing increase in the incidence of hepa- 
 tocellular carcinoma in the United States: an up- 
 date. Ann Intern Med 2003; 139:817-823.
5. Sakamoto M, Hirohashi S, Shimosato Y. Early 
 stages of multistep hepatocarcinogenesis: adeno- 
 matous hyperplasia and early hepatocellular carci- 
 noma. Hum Pathol 1991; 22:172-178.
6. Hussain SM, Semelka RC, Mitchell DG. MR ima- 
 ging of hepatocellular carcinoma. Magn Reson 
 Imaging Clin N Am 2002; 10:31-52, v.
7. Semelka RC, Martin DR, Balci C, Lance T. Focal 
 liver lesions: comparison of dual-phase CT and 
 multisequence multiplanar MR imaging including 
 dynamic gadolinium enhancement. J Magn Re- 
 son Imaging 2001; 13:397-401.
8. Hussain SM, Semelka RC. Hepatic imaging: com- 
 parison of modalities. Radiol Clin North Am 2005; 
 43:929-947, ix.
9. Iannaccone R, Laghi A, Catalano C, Rossi P, 
 Passariello R. Focal liver lesions in the cirrhotic pa- 
 tient: multislice spiral CT evaluation. Radiol Med 
 (Torino) 2004; 107:304-314; quiz 315-306.
10. Shinmura R, Matsui O, Kobayashi S, et al. Cirrhotic 
 Nodules: Association between MR Imaging Signal 
 Intensity and Intranodular Blood Supply. Radio- 
 logy 2005; 237:512-519.
11. Hussain SM, De Becker J, Hop WC, Dwarkasing S, 
 Wielopolski PA. Can a single-shot black-blood T2-- 
 weighted spin-echo echo-planar imaging se- 
 quence with sensitivity encoding replace the res-
 piratory-triggered turbo spin-echo sequence for 
hyperenhancing area in cirrhosis, a wider differential 
diagnosis is considered, which may include vascular 
shunts, early enhancing lesions, pseudo-lesions, or 
others. In these cases, careful analysis of other phases 
in the dynamic examination is useful, since the de-
layed phase will show some degree of washout in the 
visual interpretation of signal intensity, accompanied 
by enhancement of a tumor capsule. If differential di-
agnosis remains unclear, short term follow-up exami-
nation is indicated (6 to 12 week follow-up) to evalu-
ate changes or growth of the lesion. 
The lower T2-weighted SI in smaller lesions as docu-
mented in our study likely results from the following: 
1) smaller lesions have different cellular characteristics, 
including more cellularity with relatively smaller fluid 
component, and correlation between the degree 
of histological differentiation and tumor size; and 2) 
changes related to technical effects of the applied se-
quence, with a higher number of refocusing pulses in 
current echo-train FSE sequences which result in in-
creased magnetic-transfer-contrast (MTC) effects15,16. 
According to the step-wise carcinogenesis, HCC 
changes in appearance in the course of the devel-
opment. This is reflected as changing signal inten-
sity and vascularity on MR imaging. A previous study 
showed different imaging findings in developing 
HCC, which may reflect different pathways or even 
different genetic backgrounds in the step-wise de-
velopment of HCC16. This includes steadily increasing 
SI on T2-weighted sequences with gradually more 
neovascularity for most lesions. Based on the results 
of this study and prior observations, it is suggested 
that in most cases the increased signal on 
T2-weighted images lags behind the devel-
oping neovascularity of such lesions. 
The increased arterial enhancement as 
observed in this study for smaller HCC is 
beneficial for early diagnosis of HCC. This 
relates directly to the technique applied for 
the dynamic imaging series, because ad-
equate timing of the arterial phase is essen-
tial. Inaccurate timing may result in a lower 
percentage arterial enhancement, which may cause 
false-negative diagnostic results in especially smaller 
lesions. The more pronounced arterial enhancement 
in smaller lesions, as observed in this study, most likely 
corresponds to the step-wise carcinogenesis de-
scribed before, in which most lesions show hypervas-
cularity as an initial sign. Even though the exact rela-
tion and differential diagnosis from benign enhancing 
lesions remains complicated, even slight washout ac-
companied by capsule enhancement suggests HCC, 
as observed in this study. In cases in which no clear 
washout is observed in the delayed phase, observa-
tion of early enhancement warrants close follow-up 
for evaluation of potential growth18. 
The combination of MR imaging findings of smaller 
lesions in this study, including lower signal intensity 
(rendering the lesion iso- or even hypointense) on 
T2-weighted sequences and pronounced arterial en-
hancement underlines the importance of dynamic 
contrast-enhanced imaging in patients at risk for 
development of HCC. In this setting, T2-weighted 
imaging seems less important in the overall evalua-
tion, which is in correspondence with a recent study 
which described the overall confidence levels for di-
agnosis of HCC, based on different combinations of 
T1-weighted, T2-weighted and dynamic contrast-en-
hanced imaging19. However, both in our experience as 
reported in literature as well, inclusion of T2-weighted 
sequences in a full MR imaging protocol is essential 
for both detection and characterization of focal liver 
lesions of both primary and secondary nature20.  
Finally, in the quantitative, ROI-based analysis of the 
Figure 8: Small HCC in a 53-year old male patient 
with hepatitis B related cirrhosis and a 1.5-cm HCC 
in the left liver lobe (arrows), with nodule-within-
nodule appearance that shows low T2-weighted 
signal, strong arterial enhancement and some 
delayed washout (Type II enhancement). (a) In-phase 
T1-weighted GRE, showing slight hypointensity 
of the lesion. (b) Fat-suppressed T2-weighted FSE, 
showing heterogeneous, slightly higher SI of the 
lesion compared to the liver. (c) Arterial phase T1-
weighted GRE, showing marked arterial enhancement 
of the lesion. (d) Delayed phase T1-weighted GRE, 
illustrating some washout of contrast agent within 
the lesion without any capsular enhancement.
74
he
pa
to
ce
llu
la
r c
ar
ci
no
m
aL
ES
IO
N
 S
IZ
E 
AN
D
 M
R 
IM
AG
IN
G
 F
IN
D
IN
G
S
4
chapter4.3
 hepatocellular carcinoma  
 after Kasai porto-
 enterostomy
 the liver? An optimization and feasibility study. 
 J Magn Reson Imaging 2005; 21:219-229.
12. Matsui O, Kadoya M, Kameyama T, et al. Adeno- 
 matous hyperplastic nodules in the cirrhotic liver: 
 differentiation from hepatocellular carcinoma 
 with MR imaging. Radiology 1989; 173:123-126.
13. Kelekis NL, Semelka RC, Worawattanakul S, et al. 
 Hepatocellular carcinoma in North America: a 
 multiinstitutional study of appearance on T1- 
 weighted, T2-weighted, and serial gadolinium-en- 
 hanced gradient-echo images. AJR Am J 
 Roentgenol 1998; 170:1005-1013.
14. Ebara M, Fukuda H, Kojima Y, et al. Small hepato- 
 cellular carcinoma: relationship of signal intensity 
 to pathologic findings and metal content of 
 the tumor and surrounding hepatic parenchyma. 
 Radiology 1999; 210:81-88.
15. Kadoya M, Matsui O, Takashima T, Nonomura A. 
 Hepatocellular carcinoma: correlation of MR ima- 
 ging and pathologic findings. Radiology 
 1992; 183:819-825.
16. Van den Bos IC, Hussain SM, Terkivatan T, 
 Zondervan PE, De Man RA. Step-wise 
 carcinogenesis of hepatocellular carcinoma in the 
 cirrhotic liver: demonstration on serial MR 
 imaging. JMRI 2006 Nov; 24(5): 1071-80.
17. Hyslop WB, Balci NC, Semelka RC. Future horizons 
 in MR imaging. Magn Reson Imaging Clin N Am 
 2005; 13:211-224.
18. Jeong YY, Mitchell DG, Kamishima T. Small (<20 
 mm) enhancing hepatic nodules seen on arterial 
 phase MR imaging of the cirrhotic liver: clinical im- 
 plications. AJR Am J Roentgenol 2002; 178: 
 1327-1334.
19. Hecht EM, Holland AE, Israel GM, et al. Hepatocel- 
 lular carcinoma in the cirrhotic liver: gadoli- 
 nium-enhanced 3D T1-weighted MR imaging as a 
 stand-alone sequence for diagnosis. Radiology 
 2006; 239:438-447.
20. Kondo H, Kanematsu M, Itoh K, et al. Does T2- 
 weighted MR imaging improve preoperative de-
 tection of malignant hepatic tumors? Observer 
 performance study in 49 surgically proven cases. 
 Magn Reson Imaging 2005; 23:89-95.
21. Sadek AG, Mitchell DG, Siegelman ES, Outwater EK, 
 Matteucci T, Hann HW. Early hepatocellular carci- 
 noma that develops within macroregenerative 
 nodules: growth rate depicted at serial MR ima-
 ging. Radiology 1995; 195:753-756.
22. Mitchell DG, Rubin R, Siegelman ES, Burk DL, 
 Jr., Rifkin MD. Hepatocellular carcinoma within 
 siderotic regenerative nodules: appearance as 
 a nodule within a nodule on MR images. Radio- 
 logy 1991; 178:101-103.
23. Tang Y, Yamashita Y, Arakawa A, et al. Detection 
 of hepatocellular carcinoma arising in cirrhotic 
 livers: comparison of gadolinium- and ferumo- 
 xides-enhanced MR imaging. Am J Roentgenol 
 1999; 172:1547-1554.
24. Yamashita Y, Fan ZM, Yamamoto H, et al. Spin- 
 echo and dynamic gadolinium-enhanced FLASH 
 MR imaging of hepatocellular carcinoma: correla- 
 tion with pathologic findings. J Magn Reson 
 Imaging 1994; 4:83-90.
25. Kim YK, Kwak HS, Kim CS, Chung GH, Han YM, Lee JM. 
 Hepatocellular carcinoma in patients with chronic 
 liver disease: comparison of SPIO-enhanced MR 
 imaging and 16-detector row CT. Radiology 2006; 
 238:531-541.
26. Tanimoto A, Kuribayashi S. Application of super 
 paramagnetic iron oxide to imaging of hepatocel- 
 lular carcinoma. Eur J Radiol 2006; 58:200-216.
27. Kim YK, Kim CS, Chung GH, et al. Comparison of 
 gadobenate dimeglumine-enhanced dynamic 
 MRI and 16-MDCT for the detection of hepatocel- 
 lular carcinoma. AJR Am J Roentgenol 2006; 
 186:149-157.
76
he
pa
to
ce
llu
la
r c
ar
ci
no
m
aA
FT
ER
 K
AS
AI
 P
O
RT
O
EN
TE
RO
ST
O
M
Y
4 77
he
pa
to
ce
llu
la
r c
ar
ci
no
m
aA
FT
ER
 K
AS
AI
 P
O
RT
O
EN
TE
RO
ST
O
M
Y
4
urine, pruritis and a low-grade fever. Physical examina-
tion showed a jaundiced skin and sclerae with scratch 
lesions on his extremities. The abdominal examination 
revealed non-tender hepatomegaly and splenomeg-
aly. The laboratory results showed a serum bilirubin 
of 346 μmol/L (normal range 0-16 μmol/L), alkaline 
phosphatase 446 IU/l (normal range 40–120 IU/l), al-
bumin 39 g/L (normal range 35-50 g/L), International 
Normalized Ratio (INR) 1.1. The virology failed to dem-
onstrate a hepatitis B or C infection (HBsAg, anti-HBc 
and anti-HCV all negative) An ultrasound of the liver 
failed to demonstrate overt biliary obstruction, but 
did show that the above described dominant nodule 
had further increased in size. A MR imaging was ad-
vised and performed (Fig. 1). This confirmed the now 
10cm large lesion . In comparison with the previous 
MR examination, the lesion now clearly showed ar-
eas with decreased signal intensity on the opposed-
phase T1-weighted gradi-
ent-echo (GRE) sequence 
compared to the in-phase 
GRE, indicating intratu-
moral fatty infiltration (Fig. 
1 b, c). There were a few 
areas of high signal inten-
sity on the T1-weighted 
and low signal intensity on 
the T2-weighted sequence 
(Fig 1a), indicating hemor-
rhage of older date. After 
contrast administration, the dynamic series revealed 
enhancement of the tumor in the arterial phase (Fig 
1e): followed by hypointensity compared to the liver 
in the delayed phase indicating washout (Fig. 1f).  In 
addition, there was delayed enhancement of a fibrous 
tumor capsule (Fig. 1f). These findings were suspect 
for HCC given the combination of intratumoral fat, 
hemorrhage, washout and capsule enhancement. 
Taking the extensive cirrhotic changes of the liver 
into account, hepatocellular adenoma (HCA) seemed 
unlikely. Additional biochemic examination revealed 
an AFP of 1 µg/l (normal range < 20 µg/l). Percutane-
ous liver biopsy of the lesion was performed, which 
showed disturbance of the architecture and irregular 
fibrosis without portal fields or bile ducts. The hepato-
cytes were uniform with irregular arrangement, vacu-
olar steatosis, cholestasis and minimal loss of reticulin; 
and were organized in cell plates of maximum one or 
Figure 1: MR examination performed in 2003, with characteristic findings for hepatocellular carci-
noma (HCC). (a) Coronal single-shot T2-weighted fast spin-echo (Cor T2-weighted FSE), showing an 
atrophic cirrhotic liver, splenomegaly (*) and an HCC, located caudally to the right liver lobe. Note 
an area of decreased signal intensity within the tumor (arrow) indicating hemorrhage of older date; 
(b) axial in-phase T1-weighted gradient-echo (GRE) (Ax T1-weighted in-phase), showing multiple 
gamna gandy bodies in the spleen (arrow) and a high signal intensity of the tumor (*); (c) axial op-
posed-phase T1-weighted GRE (Ax T1-weighted opp-phase), illustrating patchy areas of decreased 
signal intensity (*) compared to the in-phase sequence which illustrates diffuse intratumoral fatty 
infiltration; (d) macroscopic correlation after liver explantation, illustrating a cirrhotic atrophic liver 
and HCC with multiple internal nodules. Note the surrounding fibrous tumor capsule (arrows); (e) 
axial arterial phase T1-weighted GRE (Ax art-phase) after contrast shows enhancement of the entire 
lesion (*); (f) axial delayed phase T1-weighted GRE (Ax del phase) after contrast shows washout 
of contrast rendering the tumor hypointense, and delayed enhancement of a tumor capsule.
ABSTRACT
Kasai portoenterostomy (PE) increases the survival for 
children with biliary atresia and consequently post-
pones subsequential liver transplantation. However, 
all longterm survivors develop complications of bili-
ary cirrhosis. We report a case of hepatocellular carci-
noma (HCC) in a 19-year old male patient with biliary 
atresia and Kasai PE. The preoperative abdominal 
ultrasound and magnetic resonance (MR) imaging 
showed a large hepatic mass (diameter 10cm). The se-
rum alpha-fetoprotein level was within normal range. 
Pathologic findings of the mass, after orthotopic liver 
transplantation, demonstrated a well-differentiated 
HCC (T1N0M0). HCC is a rare complication of biliary atre-
sia, but will intensively impair the survival. Therefore, 
clinicians should be alert to the development of HCC 
in this very young patient group. Repeated sequential 
MR imaging of the native liver in patients with Kasai PE 
is necessary to monitor possible malignant transfor-
mation of liver nodules that may potentially develop 
as a result of chronic cholestatic liver disease.   
INTRODUCTION
In 1959, Kasai portoenterostomy (PE) for children with 
biliary atresia (BA) was introduced in clinical practice1. 
This operation increased the survival to a 20-year pa-
tient survival without liver transplantation of 23%2. 
Nevertheless, almost all patients develop features 
of end-stage liver disease and biliary cirrhosis2. Kasai 
PE is clearly not a curative treatment, but a bridge to 
liver transplantation. Although the indication for liver 
transplantation is clear, the timing depends on devel-
opment of complications of biliary cirrhosis. 
The purpose of this paper is 1) to describe the Kasai 
procedure; 2) to inform clinicians of the possibility of 
developing hepatocellular carcinoma at a relatively 
young age; and 3) to indicate the necessity for re-
peated sequential MR imaging to monitor possible 
malignant transformation of liver nodules in patients 
with Kasai PE.
CASE REPORT
In 2000, a 19-year old Caucasian male was seen in the 
outpatient clinic of our hospital because of abdomi-
nal pain in the right upper quadrant. He underwent a 
successful Kasai procedure during his neonatal period 
for congenital biliary atresia type III and had recur-
rent episodes of jaundice, pale stools and dark urine 
without overt evidence of cholestasis during his teen 
ages. 
Since 1990, the patient was known with a macronodu-
lar appearance of the liver on ultrasound (US). A domi-
nant nodule, located caudally in the right liver lobe, 
was first visualized on US in 1991, with a diameter of 
3.8cm. The exact nature of this lesion was unknown, 
and percutaneous biopsies performed in 1991 and 
1993 of both liver and dominant nodule showed 
moderate to extensive fibrosis and chronic cholestasis, 
without malignant features. In a period of 9 years, the 
lesion steadily increased in size, including a diameter 
of 3.8cm in 1991; 5.2cm in 1992; and 6.5cm in 1996. 
For further characterization of the lesion, magnetic 
resonance (MR) imaging of the liver was performed 
in 2000, which showed an atrophic cirrhotic mac-
ronodular liver with multiple regeneration nodules. 
The dominant nodule in the right liver lobe had a di-
ameter of 9.5cm. There were some areas of high signal 
intensity on both the T1- and T2-weigthed sequences, 
which did not enhance after contrast-administration, 
suspect for hemorrhage. After contrast administra-
tion, no arterial enhancement was detected in the 
nodules nor clear washout in the delayed phase. 
Taking these characteristics into account, the differen-
tial diagnosis of the lesion was dysplastic or degen-
erative nodule; or hepatocellular adenoma (HCA), 
without clear evidence for hepatocellular carcinoma 
(HCC). The laboratory findings showed a serum alpha-
fetoprotein within the normal range. 
In 2003 the patient was re-admitted to our hospital 
with a similar episode of abdominal pain in the right 
upper quadrant. Additionally, he had pale stools, dark 
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liver explantation8-12. This diagnostic delay impairs the 
post-transplantation prognosis13, since lymph node 
involvement and tumor size are independent risk fac-
tors for recurrence of HCC after transplantation13,18. 
More crucial are distant metastatic disease or macro-
scopic vascular involvement, which are exclusion cri-
teria for liver transplantation16,17,19. This underlines, that 
early detection of (pre-) malignant hepatic lesions in 
this young patient group is of paramount importance. 
Especially, since living related liver transplantation 
makes a more timely transplantation possible. Clinical 
examination of these patients is insufficient since the 
clinical presentation of a HCC is non-specific: abdomi-
nal swelling, dull abdominal pain, progressive weight 
loss and fatigue13,17. In addition, serum AFP as a screen-
ings tool lacks specificity since 8-18% of the pediatric 
patients with a HCC have a serum AFP within a normal 
range13,19. 
Pathology is the golden standard for diagnosis of 
hepatocellular tumors. However, as demonstrated 
by this patient, sampling errors can occur due to the 
step-wise development of HCC, which may give rise 
to distinct regions of either dysplastic or truly malig-
nant features within in one tumor. Also, distinction 
between well-differentiated HCC and HCA may be 
complicated. Furthermore, the invasive character of 
percutaneous liver biopsy is associated with a rela-
tively high complication rate, especially in young chil-
dren. 
Currently, MR imaging is regarded the modality of 
choice for the work-up for patients with focal liver 
lesions20. The ability to detect intrinsic tissue charac-
teristics on T1- and T2-weighted sequences in com-
bination with dynamic contrast-enhanced imaging 
renders it a superior imaging modality for detection 
and characterization of focal liver lesions21. More im-
portantly, MR imaging compared to computed to-
mography (CT) acquires its data without radiation 
exposure, which is important for especially this young 
patient group, since routine follow-up multiphasic 
CT examinations result in high radiation dosages22. 
MR imaging of patients with Kasai PE should be per-
formed frequently to monitor eventually malignant 
transformation of liver nodules as seen in this patient. 
This step-wise process of carcinogenesis in post-Kasai 
livers can be very subtle23. In addition, the surveillance 
with MR imaging should start at an early age, since a 
HCC presents on an early age in this patient group8-12.
 In conclusion, Kasai PE increased the life expectations 
of patients with biliary atresia. The development of 
HCC in this patient population is rare, but will inten-
sively impair the survival. Therefore, clinicians should 
be alert to the development of HCC in this very young 
patient group. Follow-up MR imaging of the native 
liver is important in order to monitor and evaluate 
development of focal liver lesions in patients with a 
Kasai PE.
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  Hol (2006) 23 Incidental I 17 mo LT: alive, no recurrence
two cells in width. This resulted in a  histologic conclu-
sion of HCA (Fig 2a). Because pathology is regarded 
the gold standard for analysis of hepatocellular tumor, 
and considering the absence of clinical signs, the di-
agnosis was set to HCA beyond the opposing results 
of the MR imaging. However, it was decided to per-
form regular follow-up MR examinations to evaluate 
changes of the lesion, and to refer this patient to our 
liver transplant clinic because of recurrent and increas-
ingly frequent episodes of cholestasis. Follow-up MR 
examination performed in July 2004 revealed a stable 
tumor size, but the combination of imaging finding 
was still highly suspect for HCC despite the absence 
of growth or any changes in tumor behavior. In Janu-
ary 2005 he underwent an orthotopic liver transplan-
tation (OLT) with Roux Y reconstruction. The exami-
nation of the native liver showed entirely disturbed 
anatomy with a tumor of 10 cm diameter located 
caudally to the liver (Fig. 1d). Histologic examination 
demonstrated incomplete septal cirrhosis, and a well-
differentiated hepatocellular carcinoma without vas-
cular invasion nor lymph node involvement (T1N0M0) 
(Fig 2b). Currently, the patient is in a good condition, 
without any evidence of tumor recurrence.
DISCUSSION
Four decades of Kasai surgery increased the survival 
of patients with biliary atresia to respectively 32-60% 
at 5 year, 27-53% at 10 years and a 23% at 20 years 
(Table 1)2-7. The survival benefit of the Kasai 
procedure can delay the subsequent liver 
transplantation, since primary liver transplantation in 
very young patients has a high morbidity and mor-
tality rate. The backside of postponing a liver trans-
plantation is an increased complication rate in the 
long-time survivor group with a native liver2. This em-
phasizes the importance of accurate timing for a liver 
transplantation.   
HCC as complication of biliary atresia after Kasai PE is 
rare. The patient presented in this report developed 
a very slow growing tumor (over 14 years) with an 
extremely benign growth pattern, confirmed to be a 
well-differentiated HCC after liv-
er explantation. The prevalence 
of HCC in explanted livers of 
patients transplanted for biliary 
atresia is 0.73-2.44% (three pa-
tients with a HCC in 316 pediatric 
transplantations)8,9. Eight cases 
of HCC after Kasai PE have been 
described in literature (Table 2). 
The described cases were diag-
nosed with HCC at a very young 
age (4 to 12 years old)8-12. The 
late delayed presentation of this 
patient may be due to the extremely benign growth 
pattern of the HCC that he developed. 
Young patients that develop HCC in this group have a 
poor overall 2 and 5 year survival of 28%13. Complete 
tumor resection is the only curative option with an 
overall disease free survival of 57%13 compared to a 5 
year survival rate of 0% for unresectable tumors14,15. All 
reported patients had end-stage liver disease at the 
time of diagnosis, which made a partial resection of 
the tumor impossible. Therefore, liver transplantation 
was the only viable option. The short time survival 
(18-60 months) after liver transplantation was 86% 
(6 of 7 pts)8-12. This is comparable to the 4 and 5-year 
survival rate of all pediatric patients who underwent 
a liver transplantation for HCC  (72 and 63%, respec-
tively)16,17.  
Diagnostic delay is common in this patient group. 
This is demonstrated by this case and 3 of the 8 de-
scribed cases in which HCC was also diagnosed after 
Figure 2: (a) Photomicrograph of the biopsy speci-
men in 2003 (original magnification x 400 H-E stain) 
shows a hepatocellular adenoma. The specimen 
demonstrates: (i) disturbance of the architecture and 
irregular fibrosis without portal fields or bile ducts; 
(ii) uniform hepatocytes with irregular arrangement, 
vacuolar steatosis, cholestasis and minimal loss of re-
ticulin. (iii) hepatocyte arrangement of one or two cells 
in width. (b) Photomicrograph of a biopsy specimen 
after liver explantation in 2006 (original magnification 
x400 H-E stain) shows a well-differentiated HCC.
Table 1: Survival after a Kasai procedure for biliary cirrhosis
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  Chardot 1999 1986-1996 440 32 27 -
  Nio 2003 1989-1994 735 60 53 -
  Hung 2006 1976-2000 141 35 31 -
  Lykavieris 2005 1968-1983 271 40 32 23
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was performed, using superparamagnetic iron-oxide 
particles (SPIO) contrast agent (Resovist, Schering AG, 
Berlin, Germany). After uptake of SPIO fat-suppressed 
T2-weighted FSE showed no evident decrease of sig-
nal intensity within the lesion, indicating that it was 
not a primary tumor with abundant amount of Kupffer 
cells. This finding virtually excluded the possibility of 
a well-differentiated HCC, hepatocellular adenoma, 
and focal nodular hyperplasia. The findings of the MR 
imaging examination posed a diagnostic dilemma: 
the combination of signal intensity, morphology of 
the tumor, close proximity to the gallbladder, and 
enhancement pattern was strongly suggestive for a 
cholangiocarcinoma or another type of malignant le-
sion, which originated from the gallbladder. However, 
the elevated serum AFP, solitary nature, large size, 
non-cirrhotic liver suggested a hepatocellular carci-
noma as the most likely possibility. Therefore, the final 
differential diagnosis consisted of hepatoid adenocar-
cinoma (HAC) of the gallbladder, cholangiocarcinoma 
and HCC. Particularly, we considered HAC the most 
likely diagnosis because this entity does show hepa-
toid differentiation and can present with a liver tumor 
and elevated AFP1. 
Histology
Subsequently, ultrasound-guided percutaneous liver 
biopsy was performed. At microscopic evaluation, a 
combination of hepatocyte-like- and adeno-struc-
tures was observed, embedded in a fibrous tissue ma-
trix (Fig. 2a). Some trabecular formations were pres-
ent. Immunohistochemical analysis showed positivity 
for cytokeratin CK7 and CK19 in all areas, while CK20 
was negative. These find-
ings on itself supported 
the general diagnosis of 
a carcinoma. Also, CD10 
positivity was observed 
which indicated sporadic 
canalicular differentia-
tion (see Fig 2b-c). Stain-
ing with AFP showed 
cytoplasm positivity (Fig. 
2d). CD56 staining showed slight positivity in the cell 
membrane in some more solid areas. These findings 
provided evidence for hepatocellular differentiation of 
the tumor, suggesting HCC, or rather combined HCC 
with cholangiocarcinoma (CC). However, the combi-
nation of immunohistochemical results with positiv-
ity for CD10, the canalicular formation of some cells in 
combination with high serum AFP and the location of 
the tumor were atypical for diagnosis of either HCC or 
HCC-CC. Therefore, the most likely histological diag-
nosis was hepatoid adenocarcinoma.
Even though the location of the tumor was problem-
atic for successful resection, it was decided to perform 
exploratory hepatic surgery to assess resectability. At 
surgery however, liver metastases were detected, 
confirming the MR findings of suspected metastases 
in proximity of the tumor. 
Figure 1: (a) Axial opposed-
phase T1-weighted gradient-
echo (GRE) (T1-op)  shows 
hypointensity of the lesion com-
pared to the surrounding liver, 
and shows the lesion originates 
in the fundus of the gallblad-
der. (b) Axial fat-suppressed 
T2-weighted fast spin-echo 
(T2) shows faint hyperintensity 
of the lesion. (c) Axial arterial 
phase gadolinium-enhanced 
T1-weighted GRE (ART) shows 
patchy, predominantly periph-
eral enhancement of the lesion. 
Note the intense enhancement 
of the aorta (open arrow) and 
the spleen. (d) Axial 3D delayed 
phase fat-suppressed T1-
weighted GRE (DEL) shows the 
lesion retains the contrast mate-
rial with a patchy distribution. 
ABSTRACT
We present a case with a large gallbladder tumor in a 
patient with no known liver disease and elevated al-
pha-fetoprotein (AFP), in which differential diagnosis 
with hepatocellular carcinoma (HCC) in a non-cirrhot-
ic liver was particularly difficult given the combination 
of the size of the tumor, solitary nature, elevated AFP, 
and striking resemblance with HCC at histology. In 
presenting this patient, we would like to emphasize 
the role of MR imaging as a problem-solving tool for 
analysis of rare tumors of non-hepatocellular origin, 
including hepatoid adenocarcinoma of the gallblad-
der.
INTRODUCTION
Hepatoid adenocarcinoma (HAC) is a rare variant of 
extrahepatic adenocarcinoma, consisting of foci of 
both adenomatous and hepatocellular differentiation 
which behave like hepatocellular carcinoma (HCC) in 
morphology and functionality1. It occurs in a multi-
tude of organs, most frequently in the stomach2,3, but 
it has been reported to occur rarely in other areas as 
well, including the lung4, kidney5, female reproduc-
tive tract6,7, pancreas8 and gallbladder1,9. Typically, an 
elevated level of serum alpha-fetoprotein (AFP) is 
detected, although normal levels have also been de-
scribed2,3. We report a patient with a large tumor in 
the gallbladder detected at magnetic resonance (MR) 
imaging, combined with an elevated serum AFP. Dif-
ferential diagnosis with HCC in a non-cirrhotic liver 
was particularly difficult given the combination of the 
size of the tumor with invasion of the surrounding 
liver, solitary nature, elevated AFP, and striking resem-
blance with HCC at histology.
CASE REPORT
A 55-year old woman was referred to our hospital for 
evaluation of a hepatic mass. The lesion was discov-
ered at ultrasound (US) performed in another clinic 
for work-up of right upper quadrant abdominal pain. 
Previous history was unremarkable. At physical exami-
nation, no abnormalities were noted. Routine labora-
tory investigations were performed, showing slightly 
elevated liver enzymes and an abnormally elevated 
AFP (511 µg/ml, normal value below 20 µg/ml). Hepa-
titis B and C serology tests were negative. Magnetic 
resonance (MR) imaging was performed for further 
characterization of the lesion, which confirmed the 
presence of a well-demarcated tumor adjacent to the 
gallbladder, with longest diameter of 7 cm (Fig. 1). The 
liver showed a normal size and morphology, without 
signs of cirrhosis.
MR imaging findings
On T1-weighted gradient-echo (GRE) images, the 
lesion was hypointense to the surrounding liver pa-
renchyma (Fig. 1a). The tumor was located in the gall-
bladder fossa, with a slightly bilobar shape and with 
narrowing of the gallbladder lumen. Fat-suppressed 
T2-weighted fast spin-echo (FSE) images showed hy-
perintensity of the lesion, without evidence for inter-
nal nodules or internal heterogeneity (Fig. 1b). Specifi-
cally, the signal intensity was higher in the periphery 
of the lesion, with slightly lower values in the center 
suggestive for central fibrosis. After intravenous ad-
ministration of a non-liver specific gadolinium chelate 
(Magnevist [gadopentetate dimeglumine], Schering, 
Berlin, Germany), the lesion enhanced predominantly 
in the periphery (Fig. 1c). Dynamic gadolinium-en-
hanced images revealed peripheral enhancement 
in the arterial phase, slowly progressing centripetally 
(Fig. 1c-d). In the delayed phase, no clear washout of 
contrast material was seen. No tumor capsule could 
be detected. In addition, 3 small lesions with diameter 
< 1 cm were observed in proximity of the tumor, with 
identical signal intensity at fat-suppressed T2-weight-
ed imaging and after contrast-administration. These 
alterations were suspect for metastases or satellite le-
sions. For further characterization of the tumor, addi-
tional imaging using a liver-specific contrast medium 
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capsule formation and often a central scar10,13. HCC 
in a cirrhotic liver however, has quite different imag-
ing characteristics, including hyperintense signal 
intensity on T2-weighted images, intense arterial en-
hancement with washout in delayed phase contrast-
enhanced imaging and delayed enhancement of a 
tumor capsule10. Typical imaging findings of cholan-
giocarcinoma include hypointensity on T1-weighted 
images, hyperintensity on T2-weighted images with 
central hypointensity and peripheral enhancement, 
with centripetal progression on delayed phase im-
ages14. Imaging findings of primary gallbladder carci-
noma are different, with eccentric tumor formation in 
76%, liver invasion in 91% and marked heterogeneity 
and inhomogeneous enhancement after contrast ad-
ministration15. As demonstrated in our case, the com-
bination of imaging findings before and after contrast 
administration did not quite fit the diagnosis of HCC, 
cholangiocarcinoma nor primary gallbladder carci-
noma. Given the combination of tumor morphology 
and location, signal intensity, contrast enhancement 
and high AFP in absence of cirrhosis, HAC of the gall-
bladder was the most likely diagnosis at MR imaging, 
confirmed by histo-immunochemical analysis of the 
tumor.
In presenting this patient, we would like to emphasize 
the role of MR imaging as a problem-solving tool for 
analysis of rare tumors of non-hepatocellular origin, 
including hepatoid adenocarcinoma of the gallblad-
der.
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Currently, patient is undergoing palliative chemother-
apy and is in reasonable condition. 
DISCUSSION
Hepatoid adenocarcinoma (HAC) is a rare form of 
adenocarcinoma with hepatoid differentiation of the 
tumor cells. In this report, a case is described with a 
large gallbladder tumor in combination with high 
AFP, in which the signal intensity on T2-weighted im-
ages showed predominantly high signal intensity in 
the periphery of the lesion, with hypointensity in the 
center of the lesion without clear heterogeneity. The 
enhancement pattern on dynamic gadolinium-en-
hanced images showed slow peripheral enhancement 
with centripetal progression over time, without wash-
out or capsule enhancement. Given the combination 
of tumor morphology and location, signal intensity, 
contrast enhancement and high AFP in absence of 
cirrhosis, HAC of the gallbladder was the most likely 
diagnosis. HCC in a non-cirrhotic liver was less likely 
these tumors are usually very large at presentation, 
with striking heterogeneity and capsule formation12,13. 
These findings are clinically relevant since HCC, com-
bined HCC-CC with peripheral location or HAC all 
have a different therapeutic approach, especially 
in a non-cirrhotic liver. As 
in our patient, in case of 
localization of the tumor 
within the gallbladder wall, 
differentiation with HCC or 
combined hepatocellular 
carcinoma – cholangiocar-
cinoma (HCC-CC) is chal-
lenging. Additional immu-
nohistochemistry is often 
helpful for tumor character-
ization1,3,9,11. In our patient, 
diffuse positivity with CK7 
and CK19 was observed, 
which suggested presence of an adenocarcinoma. 
Also, CD10 was sporadically positive, indicating cana-
licular differentiation and thus hepatocellular origin. 
This was also supported by a positive AFP, although 
some rare cases of AFP negative HAC in the gallblad-
der have been described9. The combination of posi-
tivity for CD10, the canalicular formation of some cells 
in combination with high serum AFP and the location 
of the tumor supported hepatoid adenocarcinoma as 
the most likely diagnosis. As has been described by 
Sakamoto and colleagues before11, HCC or combined 
HCC-CC invading the gallbladder is the main differ-
ential diagnosis of gallbladder HAC. In these cases, 
considering the clinical presentation may be helpful, 
since for example HCC occurring in a non-cirrhotic 
liver is typically very large, with striking heterogeneity 
and capsule formation. 
The present case demonstrates the value of state-of-
the-art MR imaging for lesion characterization. The 
unique ability to detect intrinsic cellular characteristics 
combined with dynamic contrast-enhanced imaging 
render MR imaging superior for detection and charac-
terisation of focal liver lesions12. MR imaging findings 
of HCC in non-cirrhotic liver tissue are well known12,13. 
Typically, a solitary, large tumor is observed with strik-
ing heterogeneity, inhomogeneous enhancement, 
Figure 2: (a) Photomicrograph 
(hematoxylin and eosin (HE) stain, 
original magnification x200) shows 
a detailed view of the tumor with 
solid areas and adeno structures. 
(b) Photomicrograph (stained with 
endothelial marker CD 10, x400) 
shows positivity (arrows) indicating 
canalicular differentiation of areas 
within the tumor. (c) Photomicro-
graph (stained with cytokeratin CK 
7, x200) shows abundant positive 
staining, indicating epithelial dif-
ferentiation. (d) Photomicrograph 
(stained with AFP, x200) shows 
widespread positivity, and hence a 
hepatocellular origin of the tumor.
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aging protocols can help to improve image quality at 
3.0T10-12. 
However, the implementation of T2-weighted-, and 
particularly FSE sequences at 3.0T has been challeng-
ing. Such sequences are RF intensive due to applica-
tion of multiple refocusing RF pulses. This translates 
into higher specific absorption rates (SAR), which are 
quadrupled at 3.0T12. Higher SAR values diminish the 
anatomic coverage and can lengthen the exam times 
considerably. In addition, B1 inhomogeneities and di-
electric resonances may create intensity modulations 
including focal shading or local decrease in signal 
intensity, which are more pronounced at higher field 
strength13. This may degrade image quality even in 
well-shimmed imaging volumes and may result in in-
sufficient or heterogeneous fat suppression. .
One way of getting around B1-inhomogeneities is 
to apply adiabatic fast passage (AFP) RF pulses dur-
ing excitation and refocusing.  These RF pulses have 
been implemented in current FSE readout modules 
at 3.0T7,14. Nonetheless, AFP RF pulses are longer and 
necessitate higher power to overcome the inhomo-
geneous B1 excitation that otherwise would occur 
with normal RF pulses. Therefore, application of AFP 
RF pulses can increase SAR and hence result in lower 
anatomic coverage per TR with longer exam times at 
3.0T. 
In addition, variable-rate selective excitation (VERSE) 
radiofrequency (RF) pulses have been proposed and 
re-introduced to reduce SAR at 3.0T15-19. In essence, 
a VERSE-RF pulse is non-adiabatic, and is designed 
and played during an amplitude-modulated gradient 
waveform rather than during a constant gradient. By 
reshaping the gradient waveform, the gradi-
ent amplitude is lower during the main lobe 
and higher at the edges of the RF pulse. This 
reduces SAR while keeping the same excita-
tion time and essentially the same spatial 
excitation profile (Fig. 1)(16). In addition, the 
VERSE designed pulses are less sensitive to 
B1-inhomogeneity20. 
To our knowledge, none of the previous 
publications have reported the application 
of VERSE-RF pulses in T2-weighted FSE se-
quences as a mean to increase slice cover-
age and to obtain improved image quality by using 
combined partial Fourier and parallel imaging for liver 
imaging at 3.0T. 
The purpose of this paper was therefore, to deter-
mine the benefits of variable-rate selective excita-
tion (VERSE) RF pulses for extending slice coverage 
in breath-hold fat-suppressed T2-weighted fast spin-
echo (FS-T2-weighted-FSE) liver MR imaging at 3.0 T. 
MATERIALS AND 
METHODS
This study was approved by the local ethics com-
mittee as part of an ongoing sequence optimization 
project. Twelve healthy volunteers (7 male, 5 female) 
were imaged on a 3.0T MR scanner (General Electric 
Healthcare, Signa Eclipse, Milwaukee, Wisconsin, USA) 
under software release 12X (Excite HD), using a body 
coil as signal transmitter and an 8-channel phased-ar-
ray coil for signal reception. The MR system has high 
performance gradients (40 mT/m, 266 msec rise time 
to peak maximum) and parallel imaging acceleration 
factor of 2.00 for two-dimensional (2D) imaging. The 
operating mode was set to first level dB/dt and first 
level SAR limits (according to the FDA guidelines: SAR 
threshold for normal and first-level controlled modes 
are 2 and 4 W/kg respectively)21. Informed consent 
was signed by all participants after a brief interview 
to check for contraindications and explanation of the 
procedure. 
Figure 1: Schematic presentation of radio-
frequency (RF) waveform in standard en vari-
able-rate selective excitation (VERSE). 
(a) RF pulse waveform in standard and VERSE excita-
tion. Note that the standard RF pulse is stronger 
towards the center of the wav, whilst the RF amplitude 
for VERSE excitation is increased and acceleration 
towards the edges of the pulse. (b) Accompanying 
gradient waveform, which is constant during the 
entire excitation for standard excitation. Note the 
waveform has changed in VERSE excitation, with 
increased amplitude toward the edges of the pulse. 
ABSTRACT
Purpose: To determine the benefits of variable-rate-se-
lective excitation (VERSE) RF pulses for increased slice 
coverage in breath-hold fat-suppressed T2-weighted 
fast spin-echo (FS-T2-weighted-FSE) liver imaging at 
3.0T.
Material and Methods: Twelve healthy volunteers 
were imaged at 3.0T, using FS-T2-weighted-FSE. Slice 
coverage and specific absorption rate (SAR) levels 
were monitored for VERSE- and standard-RF, respec-
tively. breath-hold time was 25 sec; slice thickness 
3.5 mm. Maximum coverage was assessed for inter-
active variation of repetition time (TR), bandwidth 
(BW) and echo-train length (ETL). Image quality was 
assessed qualitatively and quantitatively.
Results: Total slice coverage was always higher us-
ing VERSE-RF, but varied depending on the selected 
parameters. For BW ≥62.5 KHz, slice coverage us-
ing VERSE increased between 38% (TR=8200 msec) 
and 58% (TR=2500 msec). Maximum coverage was 
obtained for TR=5000 msec, ETL=12 and BW ≥62.5 
KHz; with a mean of 31.8 slices for VERSE and 22.5 
slices for standard-RF, respectively (p<0.005, 41% in-
creased coverage). SAR was lower for VERSE-RF using 
BW <41.67 KHz (p<0.05), and equal to standard-RF for 
higher BW. Image quality was best for TR ≤5000 msec 
(p<0.05). Fat-suppression was more homogeneous for 
lower ETL (p<0.05). Blood suppression was best for TR 
≤5000 msec (p<0.05).
Conclusion: VERSE RF pulses can be applied for thin-
slice breath-hold fat-suppressed T2-weighted liver 
imaging at 3.0T, with significantly improved slice cov-
erage.
INTRODUCTION
Annually, magnetic resonance (MR) imaging of the 
liver is routinely performed in thousands of patients 
worldwide, as part of clinical imaging work-up in 
case of suspected or proven focal liver lesions1. The 
unique ability of MR imaging to detect intrinsic cel-
lular characteristics combined with dynamic contrast-
enhanced imaging renders it a superior technique for 
detection and characterization of liver lesions com-
pared to other imaging modalities such as computed 
tomography (CT) or ultrasound (US), without radia-
tion exposure2,3. 
At 1.5T, routine state-of-the-art imaging consists of 
T1-weighted sequences with in- and opposed-phase 
(chemical shift) imaging; single-shot T2-weighted fast 
spin echo (FSE) sequences; fat-suppressed T2-weight-
ed sequences and dynamic multiphasic gadolinium-
enhanced imaging4. Fat-suppressed T2-weighted se-
quences are essential for detection of liver nodules, 
including metastases5,6. 
The introduction of 3.0T MRI systems with the devel-
opment of coils with capability of parallel imaging has 
provided a number of potential advantages for hepa-
tobiliary MR imaging7,8. With about double the signal-
to-noise ratio (SNR) of a 1.5T system, 3.0T MR systems 
can substantially improve image quality and image 
acquisition speed, and can potentially deliver √2 im-
provement in resolution in the same acquisition time 
of a comparable study at 1.5T; or ½ slice thickness with 
identical coverage; or 4-fold speed up in scanning 
time for identical resolution settings9. Even though T1, 
and to a lesser degree also T2 relaxation times change 
with magnetic field strength, understanding of these 
changes and consequent adjustment of applied im-
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VERSE-RF provided a 38 – 58% increase in slice cover-
age over sRF, for the different measurement param-
eters evaluated (TR, ETL and BW). With measurements 
using VERSE-RF, marked increase in slice coverage was 
noted with increasing BW, whilst for sRF, total slice cov-
erage remained relatively stable (Fig. 2). A maximum 
mean of 31.8 slices was obtained for measurements 
using VERSE-RF, with TR=5000 msec, TE=80 msec, 
ETL=12 and BW≥ 62.5 KHz. For the same parameters, 
but using sRF, the mean number of slices was 22.5 (dif-
ference of 9.3 slices, p=0.003) (Fig. 2).  Better slice ef-
ficiency was obtained for measurements with shorter 
TRs. In this regard, the best performance for measure-
ments using VERSE-RF in comparison to sRF was ob-
tained with TR=2500 msec, TE=80 msec, ETL=8 and 
BW ≥ 62.5 KHz (Fig. 2). 
Specific absorption rate
The sequence program keeps SAR levels constant for 
all measurement parameter combinations so that the 
slice coverage is obtained within a set TR. For settings 
using lower BW (<41.67 KHz), lower SAR figures were 
obtained using VERSE-RF compared to sRF (Fig. 3). For 
the lowest BW (20.83 kHz), the difference between 
VERSE-RF and sRF approached significance (p=0.07). 
The SAR levels were similar for both RF pulses for BW 
>41.67 KHz, showing a slow but steady increase to-
wards the FDA limit and settling asymptotically to a 
mean value around 1.8/ 3.7 W/kg ((mean / peak SAR 
levels). The average mean/peak SAR levels were 1.73/ 
3.47 W/kg and 1.83/ 3.65 W/kg for VERSE-RF and sRF, 
respectively. 
IMAGE QUALITY
Qualitative assessment 
VERSE-RF pulses
The qualitative evaluation was performed for 
the following TR/ETL combinations, assessed for 
BW=62.5KHz, including A) 8200/ 
32; B) 5000/ 16; C) 3100/ 12; and 
D) 2500/8 (see Table 1). 
Overall image quality for the four 
above setting was assessed on a 
1-5 scale: A) 2.9 (range 2-3); B) 4.0 
(range 3-5); C) 4.2 (range 4-5) and 
D) 4.4 (range 4-5) respectively. 
These differences were statisti-
cally significant (A compared to B, 
C and D respectively, p<0.05). This shows that images 
obtained with TR/ETL = 8200/32 were of inferior over-
all quality (Fig. 4).
The delineation of the liver was assessed as: A) 3.0 
(range 3-3); B) 4.0 (range 3-5); C) 4.4 (range 4-5) and D) 
4.3 (range 4-5). These differences were statistically sig-
nificant (A compared to B, C and D respectively; and 
B compared to C, p<0.05). This shows that delineation 
of the liver is significantly better for sequences ob-
tained with lower TR and ETL, with best image quality 
for TR/ETL=3100/12 and TR/ETL=2500/8, respectively 
(Fig. 4). In addition, images obtained with BW>62.5 
KHz resulted in significantly lower SNR, which was 
detrimental to delineate liver borders.
The mean score for tissue sharpness related to blurring 
was assessed as: A) 3.0 (range 2-4); B) 3.7 (range 3-4); 
C) 3.9 (range 3-4) and D) 4.0 (range 3-5). These differ-
ences were statistically significant (A compared to B, 
C and D respectively, p<0.05). This shows that images 
obtained with TR/ETL=8200/32 have significantly in-
creased blurring in the phase encoding direction with 
any BW selected (Fig. 4). Conversely, images acquired 
at lower BW (e.g. ≤ 31.25 KHz) demonstrate blurring 
with ETL ≥12.  It is regarded that all images collected 
with acquisitions windows over 150 msec during the 
FSE readout show increased blurring from T2 decay. 
This is related to faster T2 signal decay for longer T2 
species compared to shorter species, an effect which 
is more pronounced for sequences obtained with lon-
ger ETL. Since longer ETL values allow more time for 
signal decay, this results in increased image blurring. 
The quality and homogeneity of the fat-suppression 
was assessed as: A) 2.5 (range 2-3); B) 3.9 (range 3-4); 
C) 4.1 (range 4-5) and D) 4.4 (range 4-5). These differ-
ences were statistically significant (A compared to B, C 
and D respectively; and B compared to C, p<0.05). This 
confirms that images obtained with lower ETL values 
have better and more homogeneous fat-suppression 
(Fig. 4).
Figure 3: Peak SAR levels in VERSE 
and normal RF pulses respectively, 
for TR=5000 msec and ETL=16. 
Note that peak SAR levels in VERSE 
RF pulse sequences were lower 
for bandwidth <41.67 kHz.
MR imaging sequence
Imaging was performed with a breath-hold fat-sup-
pressed T2-weighted fast spin-echo (FS-T2-weighted-
FSE) sequence using VERSE and standard RF (sRF) 
pulses, respectively. The goal was to acquire full ana-
tomic coverage of the liver in a maximum of 2 breath-
hold acquisitions of 25 seconds each. Thin slices (3.5 
mm, no interslice gap) were prescribed to obtain 
better through-plane resolution for improved mul-
tiplanar sections in all orientations. To assess image 
quality and slice coverage, an interactive variation of 
repetition time (TR) (8200, 5000, 3100 and 2500 msec), 
read bandwidth (BW) (125, 83.33, 62.50, 41.67, 30.83 
and 20.83 KHz), echo-train length (ETL) (32, 16, 12 and 
8 respectively) was performed using both VERSE and 
sRF pulses. The echo time (TE) was kept constant at 
80 msec. Imaging matrix was set to 320 x 288; field of 
view (FOV) 320-400 x 240-300 cm2 (to fit the anatomy); 
rectangular FOV of 75%; frequency direction left-to-
right; standard fat suppression pulse; partial Fourier 
(1/2 NEX); and parallel imaging acceleration factor 
(ASSET, Array Spatial Sensitivity Encoding Technique) 
of 2.00, resulting in a final voxel size of 1.0-1.25 x 0.83-
1.0 x 3.5 mm3. The shim was adjusted once at the be-
ginning of the measurements and kept constant for 
all the iterations performed. 
Image analysis
On scans collected with VERSE-RF and sRF pulses, the 
maximum number of slices obtained within one 25-
second breath-hold was registered. SAR parameters 
(mean and maximum levels) were recorded for each 
scan. The following items were evaluated qualitatively 
(subjectively): 1) overall image quality; 2) delineation 
of the liver (i.e. how well the liver contours could be 
identified); 3) tissue blurring from T2 decay during 
the FSE train; 4) fat-suppression homogeneity and 5) 
blood signal inside the hepatic vessels. These items 
were rated on a 1-5 scale (1 = unacceptable, 2 = poor, 
3 = fair, 4 = good and 5 = excellent). For quantitative 
measurements, region-of-interest (ROI) of approxi-
mately 100 mm2 were placed in liver, subcutaneous 
fat (where the largest variation in signal was observed 
with changes in ETL) and spleen. Care was taken to 
exclude vessels or biliary structures. For quantitative 
analyses of SNR of liver, signal intensity (SI) measure-
ments close to the anterior coils of the array coil were 
compared to SI of central liver parenchyma. SNR was 
calculated as mean signal intensity scaled to back-
ground noise. ROI measurements were performed 
in the ventral subcutaneous fat (close to the anterior 
coils) and in the dorsal subcutaneous fat for analysis 
of the homogeneity and quality of the fat-suppres-
sion. In addition, to compare the SNR of measure-
ments using the VERSE and the normal RF pulses, the 
optimally selected VERSE sequence parameters were 
compared to the corresponding one using normal RF 
pulses, with ROI evaluations performed in liver, kidney, 
spleen and muscle in identical locations. For analysis 
of the liver-to-spleen (which can be used for an indi-
cation for liver-to-lesion contrast) contrast-to-noise 
ratio (CNR), ROI measurements were performed both 
in spleen and liver at approximately 5 cm from the 
posterior coil array. CNR was calculated as difference 
in signal intensity between lesion and liver scaled to 
standard deviation of background noise of the liver SI 
sample.
Statistical analysis
Statistical parameters (mean, median, standard devia-
tion, and range) were calculated using the Statistical 
Package for Social Sciences (SPSS) program. Signifi-
cance levels were determined by a Wilcoxon signed 
rank test analysis. A p-value of less than 0.05 was con-
sidered statistically significant. 
RESULTS
Slice coverage
For the set 25 sec breath-hold period, the use of 
Figure 2: Slice coverage 
in VERSE and normal RF 
pulses respectively.
The maximum amount 
of slices can be obtained 
using a combination of 
repetition time (TR) of 
5000 msec and echo train 
length (ETL) of 16 respec-
tively, for bandwidth (BW) 
> 62.5 KHz. For this set of 
parameters, a mean total of 
31.8 slices can be achieved, 
compared to 22.5 slices for 
sequences obtained with 
the same parameters and 
the application of a stan-
dard RF pulse (p=0.003).
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5). This showed a range of slightly decreased signal 
intensity of VERSE-RF compared to normal RF of 0.8 - 
10.5% for liver, spleen, kidney and muscle respectively 
(Table 3). 
DISCUSSION
In this study, we evaluated the application of SAR-
reduced VERSE-RF pulses as a means for providing 
increased slice coverage for liver imaging at 3.0T. A 
FS-T2W-FSE sequence was selected for performance 
comparison of VERSE-RF and sRF pulses respectively, 
because of proven benefits of similar sequences for 
lesion detection at 1.5T. 
The most important findings 
of our study include: 1) fat-sup-
pressed T2-weighted imaging of 
the liver at 3.0T can be improved 
and facilitated by the application 
of VERSE-RF pulses; 2) the use of 
VERSE-RF pulses provides a 38 – 
58% increase in slice coverage for breath-hold fat-sup-
pressed T2-weighted imaging of the liver at 3.0T; 3) 
the potential for large volume coverage using VERSE 
permits thin-slice volumetric imaging, showing better 
suppression of the blood signal, which, in turn, facili-
tates the detection of smaller liver lesions. 
These findings are clinically relevant for a number of 
reasons. First, imaging restrictions for abdominal im-
aging at 3.0T associated with higher SAR deposition 
can be relieved by use of VERSE-RF. SAR scales propor-
tional to square the static magnetic field strength B0, 
which implies that sequences using sRF will produce 
fourfold SAR increase at 3.0T8. RF intensive sequences 
such as breath-hold FS-T2-weighted-
FSE scans used had severe limitations at 
3.0T in prior software implementations 
in which SAR levels dramatically limited 
the amount of refocusing pulses per unit 
time8,12. This provided poor slice cover-
age performance per breath-hold that 
translated into prolonged scan durations 
for full anatomic liver coverage. 
Secondly, state-of-the-art MR imag-
ing protocols typically include FS-T2-
weighted-FSE sequences, which many 
centers consider as an essential part of 
Figure 5: Comparison of image quality 
in VERSE versus standard-RF, for TR=5000 
msec, ETL=16, and BW=62.5 KHz (slice thick-
ness 3.5mm, no interslice gab), illustrating 
that the visual image quality is comparable.
Figure 6: Multiplanar reformatting capabilities for volumetric fat-suppressed T2-weighted FSE with VERSE (TR=5000 msec, ETL=12, 
BW=62.5 KHz). (a) Axial image acquired with slice thickness 3.5mm, allowing for multiplanar reformatting capabilities; (b) sagittal  
reconstruction and (c) coronal reconstruction. Note the clear and homogeneous suppression of the blood signal.
  VERSE-RF standard-RF
  Overall image quality 4.0 (3.0-5.0) 3.7 (3.0-4.0)
  Liver delineation 4.0 (3.0-5.0) 3.6 (3.0-4.0)
  Tissue blurring 3.7 (3.0-4.0) 3.4 (3.0-4.0)
  Suppression fat signal 3.9 (3.0-4.0) 3.7 (3.0-4.0)
  Suppression blood signal 4.0 (4.0-4.0) 3.4 (3.0-4.0)
Table 2 
Comparison of qualitative image quality for VERSE-RF compared to standard-RF, for
TR=5000 msec, ETL=16, and BW=62.5 KHz (slice thickness 3.5mm, no interslice gab),
using a 1-5 scale
The quality of blood signal suppression in vessels was 
assessed as: A) 3.4 (range 3-4); B) 4.0 (range 4-4); C) 4.0 
(range 4-4) and D) 4.0 (range 4-4). These differences 
were statistically significant (A compared to B, C and 
D respectively (p<0.05). Sequences obtained with 
TR/ETL=8200/32 showed more remnant blood sig-
nal. The optimized sequence using TR/ETL=5000/16 
showed homogeneous, good suppression of the sig-
nal from inflowing blood (Fig. 4).
VERSE compared to standard-RF pulses
The image quality of the VERSE-RF sequence with 
optimal coverage (TR=5000msec, ETL=16, and 
BW=62.5KHz) was compared to the sequence ob-
tained with standard-RF pulses, illustrating compara-
ble subjective image quality, and better suppression 
of the blood signal on images obtained with VERSE-
RF (p=0.008) (Table 2, Fig. 5). 
 
Quantitative measurements
VERSE-RF pulses
The mean SNR of liver was significantly higher close to 
the anterior section of the cardiac array coil, when com-
pared to mean SNR of central liver parenchyma (Fig. 
7) (p<0.05). Although SNR varied significantly over the 
entire liver, the lowest SNR recorded was considered 
good enough to delineate structures with the select-
ed BW of 62.5 KHz and 3.5 mm slices. SNR increased 
for images obtained with 
TR/ETL=2500/8, related to 
automatic system adjust-
ment of TE, with lower-
ing to 50 msec.  For scans 
obtained with decreasing 
ETL, significant decrease 
in mean SI of subcutane-
ous fat was observed. This 
confirmed the quantita-
tive measurement data 
(Fig. 8). 
The CNR measurements 
between liver and spleen 
decreased with lower TR, 
providing values of 5.66 / 4.44 / 3.77 / 2.26 for TR 8000 
/ 5000 / 3100 / 2500, respectively (p<0.05). This illus-
trates that maximum CNR is obtained for measure-
ments with longer TR.
VERSE compared to standard-RF pulses
The SNR and CNR of the VERSE sequence with optimal 
coverage (TR=5000 msec, ETL=16, and BW=62.5 KHz) 
was compared to the data obtained in the standard-
RF sequence obtained with identical parameters (Fig. 
Table 1
Qualitative assessment of image quality in VERSE, assessed on a 1-5 scale.
                 Repetition time / echo train length
8000 / 32 5000 / 16 3100 / 12 2500 / 8
  Overall image quality 2.9 (2.0-3.0) 4.0 (3.0-5.0) 4.2 (4.0-5.0) 4.4 (4.0-5.0)
  Liver delineation 3.0 (3.0-3.0) 4.0 (3.0-5.0) 4.4 (4.0-5.0) 4.3 (4.0-5.0)
  Tissue blurring 3.0 (2.0-4.0) 3.7 (3.0-4.0) 3.9 (3.0-4.0) 4.0 (3.0-5.0)
  Suppression fat signal 2.5 (2.0-3.0) 3.9 (3.0-4.0) 4.1 (4.0-5.0) 4.4 (4.0-5.0)
  Suppression blood signal 3.4 (3.0-4.0) 4.0 (4.0-4.0) 4.0 (4.0-4.0) 4.0 (4.0-4.0)
Figure 4: Variation in repetition 
time (TR) and echo train length 
(ETL) for VERSE sequences, 
with fixed bandwidth (BW) 
of 62.5 KHz and TE=80 msec. 
Note that in image (a), more 
blurring and more inhomoge-
neous fat-suppression is noted 
compared to the other images.
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acquired and not in SAR levels recorded for the same 
settings. Therefore, we assume that MTC effects are 
similar. 
Third, it is well recognized that fat-suppression is diffi-
cult using FSE readout modules because of j-coupling 
effects that enhance fat signal. This effect is more 
noticeable with larger ETL values (e.g., as observed in 
long TE, plain or fat suppressed single shot FSE scans). 
It is well documented that elimination of fat provides 
an increased dynamic range for effective lesions de-
tection. Also, fat-suppression helps to reduce anterior-
posterior ghosting when patients are not able breath-
hold adequately, arising from high fat signal due to 
its proximity to the coil placed over chest and upper 
abdomen. Another advantage of fat-suppression is 
improved SNR and resolution, by optimizing signal re-
ception gain and elimination of quantification errors 
at the edges of k-space. In our study, fat-suppression 
improved for lower ETL selections, since lowering the 
number of RF refocusing pulses reduces j-coupling 
effects.  Likewise, shorter ETL, specifically with larger 
BW readouts, reduces the module duration which 
promotes a more frequent fat-suppression pulse ap-
plication with further reduction in fat signal. 
Fourth, the larger volume coverage that is possible 
using VERSE-RF can be used for thin-slice volumet-
ric liver imaging at 3.0T. The acquisition of thin slices 
results in better suppression of blood signal, facilitat-
ing detection of smaller liver lesions. Alternatively, the 
slice thickness can be increased to further improve 
anatomic coverage and SNR.
Our study has a number of limitations. The most im-
portant limitation is the use of only volunteers as test 
subjects, without inclusion of patients with focal liver 
disease. However, to address slice efficiency for VERSE 
RF pulses in FSE scans, in our opinion, evaluating a 
group of healthy volunteers would sufficiently answer 
our research question. Additionally, the selection 
of sequence parameters was wide, but limited and 
based on assumptions made from our own experi-
ences as well as based on current literature. Our deci-
sion to aim at varying TR and ETL rather than varying 
TE was based on the fact that the T2 relaxation time 
of tissues at 3.0T are similar to 1.5T but T1 relaxation 
times are prolonged and longer TR (in conjunction 
with partial Fourier and parallel imaging) can be ef-
fectively prescribed to compensate.  Also, longer TR 
requires larger ETL values (or, alternatively, reduced 
matrix size) in order to keep the breath-hold limited 
to 25 seconds.  
To our knowledge, none of previous reports have 
described the potential of VERSE-RF to increase slice 
coverage for SAR-intensive MR imaging sequences. In 
some review articles, the limitations of T2-weighted 
imaging at 3.0T have been discussed, including de-
creased T2 signal differences between tissues8-10 and 
prolonged scan times related to SAR limits7. More re-
cently, Busse and colleagues have described a tech-
nique to generate a sequence of reduced and varying 
refocusing flip angles that can provide a lower SAR. 
In this set-up, SNR is maintained at but T2 contrast is 
managed differently through the use of T2-magneti-
zation preparation schemes22. Several other studies 
have compared imaging findings for abdominal dis-
eases at 1.5T and 3.0T23-25. These reports conclude that 
imaging at 3.0T is feasible and promising, although 
some problems related to signal homogeneity, ar-
tifacts and SNR optimization remain to be solved. 
The present study shows that improvements can be 
made for liver imaging at 3.0T, making use of imaging 
potential at higher magnetic field strength and pro-
viding solutions for known restrictions. Currently, the 
described optimized FS-T2-weighted-FSE VERSE-RF 
sequence is being evaluated at 3.0T, in patients with 
liver disease.
In conclusion, the results of our study indicate that 
VERSE-RF can be applied for thin-slice breath-hold 
fat-suppressed T2-weighted liver imaging at 3.0T, 
with significantly improved slice coverage compared 
to sequences obtained with normal RF pulses. These 
preliminary findings are important for all centers that 
have the intention to apply 3.0T MR systems for body 
imaging.
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lenging for several reasons. First, fourfold higher en-
ergy (higher B1) radio-frequency (RF) pulses are need-
ed for proton excitation, which result in increased RF 
heating and SAR levels12. Higher SAR values limit the 
efficiency for all sequences based on FSE-readouts 
and steady-state free precession, resulting in lower 
number of slices per TR. This diminishes anatomic cov-
erage and necessitates multiple breath-hold periods 
for anatomic liver coverage, with considerably longer 
exam times at 3.0T to obtain comparable diagnostic 
information as routinely acquired at 1.5T. Second, B1-
field inhomogeneities and dielectric resonances are 
more pronounced at higher field strength, resulting in 
intensity modulations (focal shading or local decrease 
in signal intensity). Implementation of alternative T2-
weighted sequences with lower RF energy deposition 
and less B1-inhomogeneities may circumvent many of 
these issues. One of these sequences may be based 
on echo-planar imaging (EPI).
EPI has been evaluated as potential ultrafast imag-
ing method for evaluation of abdominal diseases13,4, 
and can be applied for both morphologic imaging 
and more functional-oriented imaging, including ap-
parent-diffusion coefficient (ADC) mapping13-15. It has 
been advocated as promising imaging sequence at 
1.5T13,16, because it is fast, provides consistent image 
quality and provides higher contrast-to-noise ratio 
(CNR) for lesions14,17. 
To our knowledge, none of the previous studies have 
reported the implementation of a diffusion-induced, 
black-blood echo-planar imaging at 3.0T with thin-
sections for volumetric coverage of the entire liver 
within a single breath-hold. 
The purpose of this paper was to evaluate breath-hold 
diffusion-weighted black-blood echo-planar-imaging 
(BBEPI) with short and long echo time as potential al-
ternative for specific absorption rate (SAR) intensive 
echo-train spin-echo sequences for liver imaging at 
3.0T.
MATERIALS AND 
METHODS
Subjects and imaging systems
Fourteen healthy volunteers with no previous history 
of liver problems nor recent heavy alcohol consump-
tion (7 male, 7 female; mean age 32.6 years (+/- 6.8 
years)) were imaged on a General Electric 3.0T MRI 
(General Electric Healthcare, Signa Eclipse, Milwaukee, 
Wisconsin, USA), using the whole-body coil for RF ex-
citation, and an 8-channel phased-array cardiac coil 
for signal reception. The system was equipped with 
high performance gradients (40 mT/m, 266 msec rise 
time to peak maximum) and the option of using paral-
lel imaging (ASSET, array spatial sensitivity encoding 
technique) with a maximum acceleration factor of 
2.00 for two-dimensional (2D) imaging.  A subset of 
6 volunteers was imaged at a 
General Electric 1.5T MRI (Gen-
eral Electric Healthcare, Signa 
CV/i, Milwaukee, Wisconsin, 
USA) unit for signal-to-noise 
(SNR) and contrast-to-noise 
ratio (CNR) comparisons using 
identical gradient hardware 
specifications and identical 
imaging parameters. Informed 
consent was signed by all par-
ticipants after a brief interview 
to check for contraindications 
and explanation of the procedure. The study followed 
approval by the institutional review board, as part of 
an ongoing sequence optimization project.
Figure 1: Schematic presentation 
of fast spin-echo (FSE) and echo-
planar imaging  (EPI) sequences, 
illustrating multiple 180o pulses 
after the initial 90o degree pulse in 
FSE module, while in EPI, there is 
only one single 180o pulses after the 
initial 90o degree pulse. This results 
in decreased magnetic-transfer 
contrast effects, facilitating the 
detection of focal liver lesions.
ABSTRACT
We evaluated breath-hold diffusion-induced black-
blood echo-planar-imaging (BBEPI) as potential al-
ternative for SAR-intensive spin-echo sequences, in 
particular the fast spin-echo (FSE) sequences, at 3.0T. 
Fourteen healthy volunteers (7 male, 7 female; mean 
age 32.6 years (range +/- 6.8 years)) were imaged af-
ter institutional review board approval and informed 
consent were obtained. Imaging parameters were ad-
justed to obtain isotropic liver coverage in one breath-
hold (max 25 seconds). BBEPI with short and long TE 
(25 and 80 msec respectively) were evaluated and 
compared to breath-hold fat-suppressed T2-weighted 
fast spin-echo (FS-T2-weighted-FSE) by two radiolo-
gists in consensus, providing: 1) comparable diagnos-
tic image quality, including liver delineation, blurring 
and geometric distorsions; 2) improved suppression 
of fat- and blood-signal and 3) higher CNR and SNR. In 
6 of 14 volunteers, the images were obtained both on 
1.5T and 3.0T, showing higher SNR and CNR for BBEPI 
on 3.0T. In conclusion, BBEPI can be used for ultrafast, 
low SAR, thin-slice morphologic imaging of the entire 
liver in a single breath-hold at 3.0T.
INTRODUCTION
Magnetic resonance (MR) imaging is considered to be 
an imaging modality with high accuracy for diagnos-
tic work-up of patients with suspected or proven focal 
liver lesions1. Typically, the routine MR imaging proto-
col for diagnostic work-up of liver diseases consists of 
T1-weighted gradient-echo (GRE) sequences before- 
and after injection of gadolinium; and various echo-
train fast spin-echo (FSE) sequences, with- and with-
out fat-suppression. Particularly, multi-shot echo-train 
FSE sequences are important for lesion detection2,3.
Currently, the transition of imaging protocols from 
1.5T to 3.0T is being evaluated by several authors4-8. 
The introduction of 3.0T MR imaging systems and coil 
development with capability of parallel imaging has 
shown to be promising for improved hepatobiliary 
imaging5,9. The combination of higher signal-to-noise 
ratio (SNR) compared to 1.5T (theoretically 2x higher), 
high performance gradient-systems and advanced 
software platforms allow a number of potential ad-
vantages4. Consequently, 3.0T systems can deliver 
√2 improved spatial resolution, ½ slice thickness with 
identical coverage; or 4-fold speed up in scanning 
time for identical resolution settings9. Nonetheless, 
the 4-fold higher specific absorption rate (SAR) as 
compared to 1.5T, T1-lengthening and slight shorten-
ing of T2-relaxation times necessitate a revision of the 
imaging parameters for optimal imaging sequences, 
to provide better image quality and performance at 
3.0T. In addition, the theoretically doubled SNR on 3.0T 
is usually lowered by a combination of several factors, 
including B1 inhomogeneities, lengthening of T1-re-
laxation times and higher readout bandwidths10,11. 
These factors limit the introduction of routine clinical 
imaging of the abdomen on 3.0T.
T1-weighted GRE sequences at 3.0T have taken full 
advantage of increased SNR, translating into fat-sup-
pressed thin-section three-dimensional imaging with 
high in-plane resolution and good imaging quality9. 
However, T2-weighted FSE sequences at 3.0T are chal-
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the FSE sequence as the reference standard. These 
items were rated using a 1–5 scale (1=unacceptable, 
2=poor, 3=fair, 4=good and 5=excellent). For quan-
titative measurements, operator-defined regions-of-
interest (ROI) of approximately 100 mm2 were placed 
in liver and spleen for measurement of mean signal 
intensity (SI), all performed by one of the authors (IB). 
Care was taken to exclude vessels or biliary structures. 
For analysis of the liver-to-spleen CNR (which can be 
used for an indication for liver-to-lesion contrast), ROI 
measurements were performed in both spleen and 
liver at approximately 5 cm from the posterior coil ar-
ray. The SI was normalized to the standard deviation 
(SD) of background noise of the liver SI sample, and 
expressed as SNR. CNR was calculated as difference 
in SI between lesion and liver scaled to SD of back-
ground noise. 
Statistical analysis
Statistical parameters (mean, median, standard de-
viation, and range) were calculated using the Statisti-
cal Package for Social Sciences (SPSS, version 12.0.1) 
program. Significance levels of the data 
obtained in the qualitative and quantita-
tive assessements were determined by a 
non-parametric Wilcoxon’s signed rank test 
analysis. A p-value of less than 0.05 was con-
sidered the limit for statistical significance. 
 
RESULTS
The optimized short-TE- and long-TE-BBEPI 
provided 1) comparable image quality, liver 
delineation and blurring; 2) improved sup-
pression of fat- and blood-signal and 3) 
higher CNR and SNR compared to FS-T2-
weighted-FSE. Geometrical distortions in 
BBEPI were acceptable. Comparison of the 
data for BBEPI on 1.5T versus 3.0T showed 
comparable, or even improved SNR and 
CNR for both short-TE and long-TE-BBEPI. 
The results are described in more detail 
below. 
Sequence and parameter optimization
The selected short-TE- and long-TE-BBEPI sequences 
(Fig. 2) were optimized for maximum slice cover-
age, resulting in imaging parameters as provided in 
Table 1. The optimization process involved the follow-
ing steps: 
1) Slice coverage: within the set 25 second breath-
hold, complete anatomic thin-slice liver coverage 
was possible using short-TE-BBEPI (2 mm slices). Slice 
thickness was doubled (4 mm) for long-TE-BBPEPI to 
increase SNR and to keep total liver coverage similar 
to short-TE-BBEPI, because the selection of longer TE 
resulted in an approximate 40% reduced slice cover-
age. 
2) b-value: slice efficiency and image quality (sensitiv-
ity to bulk motion) were dependent on the selected 
b-value (Fig 3). Increased b-values resulted in lower 
slice efficiency, but with more consistent blood sup-
pression, especially in the region of the inferior ca-
val vein. Higher b-values increased the sensitivity to 
bulk motion, demonstrating better suppression of 
slow-flowing blood but with appearance of darker 
Figure 3: Variation in diffusion factor (b-factor) 
for short-TE-BBEPI in the same volunteer (TR=6300 
msec). (a) b=10 s/mm2, TE=24.1 msec; (b) b=20 s/mm2, 
TE=26.4 msec; (c) b=50 s/mm2, TE=30.6 msec; (d) 
b=100 s/mm2, TE=34 msec; (e) b=250 s/mm2, TE=42 
msec; (f) b=500 s/mm2, TE=50 msec. SNR decreases 
with increasing b-factor as a result of resulting 
longer TE necessary to accommodate the requested 
b-factor value.  With increasing b-value, signal 
dephasing in regions with motion is more prominent, 
mainly from bowel motion and cardiac pulsation.
MR imaging sequence
Diffusion-induced black-blood echo-planar imaging 
(BBEPI) (Fig. 1) providing a trace diffusion-induced im-
age (addition of three independent scans with diffu-
sion sensitizing gradients in x, y and z, respectively) 
was chosen for volumetric liver imaging.  The se-
quence was selected from an existing pulse sequence 
program on the system: pulse sequence family EPI, 
DW-EPI, 2D imaging mode. A 25-second breath-hold 
at end-expiration was considered for evaluation. The 
following imaging parameters were varied interac-
tively to obtain full liver coverage in an optimization 
setting: slice thickness (2, 3 and 4 mm), ASSET accel-
eration factor (none, 2) and diffusion b-value (10, 20, 
40, 50, 100, 250 and 500 s/mm2). Matrix size was set to 
160x192 (frequency and phase-encoding directions); 
field of view (FOV) 520 x 260 cm2, rectangular FOV 
of 50% and number of excitations (NEX) of one. The 
resulting voxel size was 3.00x2.70x(1.60-4.00)mm3. A 
standard fat-suppression pulse was used. Repetition 
time (TR) was kept constant at 6300msec. Echo time 
(TE) was internally adjusted by the sequence program, 
but could be varied using an “optimize TE” setting (re-
sulting in TE variation of 20-35msec, depending on b-
value setting).  For low-TE setting (< 35msec), full liver 
coverage with 2.0-mm slice thickness was obtained. 
The high-TE setting (80msec) slice thickness of 4.0-
mm was chosen to obtain identical coverage, since 
this resulted in 40% reduced slice coverage. To evalu-
ate the extent of geometrical distortions and signal 
loss around air-tissue interface regions (e.g., vascular 
structures), three matrix sizes were collected: 64 x 192, 
160 x 192 and 192x192.  The optimized sequences were 
prescribed with parameters as described in Table 1.
Fa t- s u p p r e s s e d 
T2-weighted fast 
spin-echo (FS-T2-
weighted-FSE) (Fig. 
1) was performed 
in a 25-second 
breath-hold pe-
riod, using the 
following parame-
ters: TR 5000msec, 
TE 80msec, echo-
train-length (ETL) 
12, read-out band-
width 62.5 KHz, 
imaging matrix 
320x288, field of 
view (FOV) 320-
400 x 240-300cm2 
(to fit the anato-
my); rectangular FOV of 75%; frequency direction left-
to-right; standard fat suppression pulse; partial Fourier 
(1/2 NEX); and acceleration factor (ASSET) 2.00, result-
ing in a final voxel size of 1.0-1.25x0.83-1.0x3.5mm3.  
Image analysis
Image quality was assessed both qualitatively (sub-
jectively) and quantitatively on the optimized short-
TE- and long-TE-BBEPI sequences. For the qualitative 
assessment, the following items were evaluated by 
two authors in consensus (IB, SH; 3 and 11 
years experience in interpretation of ab-
dominal MR respectively): 1) overall image 
quality; 2) delineation of the liver (e.g. how 
well the liver can be distinguished from 
the surrounding tissues); 3) tissue blurring; 
4) fat-suppression homogeneity; 5) suppression of 
the blood signal inside the hepatic vessels; and 6) 
geometric distortion at air-tissue interfaces, using 
Figure 2: Optimal BBEPI settings in a healthy 
volunteer (a) Axial short-echotime black-blood 
EPI scan (short-TE-BBEPI) (TE=25 msec, TR=6300 
msec and b=10 s/mm2); (b) Axial long-echotime 
black-blood EPI scan (long-TE-BBEPI)  (TE=80 
msec, TR=6300 msec and b=10 s/mm2).
Table 1
 
Selected optimized parameters for short-TE diffusion-induced black-blood echo-planar imaging (BBEPI), long-TE-
BBEPI, and fat-suppressed T2-weighted fast spin-echo (FS-T2-weighted-FSE); with the objective to reach full  
anatomic liver coverage (25-cm max) within one breath-hold period (25 sec).
  short-TE-BBEPI long-TE-BBEPI FS-T2-weighted-FSE
  Slice thickness 2.0 mm 4.0 mm 3.5 mm
  Matrix size 160 x 192 160 x 192 320 x 288
  Field-of-view 520 x 260 cm2 520 x 260 cm2 400 x 300 cm2
  Voxel size 3.1 x 2.6 x 2.0 mm3 3.1 x 2.6 x 4.0 mm3 1.25 x 1.0 x 3.5 mm3
  Echo time (TE) 25 msec 80 msec 80 msec
  Repetition time (TR) 6300 msec 6300 msec 5000 msec
  b-value (x, y, z) 10 s/mm2 10 s/mm2 -
  Number of excitations (NEX) 1 1 1/2
  Acceleration factor (ASSET) 2.00 2.00 2.00
104
hi
gh
 m
ag
ne
ti
c 
fie
ld
 st
re
ng
th
BB
EP
I
5 105
hi
gh
 m
ag
ne
ti
c 
fie
ld
 st
re
ng
th
BB
EP
I
5
the FSE sequence. 
Blurring was as-
sessed as 3.2 (range 
3-4) in short-TE-
BBEPI, 3.0 (range 3-
3) in long-TE-BBEPI 
and 3.4 (range 3-4) 
in FS-T2-weight-
ed-FSE. Although 
there was slightly 
increased blurring 
in the BBEPI se-
quences, this was not significantly different. 
The quality of the fat-suppression was assessed as 
4.4 (range 4-5) in short-TE-BBEPI, 4.2 (range 3-5) in 
long-TE-BBEPI and 3.7 (3-4) in FS-T2-weighted-FSE. 
Fat-suppression was more homogeneous in BBEPI, il-
lustrating improved fat-suppression compared to FSE 
sequences (p<0.05). 
The suppression of the blood signal inside the hepatic 
vessels was assessed as 4.9 (range 4-5) in short-TE-BBE-
PI, 4.4 (range 4-5) in long-TE-BBEPI and 3.4 (range 3-4) 
in FS-T2-weighted-FSE (p<0.05). This shows improved 
suppression of the signal resulting from inflowing 
blood in sequences obtained with BBEPI. 
The extent of geometric distortions at air-tissue inter-
faces was assessed as 3.4 (3-4) in short-TE-BBEPI, 3.2 (3-
4) in long-TE-BBEPI and 5 (5-5) in FS-T2-weighted-FSE. 
This shows that geometric distortions are significantly 
lower in FSE (p<0.05), but the extent of distortions is 
acceptable for BBEPI (mean score of 3 means fair im-
age quality) (Fig. 5). 
Quantitative assessment
For the quantitative assessment, SNR of liver and 
spleen, and CNR were calculated (Table 3). 
These results show that in all cases, SNR and CNR is 
lowest in FS-T2-weight-
ed-FSE, compared to the 
BBEPI sequences (p=0.03 
compared to long-TE-BBEPI and p=0.06 for short-TE-
BBEPI) (Fig. 6, 7). SNR was highest in short-TE-BBEPI 
for both liver and spleen, statistically significant for 
liver (p<0.05). (see Fig. 6, 7 for illustrations). CNR was 
highest in long-TE-BBEPI (15, compared to 7.8 and 4.8 
in short-TE-BBEPI and FS-T2-weighted-FSE) (p< 0.05). 
This shows that BBEPI is likely to be superior to FS-T2-
weighted-FSE for lesion detection. 
Comparison 3.0T and 1.5T 
Overall image quality of BBEPI sequences at 3.0T was 
improved due to increased SNR compared to 1.5T 
(Fig. 8). The comparison of SNR at short-TE-BBEPI for 
images acquired at 1.5T versus 3.0T shows that differ-
ent slice thickness acquired at 1.5T results in increas-
ing SNR for thicker slices, but SNR is lower compared 
to 3.0T (Table 4, Fig. 8). When comparing CNR for both 
  short-TE-BBEPI
3.0T
2 mm
1.5T
2 mm
1.5T
4 mm
  SNR liver 11.5 (5.2 – 19.8) 5.6 (3.8 – 7.6) 10 (4.3 – 15.2)
  SNR spleen 13.8 (8.7 - 25.6) 9.9 (8.1 – 12) 10.6 (9.7 – 12.5)
  CNR 7.8 (1.1 – 12) 4.9 (3.1 – 7.4) 7.2 (4.2 – 8.8)
Table 4
Comparison of SNR on short-TE diffusion-induced black-blood echo-planar imaging (BBEPI),for images acquired
at 1.5T versus 3.0T show that different slice thickness acquired at 1.5T results in increasing SNR for thicker slices,
but SNR is still lower compared to 3.0T images (see Table 3). Even with double the slice thickness on 1.5T, (4 mm
compared to 2 mm at 3.0T), SNR is lower.
Figure 5: Geometrical distor-
tions comparison between 
FSE and EPI scans. (a,b) Axial 
breath-hold 3.5 mm T2-weight-
ed fat-suppressed FSE (TE=80 
msec, TR=5000 msec); (c,d) 
Corresponding axial 2 mm thick 
section short-TE-BBEPI (TE=25 
msec, TR=6300 msec and b=10 
s/mm2), showing locations 
where geometric distortions 
occur.  The solid arrows point 
at air close to the liver from the 
small bowel inducing in the 
short-TE-BBEPI scan geometrical 
distortions and signal loss. In 
this particular volunteer, the 
geometrical distortions close to 
the liver-lung interface (dotted 
arrows) were the largest among 
all volunteers evaluated.
regions around the heart and bowel, especially with 
thin imaging sections (2.0 mm). Because SNR and CNR 
between liver and vascular structures decreased with 
longer TE, a b=10 s/mm2 was taken as optimal, even 
though some remnant blood signal was sometimes 
observed in peripheral intrahepatic veins when thick-
er slices were selected.
3) Matrix size: variations in the number of frequency 
encoding points used demonstrated increased geo-
metrical distortions for higher frequency encoding 
points, as well as 
increased signal 
loss (Fig. 4). As pre-
vious experience 
demonstrated op-
timal image qual-
ity for measure-
ments with fewer 
frequency points 
than phase-en-
coding steps14, the 
optimal imaging 
matrix was set to 
160x192. 
Image quality
Qualitative assess-
ment
The subjective 
analysis was per-
formed for the two 
optimized EPI se-
quences (short-TE- 
and long-TE-BBEPI) 
and FS-T2-weight-
ed-FSE (Table 2). 
Overall image 
quality was 3.6 
(range 3-4) in short-TE-BBEPI, 
3.2 (range 3-4) in long-TE-BBE-
PI and 3.7 (3-4) in FS-T2-weighted-FSE. These results 
were not significantly different, showing that image 
quality in BBEPI is comparable to FSE sequences. 
The delineation of the liver was assessed as 3.9 (range 
3-4) in short-TE-BBEPI, 3.0 (range 3-3) in long-TE-BBEPI 
and 3.6 (range 3-4) in FS-T2-weighted-FSE. This was 
not significantly different, showing comparable delin-
eation for the optimized BBEPI sequence compared to 
Table 2
Qualitative analysis of short-TE diffusion-induced black-blood echo-planar imaging (BBEPI), long-TE-BBEPI and
 fat-suppressed T2-weighted fast spin-echo (FS-T2-weighted-FSE) (rated using a 1–5 scale (1=unacceptable, 
2=poor, 3=fair, 4=good and 5=excellent)).
  short-TE-BBEPI long-TE-BBEPI FS-T2-weighted-FSE
  Overall image quality 3.6 (3 - 4) 3.2 (3 – 4) 3.7 (3 – 4)
  Liver delineation 3.9 (3 – 4) 3.0 (3 – 3 3.6 (3 – 4)
  Tissue blurring 3.2 (3 – 4) 3.0 (3 – 3) 3.4 (3 – 4)
  Suppression fat signal 4.4 (4 – 5) 4.2 (4 - 5) 3.7 (3 - 4)
  Suppression blood signal 4.9 (4 – 5) 4.4 (3 – 5) 3.4 (3 – 4)
  Geometrical distorsions 3.4 (3 - 4) 3.2 (3 - 4) 5.0 (5 - 5)
Table 3
Qualitative analysis of signal-to-noise ratios (SNR) for liver and spleen on 3.0T, and contrast-to-noise ratio (CNR)
for short-TE diffusion-induced black-blood echo-planar imaging (BBEPI), long-TE-BBEPI and fat-suppressed T2-
weighted fast spin-echo (FS-T2-weighted-FSE), illustrating that CNR is always lowest in FS-T2-weighted-FSE, 
compared to the BBEPI sequences (p=0.03 compared to long-TE-BBEPI and p=0.06 for short-TE-BBEPI). CNR is 
highest in long-TE-BBEPI (15, compared to 7.8 and 4.8 in short-TE-BBEPI and FS-T2-weighted-FSE) (p<0.05). SNR 
was highest in short-TE-BBEPI for both liver and spleen (p<0.05). Values represent means (range).
  short-TE-BBEPI long-TE-BBEPI FS-T2-weighted-FSE
  SNR liver 11.5 (5.2 – 19.8) 4.04 (2 – 8.4) 5.6 (4 – 6.7)
  SNR spleen 13.8 (8.7 - 25.6) 11.4 (8.8 – 18) 9.9 (6 – 16.7)
  CNR liver-spleen 7.8 (1.1 – 12) 15 (10.9 – 24.2) 4.8 (2.2 – 9.6)
Figure 4: Effect of matrix 
size in signal loss, geo-
metrical distortions and 
resolution: short-TE-BBEPI 
(TE=25 msec, TR=6300 
msec and b=10 s/mm2). 
(a) matrix size of 192 x 
192; (b) 160 x 192 and 
(c) 64x192, using 2 mm 
slice thickness.  On the 
upper row the effect of 
decreasing frequency 
points (left-right direc-
tion) is shown, illustrating 
increased geometrical 
distortions and signal loss 
in regions of increased 
magnetic susceptibility for 
higher frequency encod-
ing points (a and d), with 
approximately a three-
fold inter-echo spacing 
as compared to (c and f).
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tensive due to multiple refocusing RF-pulses (Fig. 1). 
At 3.0T compared to 1.5T, radio-frequency (RF) pulses 
with fourfold higher energy (higher B1) are needed to 
excite the protons, resulting in more RF heating and 
a fourfold higher SAR at 3.0T9,12. Total anatomic cover-
age within a single breath-hold diminishes, resulting 
in several breath-hold sessions to cover the entire liv-
er. Since T2-weighted fat-suppression sequences are 
essential for diagnostic liver imaging, development of 
low SAR T2-weighted protocols is important for im-
provement of liver imaging at higher magnetic field 
strength, including 3.0T or higher strength, including 
7.0T. 
Second, BBEPI may provide a solution for increased 
B1-inhomogeneity, dielectric resonances and prob-
lematic fat-suppression using FS-T2-weighted-FSE se-
quences on 3.0T. B1-inhomogeneity results from eddy 
currents, which act against the applied external RF-
pulses. Since RF wavelength is reduced at 3.0T due to 
higher operational frequency of 128 MHz (compared to 
64 MHz at 1.5T), conductivity increases, which results 
in stronger eddy currents. B1-inhomogene-
ities, in combination with the nature of the 
fat-suppression and refocusing pulses in 
echo-train spin-echo sequences, may also 
be responsible for relatively poorer fat-sup-
pression quality. Fat-suppression is essential 
for diagnostic T2-weighted imaging of the 
liver, as it is utilized to improve the dynamic 
range of the acquisition, which translates 
into an easier reading when bright lesions 
are found against a darkened surround-
ing3,14. Therefore, improved fat-suppression 
is important, for which the optimized BBEPI 
may provide an alternative. 
Third, in many centers diffusion-weighted 
EPI with relatively short TE is routinely ap-
plied in the liver to obtain ADC maps that 
can potentially help to improve differentia-
tion between benign and malignant liver 
lesions15. The results of our study show that 
such short-TE EPI sequence can also be 
utilized as black-blood sequence with the 
application of a low b-value in three or-
thogonal directions, with an inherent high SNR and 
CNR for morphologic imaging of the liver14,18. BBEPI 
images collected with good suppression of blood 
can therefore augment the sensitivity for visualiza-
tion of smaller liver lesions. Even though current EPI 
parameters are limited by a relatively low in-plane 
resolution, the detection of focal liver lesions at MR 
imaging mainly depends on contrast resolution and 
less on the in-plane spatial resolution. Therefore, the 
combination of inherent high contrast resolution, the 
absence of magnetic transfer contrast (MTC) effects 
(hence with higher liver-to-lesion contrast than echo-
train spin-echo sequences) and dark vessels allow for 
optimal detection of even very small liver lesions, in-
cluding high fluid-content lesions such as cysts and 
hemangiomas, as well as solid liver lesions such as 
liver metastases. 
Finally, the possibility to collect isotropic datasets with 
black-blood contrast can be of interest for detection of 
intravascular thrombi in the portal and hepatic veins, 
as an adjunct to gadolinium-enhanced T1-weighted 
Figure 8: Image quality of FS-T2-weighted-FSE 
(TE=80 msec, TR=5000 msec), short-TE-BBEPI 
(TE=25 msec, TR=6300 msec and b=10 s/mm2)and 
long-TE-BBEPI (TE=80 msec, TR=6300 msec and 
b=10 s/mm2)on 1.5T and 3.0T in the same volunteer 
as in Fig 7.Note comparable, or even slightly better 
image quality of 2-mm thick short-TE-BBEPI on 3.0T 
compared to 1.5T, and comparable image quality 
of 4-mm thick long-TE-BBEPI on 3.0T compared to 
1.5T. The long-TE-BBEPI images show lower signal 
intensity of the liver parenchyma compared to 
1.5T, explaining the higher CNR values on 3.0T.
short-TE-BBEPI and long-TE-BBEPI, values are higher 
for 3.0T compared to 1.5T imaging, although this did 
not reach statistical significance (Fig. 9). This suggests 
that lesion detection on BBEPI at 3.0T will at least be 
comparable or perhaps even better than at 1.5T.
DISCUSSION
In this study, we evaluated the application of black-
blood echo-planar imaging (BBEPI) at 3.0T as an al-
ternative for SAR-intensive T2-weighted echo-train 
spin-echo sequences. Our results indicate 
that: 1) thin-section volumetric imaging of 
the entire liver can be acquired in a single 
breath-hold, providing good overall image 
quality, acceptable anatomic distortion and 
diagnostic SNR and CNR; 2) the optimized 
BBEPI sequence shows high SNR and CNR 
on 3.0T compared to 1.5T; 3) near-isotro-
pic data obtained in short-TE-BBEPI allows 
multi-planar reformats with completely 
darkened hepatic vessels; 4) our findings 
favor the implementation of combined 
short-TE- and long-TE-BBEPI as a part of a comprehen-
sive protocol for routine liver imaging at 3.0T. BBEPI, in 
combination with other (gadolinium-enhanced) T1- 
and T2-weighted sequences, may facilitate improved 
detection and characterization of liver lesions at 3.0T.  
The results of our study are clinically relevant for a 
number of reasons. First, the optimized short-TE- and 
long-TE-BBEPI sequence provides an alternative for 
more SAR-intensive FS-T2-weighted-FSE sequences. 
Routinely, T2-weighted sequences for liver imaging 
are acquired using FSE sequences, which are RF-in-
Figure 6: Image quality of FSE and BBEPI sequences 
in the same volunteer. (a) Breath-hold 3.5 mm thick 
section T2-weighted single-shot FSE (TE=80 msec, 
TR=infinity), showing high signal of the subcutaneous 
fat;  (b) Breath-hold 3.5 mm thick section T2-weighted 
fat-suppressed FSE (TE=80 msec, TR=5000 msec); 
(c) 2 mm thick section short-TE-BBEPI, showing 
improved suppression of fat and blood signals ; 
(d) 4 mm thick section long-TE-BBEPI, showing 
marked decrease in signal intensity of the liver, but 
maintained signal of the spleen indicating good CNR.
Figure 7: Image quality in a healthy volunteer with 
small liver hemangioma as an incidental finding. (a) 
Delayed-phase contrast-enhanced multiphasic 3D 
fat-suppressed T1-weighted gradient-echo (1.5T) 
(TE=shortest, TR=shortest), which was performed 
in a routine follow-up clinical MR imaging after the 
incidental finding in the sequence optimization study, 
showing peripheral nodular enhancement, slowly 
increasing over time (other phases not shown) and fill-
ing in towards the center, as is characteristic for hem-
angioma (arrow and open arrow); (b) 3.0T T2-weighted 
fat-suppressed fast spin-echo (FSE) (TE=80 msec, 
TR=5000 msec), showing the two hyperintense lesions 
(arrows); (c) Axial 3.0T short-TE-BBEPI (TE=25 msec, 
TR=6300 msec and b=10 s/mm2), showing improved 
suppression of the fat- and blood-signal, with im-
proved conspicuity of the two lesions (arrows); (d) Axi-
al 3.0T long-TE-BBEPI (TE=80 msec, TR=6300 msec and 
b=10 s/mm2), showing marked darkening of the liver, 
but with high SNR and CNR of the two lesions (arrows).
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scribed optimized BBEPI sequence is being evaluated 
in patients with liver disease. 
In conclusion, the results of our study indicate that 1) 
thin-section volumetric imaging of the entire liver can 
be acquired in a single breath-hold, providing good 
overall image quality, acceptable anatomic distortion 
and diagnostic SNR and CNR; 2) the optimized BBEPI 
sequence shows high SNR and CNR on 3.0T compared 
to 1.5T; 3) near-isotropic data obtained in short-TE-
BBEPI allows multi-planar reformats with completely 
darkened hepatic vessels; 4) our findings favor the 
implementation of combined short-TE- and long-TE-
BBEPI as a part of a comprehensive protocol for rou-
tine liver imaging at 3.0T. BBEPI, in combination with 
other (gadolinium-enhanced) T1- and T2-weighted 
sequences, may facilitate improved detection and 
characterization of liver lesions at 3.0T.  
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images, for improved diagnostic confidence. Such 
findings may potentially have an impact on clinical 
decision making in patients with known or suspected 
hepatocellular carcinomas. In addition, patients with 
suspected or known Budd-Chiari syndrome  may 
benefit from liver MR imaging protocols that include 
BBEPI sequences. Apart from hepatic imaging, the op-
timized BBEPI sequence may have potential applica-
tions in other anatomic areas as well. 
Our study indicates that the selection of a long-TE-
BBEPI improves CNR at the cost of thicker slices, whilst 
lower TE values provide a lower CNR but higher SNR 
to provide isotropic voxel imaging (~8mm3). The com-
bination of these two acquisitions can prove useful for 
a simplified, highly sensitive liver protocol at higher 
magnetic field strengths. In this case, the implemen-
tation of a dual-echo BBEPI to acquire both contrasts 
simultaneously would result in a further decrease in 
total scan duration.
To our knowledge, none of the previous reports have 
evaluated the application of black-blood echo-pla-
nar imaging (BBEPI) at 
3.0T as an alternative 
for SAR-intensive T2-
weighted echo-train 
spin-echo sequences. 
Previously, other al-
ternatives have been 
proposed to address 
problems related to 
high SAR values associ-
ated with T2-weighted 
FSE sequences, includ-
ing RF-pulses with 
reduced flip angle, hy-
per-echo mechanism, “transition between pseudo–
steady-states” (TRAPS) and specialized RF-pulses19-22. 
Hyperechoes are based on a spin refocusing strat-
egy that maintains the benefits of FSE by employing 
echoes of echoes, preserving SNR as in conventional 
FSE sequences but with dramatically reduced SAR19,20. 
In TRAPS, high flip-angles are only used for data en-
coding for the central part of k-space, which results in 
a considerable reduction in RF power20.  Specialized 
RF pulses including variable-rate-selective excitation 
(VERSE) have been proposed to reduce SAR as well, 
based on an amplitude-modu-
lated gradient waveform which 
reshapes the RF excitation to 
reduce SAR while keeping the 
same spatial excitation pro-
file22. Our study shows that an 
EPI-based sequence can be 
optimized on a clinical 3.0T sys-
tem without additional require-
ments, which provides thin-slice 
volumetric anatomic coverage 
of the entire liver within a single breath-hold; better 
fat-suppression; lower SAR with increased coverage in 
the z-axis; higher SNR and low MTC effects. Our study 
is limitated by the fact that only volunteers were used 
as test subjects and that no patients were included. 
The aim of this study however, was merely to evalu-
ate the potential of BBEPI for morphologic imaging 
at 3.0T, to evaluate image quality including fat-sup-
pression and anatomic coverage compared to fat-
suppressed T2-weighted FSE sequences, for which, in 
our opinion, evaluating a group of healthy volunteers 
would sufficiently answer our research question. Also, 
the comparison between 1.5T and 3.0T was limited to 
a few volunteers only, using a cardiac-array coil for re-
ception with slightly different sizes, which may have 
influenced the outcome. However, this was merely 
included to illustrate the capacity of BBEPI to provide 
comparable image quality on 3.0T. Currently, the de-
Figure 9: Contrast-to-noise ratio 
of EPI, on 3.0T versus 1.5T. Note 
the lower CNR for both long-TE-
BBEPI and short-TE-BBEPI.
Figure 10: Multiplanar reformatting capability in short-TE-BBEPI. (a) Axial short-TE-BBEPI. (b) Coronal recon-
struction, using the minimum-intensity projection module (14 mm thick slices). Note the excellent
 suppression of the blood signal. (c) Reconstruction in the sagittal plane (14 mm thick slices).
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MR imaging to detect intrinsic tissue components, in 
combination with capability of multiphasic dynamic 
imaging after gadolinium administration renders it a 
superior technique for both the detection and char-
acterization of focal liver lesions, without radiation ex-
posure10. In addition, in the future, the combination of 
diffusion-weighted imaging of the liver, MR-elastog-
raphy and perfusion imaging may provide additional 
tools to assess the liver function, enabling a combina-
tion of both morphologic and metabolic imaging in 
a one-step imaging protocol13. MR imaging has been 
proposed as well for quantification of hepatic perfu-
sion and biliary excretion14,15, using different types of 
contrast agents including T1-shortening agents, T2-
shortening agents and macromolecular agents16.
The purpose of this review article is to explain and il-
lustrate the current status and potential applications 
of automated and color-coded post-processing tech-
niques for analysis of dynamic multiphasic gadolini-
um-enhanced MR imaging of the liver using state-of-
the-art MR imaging exams.
MR imaging technique for dynamic multiphasic 
imaging
Breath-hold T1-weighted contrast-enhanced dy-
namic magnetic resonance imaging of the liver can 
be performed on any modern MR imaging unit, with 
a magnetic field strength >1.0 Tesla (T). Because the 
introduction of parallel imaging has facilitated fast 
acquisition of sequences, with increased possibilities 
for dynamic contrast-enhanced imaging of the abdo-
men, this will be discussed shortly. 
Parallel MR imaging (pMRI) is based on a method to 
undersample K-space in order to reduce total scan 
time. Currently, pMRI is routinely available on all com-
mercial MR scanners, including sensitivity-encoded 
imaging (SENSE), array spatial sensitivity encoding 
technique (ASSET), simultaneous acquisition of spatial 
harmonics (SMASH) and others17,18. The undersam-
pling of the k-space data, with some loss of the signal-
to-noise ratio (SNR), results in considerably increased 
temporal resolution which is essential for a better TIC 
fit. Currently, pMRI is still being improved, and new 
methods are being published on a regular basis19-21.  
For dynamic contrast-enhanced imaging, scan pro-
tocols are tailored for the desired measurements. 
The choice of sequence and parameters therefore, 
will depend on anatomic coverage, acquisition times, 
susceptibility to artifacts resulting from magnetic 
field inhomogeneities and need for quantification22. 
For dynamic multiphasic imaging, 2D/3D T1-weight-
ed sequences (gradient-echo (GRE), saturation re-
covery / inversion recovery snapshot sequences, or 
echo-planar sequences) can be performed after ad-
ministration of an intravenous bolus of 0.1 mmol/kg 
of a non-liver-specific gadolinium-chelate such as 
gadolinium-DTPA (Magnevist, Schering AG, Berlin, 
Germany) or gadolinium-DTPA-BMA (Omniscan, GE 
Healthcare, Oslo, Norway). To correct additionally for 
the loss in SNR by the use of pMRI, the total dosage 
may be slightly increased for compensation. Rou-
tinely, an injection rate of 3ml/s is used by means of 
a power injector, followed by a bolus of saline (15 or 
20ml total). The higher injection rate compensates for 
the SNR loss due to the pMRI application.
Dynamic imaging of the liver entails imaging in at least 
four different vascular phases that may be extended 
depending on performance of the system. The phas-
es that should be included are: 1) precontrast phase, 
2) arterial phase, 3) portal (or equilibrium) phase and 
4) delayed (or venous) phase). To accurately capture 
the arterial phase, a timing bolus technique can be 
applied, using 2ml of the same contrast agent with 
inject rate 3ml/sec bolus followed by 15ml saline. The 
timing bolus technique and adjustment of the total 
amount of contrast according to the body weight will 
compensate for differences in cardiac output and dis-
tribution volume. The portal phase is usually acquired 
at 45 seconds after the arterial phase, and the delayed 
phase at least 120 seconds after acquisition of the 
arterial phase23-25. The sequence should be adjusted 
to obtain full anatomic coverage of the liver in each 
scanned phase within a maximum of one breath-hold 
period (<25 sec). Routinely, a slice thickness of 6-8 mm 
is used for 2D GRE sequences, which can be thinner (3 
or 4mm) in 3D GRE sequences. Ideally, a time-resolved 
gadolinium-enhanced sequence should be applied 
to have more data points on the TIC. In the abdomen, 
however, due to the breath-holding requirements it is 
not always possible yet to have continuous scanning 
in order to obtain multiple scans within each vascular 
phase. Therefore, most body MRI centers acquire at 
least four distinct phases. 
With the introduction of higher-field-strength mag-
nets (3.0T), improved dynamic imaging of the abdo-
men became feasible through inherently increased 
SNR (theoretically in the order of 2), high performance 
gradient-systems and advanced software platforms. 
This has enabled increased spatial resolution, scan-
ning with thinner slices or accelerated scanning times, 
which is particularly useful for angiographic MR imag-
ing26,27. 
Contrast agents for dynamic multiphasic imag-
ing 
Dynamic multiphasic contrast-enhanced MR imag-
ing may be performed with low- or high-molecular-
weight agents, non-liver-specific gadolinium chelates 
or liver-specific gadolinium-chelates. After injection 
into the intravascular compartment, non-liver-spe-
cific gadolinium-chelates such as Magnevist ([gado-
pentetate dimeglumine], Schering, Berlin, Germany) 
ABSTRACT
The purpose of this article is to explain and illustrate 
the current status and potential applications of auto-
mated and color-coded post-processing techniques 
for analysis of dynamic multiphasic gadolinium-en-
hanced MR imaging of the liver. Post-processing of 
these images on dedicated workstations allows gen-
eration of time-intensity curves (TIC) as well as color-
coded images, which provides useful information on 
(neo)-angiogenesis within a liver lesion, if necessary 
combined with information on enhancement pat-
terns of surrounding liver parenchyma. Analysis of TIC 
and color-coded images, which are based on phar-
macokinetic modeling, provides an easy to interpret 
schematic presentation of tumor behavior, providing 
additional characteristics for adequate differential di-
agnosis. Inclusion of TIC and color-coded images as 
part of the routine abdominal MR imaging work-up 
protocol may help to further improve the specificity 
of MR imaging findings and may facilitate the diag-
nostic work-up of disease for detection, staging, and 
monitoring of anti-tumor therapy.
INTRODUCTION
In the analysis of liver diseases, dynamic multiphasic 
gadolinium-enhanced magnetic resonance (MR) im-
aging is routinely used as part of the imaging proto-
col, since it provides information on a multitude of 
parameters, including information on tumor angio-
genesis related to tumor growth, tumor grade, meta-
static potential and anti-tumor therapy response1,2. 
Since hepatic perfusion regarding blood flow per 
tissue unit is essential for analysis and differential di-
agnosis of either focal or diffuse liver abnormalities, 
quantification of these parameters may facilitate im-
proved evaluation of hepatic diseases3. 
Analysis of hepatic enhancement is more complex 
compared to other abdominal organs such as kid-
neys, pancreas or spleen, because the blood inflow 
of the liver is made up by two components, which 
include inflow from both the hepatic artery and the 
portal vein4,5. These two vessels provide blood to the 
liver in two different time settings, which are related 
to each other in the analysis of arrival, distribution and 
excretion of contrast media. Additionally, the analysis 
of data may potentially be influenced by different flow 
curves, which include a typical arterial enhancement 
curve (diastolic and systolic peaks) for the hepatic ar-
tery, and a continuous positive venous inflow curve 
for the portal vein6. 
In previous studies, several imaging methods for non-
invasive quantification of hepatic hemodynamics 
have been proposed3. Ultrasound can be applied for 
quantification by means of Doppler ultrasonography 
or contrast-enhanced ultrasonography7-9. However, 
the main limitation of ultrasound examinations is that 
it is operator dependent, hence with low reproducibil-
ity, and has low sensitivity10. Computed tomography 
(CT) has been proposed and evaluated for quantifica-
tion of enhancement patterns11. With the introduction 
of modern multislice multidetector CT scanners, even 
more robust data can be obtained, allowing for a mul-
titude of post-processing techniques, but this remains 
yet to be defined12. MR imaging is increasingly being 
used for analysis of liver diseases. The unique ability of 
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described potential neurotoxic side effects (Parkin-
son-like progressive extrapyramidal disorder)33. 
Post-processing hardware and software
Currently, several vendors provide software pack-
ages to facilitate the post-processing of gadolinium-
enhanced dynamic MRI data on a workstation. For 
example, Easy Vision (Philips), which runs the Quan-
titative Analysis package; and 2) Advantage Windows 
(GE), which supports the Functool package. The Easy 
Vision package provides the display of a reference 
image, a subtraction imaging, and nine functional 
images: relative enhancement, maximum enhance-
ment, maximum relative enhancement, wash-in rate, 
washout rate, brevity-of-enhancement, area-under-
curve, time-to-peak, T0. Advantage Windows can 
display a subtraction imaging, and seven functional 
images: mean time to enhance, time to maximum 
enhancement, positive enhancement integral, nega-
tive enhancement integral, signal enhancement ratio, 
maximum slope of increase, and maximum slope of 
decrease in enhancement. Both software packages 
allow the display of the time-intensity curves and sta-
tistics of region-of-interest (ROI), either as a graph or 
a table format. 
 
Time intensity curves and derived parameters
The software package analyses these data over time, 
to provide a plotted corrected graph which illus-
trates the step-wise changes in enhancement over 
time in different vascular phases after contrast ad-
ministration34. The pharmaco-kinetic time intensity 
curves (TIC) model provides a number of different 
parameters that can be used to characterize specific 
tumor enhancement patterns. These parameters can 
be used to obtain data on microvessel density, flow 
through the vessels, vascular resistance, capillary wall 
permeability, composition of the extracellular space, 
and venous outflow. Currently the two most widely 
applied models for analyzing dynamic MRI gadolini-
um-DTPA data are shutter-speed model proposed by 
Charles S. Springer Jr. and Tofts model proposed by 
Paul S. Tofts35,36.
The color-coded images are based on qualitative pix-
el-wise display of various quantitative modeling pa-
rameters, which can be derived from the quantitative 
data of the TIC at each pixel. This method provides an 
automatic conversion of kinetic contrast information 
into easy to interpret color-scaled images, which pro-
vides a quick overview of degree and heterogeneity 
of enhancement within the tissue. 
The generation of TIC is based on signal intensity 
measurements obtained by defining region-of-inter-
est (ROI) areas on the color-coded images, which are 
placed by the operator. To correct for minimal differ-
ences in signal intensity in images acquired before and 
after injection of the contrast agent, measurements 
for TIC generation are based on subtracted images 
only. Subtracting the analyzed contrast-enhanced im-
age with the precontrast image, acquired at the same 
level, creates these subtractions. This is performed au-
tomatically by the software program. It is important to 
note that semi-automated interpretation of dynamic 
examination may suffer from respiratory motion, 
which may potentially cause a varying position of the 
liver in the z-axis over time. In our experience, this is 
most frequently encountered in sub-cm focal lesions 
located under the diaphragm.  
An example of a baseline TIC illustrates that a num-
ber of parameters can be derived, including specific 
enhancement patterns such as maximum intensity, 
maximum enhancement, time to peak, wash-in- and 
washout rate, and brevity of enhancement (Fig. 1). In 
literature37, a number of typically shaped TIC have been 
described (Fig. 2). Type I (steady enhancement) curve 
shows continuously increasing signal intensity within 
the lesion, which is considered a benign feature. Type 
II enhancement curve shows a steep increase in signal 
intensity in the first phases after contrast administra-
tion, which becomes less steep in the more delayed 
phases, sometimes with plateau formation. This type 
of curve is considered to be an indicator of viable 
tumor with stable microcirculation. Type III enhance-
ment curve shows steep arterial enhancement, with 
loss of signal intensity in the delayed phases, render-
ing the curve to a negative slope, which is interpreted 
as washout of contrast within the tumor. This is con-
sidered a strong indicator of malignancy, proliferating 
edge of tumor or vessels. 
TIC is determined by contrast agent in the intravascu-
lar and extravascular compartments. During the first 
pass, the contrast agent is predominantly intravascu-
lar and contrast enhancement reflects perfusion and 
blood volume. Delayed enhancement is determined 
by the passage of contrast agent into and out of the 
extravascular space, as determined by rate constants 
ktrans and kep.
Definitions of parameters derived from TIC or 
multicompartment pharmacokinetic modeling:
1. T0: Time of arrival of contrast inflow, which deter- 
 mines the arrival moment of the contrast agent at 
 the tissue.
2. S0: Intensity before arrival of contrast inflow.
3. Maximum intensity: absolute peak value of curve.
4. Maximum enhancement: difference between 
 peak value and S0.
5. Time to peak (uptake speed): time between T0 
 and time of peak intensity.
6. Wash in rate: maximum slope between T0 and 
 time of peak intensity, which determines the 
 maximum rate of contrast agent uptake during 
and similar low molecular-weight agents are rapidly 
diluted in the circulating plasma volume. They rapidly 
leak out of this space into the extra-vascular (or extra-
cellular) space (interstitium) and then equilibrate be-
tween the intravascular and interstitial spaces. Only 1–
2% at most of an administered dose enters cells28. The 
non-liver-specific gadolinium chelates that are most 
frequently used in humans are extracellular agents. In 
these contrast agents, tissue enhancement depends 
on arterial input function, kinetic of distribution of 
blood into the capillary bed, leakage across the capil-
lary walls, and volume of the interstitial space. How-
ever, they have inherent disadvantages in estimating 
blood volume and capillary permeability exclusive of 
the brain due to the high rate 
of their vascular extraction, 
even in normal vessels. 
Macromolecular contrast 
agents, also called blood 
pool agents, have been de-
veloped, such as gadopen-
tetate dimeglumine–labeled 
albumin29. Blood pool con-
trast agents have advantages 
for both spatial resolution 
and SNR at vascular imag-
ing. However, the availability 
as well as the direct clinical 
applicability of blood pool 
agents is limited, due to the 
slow glomerular filtration rate 
(GFR) and weak and revers-
ible protein-binding. 
The development of liver-
specific gadolinium chelates has increased the accu-
racy of MR for identification and characterization of 
focal liver lesions30. Liver-specific gadolinium-chelates 
including gadobenate dimeglumine (gadolinium-
BOPTA) and gadolinium-ethoxybenzyl-diethylene-
triaminepentaacetic acid (gadolinium-EOB-DTPA) 
with a first phase of extracellular distribution give 
both dynamic (morphologic) and late phase (func-
tional) information useful for lesion characteriza-
tion30. They combine the properties of a conven-
tional extracellular  gadolinium-chelate with those 
of an agent targeted specifically at the liver and 
behave in a manner analogous to conventional gado-
linium-chelates during the dynamic phase of con-
trast enhancement31 In the 
delayed phase it improves 
the impact of MRI for the 
detection of liver lesions30. 
Some liver-specific contrast 
agents such as mangafodipir 
(Teslascan, Mn-DPDP, Am-
ersham, GE Health Care) or 
superparamagnetic iron-ox-
ide particles (SPIO) have no 
dynamic imaging capability. 
The possibility of sequential 
administration of gadolini-
um-chelates and Teslascan 
in a single visit to obtain both 
dynamic and late imaging 
was proposed32. However, 
such combinations are high-
ly undesirable because of 
the high cost; complex com-
bined T1-shortening effects 
of two agents, and recently 
Figure 1: Basic time-intensity curve 
Figure 2: Typical time-intensity curves (TIC)
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cellular adenoma, and FNH are provided below.
Hemangiomas are the most common hepatic neo-
plasms, with an incidence between 0.4-20%43. Hem-
angiomas are lesions with long T2 values, so they 
have high signal intensity on T2-weighted images. 
Also, they maintain their signal intensity on images 
with longer echo times that illustrates the lesion con-
sists of multiple fluid-filled spaces. The vast majority 
of hemangiomas show a typical peripheral nodular 
enhancement pattern with complete fill-in of the en-
tire lesion over time. This enhancement pattern is of a 
typical benign lesion with a Type I curve (Fig. 3). 
Hepatocellular adenoma often occurs in young adult 
women and is associated with the used of birth oral 
contraceptives42. Hepatocellular adenomas vary in 
signal intensity on T1- and T2- weighted images. Char-
acteristically, liver adenomas show a transient blush 
in the arterial phase of the dynamic gadolinium-en-
hanced images, and fade to isointensity on delayed 
images (Fig. 4).
Focal nodular hyperplasia (FNH) most commonly oc-
curs in adult female patients, but can also occur in 
men44. FNH is not related to the use of oral contra-
ceptives and is solitary in 2/3 of cases. FNH is mostly 
slightly hypointense on T1- and slightly hyperintense 
to the liver on T2-weighted images, and typically has 
a central scar which enhances in the delayed phase 
after gadolinium adminis-
tration.44,45. Typically, FNH 
shows very intense homo-
geneous enhancement 
in the arterial phase, with 
fading to isointensity in 
the delayed phase. The central scar is enhanced on 
delayed images. Even though FNH is a benign liver 
lesion, typically, this type of lesion does not show a 
Type I, but rather a Type III enhancement curve.  The 
exact reason for this is not clear, but it is important 
to notice that in the delayed phase, the enhancement 
curve of FNH remains higher than the liver, indicating 
absence of washout. The time-intensity curve for FNH 
is characterized as showing signs of “arterialization” 
(steep enhancement) in the first part of the curve and 
subsequently showing signs of “hepatization” (curve 
running slightly above but parallel to the curve of the 
liver), as was described in a recent study assessing the 
MR imaging findings of FNH (Fig. 5)45. 
Malignant liver lesions
Malignant liver lesions are common, and include pri-
mary liver lesions such as HCC, which develops in a 
step-wise fashion in patients with cirrhotic liver dis-
ease. In this sequence, dysplastic foci may develop 
into dysplastic nodules, and eventually in HCC. Meta-
static liver disease is a major health problem, which 
occurs most commonly in patients with colorectal 
malignancies. To illustrate the role of the subtraction 
images, color-coded images, and the TIC in primary 
and secondary liver lesions, examples of HCC and liver 
metastasis are provided below.
Figure 4: Hepatocel-
lular adenoma
32-year old female with a hepa-
tocellular adenoma in the right 
lobe of liver and a hemangioma 
in the left lobe of the liver. (a) 
(Subtraction image from the arte-
rial phase) Hypervascular lesion. 
(b) (Color-coded parameter image 
from the arterial phase, calculated 
using relative enhancement) 
Homogeneous blush of the lesion. 
(c) (Color-coded parameter image 
from the portal phase, calculated 
using relative enhancement) 
Isointensity of the lesion with the 
surrounding liver. (d) (Delayed fat-
suppressed T1-weighted image) 
Isointensity of the adenoma in the 
right lobe of the liver and homo-
geneously enhanced heman-
gioma in the left lobe of the liver. 
Note: decremental value in color 
spectrum: red > orange > yellow 
> green > blue > indigo > violet.
 the acquisition and can adequately estimate the 
 degree of early strong enhancement of tumor tis- 
 sue..
7. Washout rate: absolute value of maximum slope 
 between time of peak intensity and last measure- 
 ment point, which determines the maximum rate 
 of contrast agent outflow during the acquisition.
8. Brevity of enhancement: time between wash in 
 and washout.
9. Relative enhancement: percentage of signal in- 
 tensity increases between the post-contrast and 
 the pre-contrast signal intensities respectively. 
 Relative enhancement reflects the plasma volume 
 and is highly correlated with microvessel density
10. Maximum relative enhancement: percentage of 
 signal intensity increase between the maximum 
 post-contrast and the pre-contrast signal intensi- 
 ties. 
11. Area under curve: sum (integral) of the area un-
 derneath the time intensity curve.
12. Volume transfer constant (ktrans): the constant 
 determines the passage of contrast agent into 
 the extravascular compartment from the intra 
 vascular compartments. ktran approximates to 
 endothelial permeability surface area product 
 (kfp)
13. Rate constant (kep): the constant determines the 
 passage of contrast agent out of the extravascular 
 compartment to the intravascular compartments. 
 kep is highly influenced by the vessel permeabi- 
 lity and is highly correlated with microvessel den- 
 sity38 and relative blood volume (rBV)39,40. 
14. Extracellular extravascular space (Ve): the constant 
 determines leakage volume of fractional intersti- 
 tial space. Ve  is the volume of extravascular extra- 
 cellular space per unit volume of tissue38.
Time intensity curves and color-coded imaging 
of focal and diffuse liver lesions
Benign liver lesions 
According to the currently used nomenclature for 
hepatocellular focal liver lesions, two types of liver le-
sions exist: regenerative and neoplastic or dysplastic 
lesions41. Regenerative lesions include regenerative 
nodules, segmental or lobar hyperplasia, and focal 
nodular hyperplasia. Neoplastic or dysplastic lesions 
include hepatocellular adenoma, dysplastic foci, dys-
plastic nodules, and hepatocellular carcinoma (HCC). 
Hepatocellular lesions with benign growth behavior 
are common, and include cysts, hemangiomas, focal 
nodular hyperplasia (FNH) and hepatocellular adeno-
mas, although the latter one is referred to as neoplas-
tic lesion because of rare reports of malignant trans-
formation23,42. To illustrate the role of the subtraction 
images, and the time-intensity curves in various types 
of benign lesions, examples of hemangioma, hepato-
Figure 3: Hemangioma
40-year old female with a 
48×35mm hemangioma in the 
right lobe of the liver. (a) (Color-
coded parameter image from the 
arterial phase, calculated using 
relative enhancement) Nodular 
enhancement in the periphery 
of the lesion. (b) (Color-coded 
parameter image from the delayed 
phase, calculated using relative 
enhancement) Complete fill-in 
of the entire lesion.  The lesion 
is entirely red. (c) (T2-weighted 
image, TR/TE= 1059/99.4 msec) 
High signal intensity, lobulated and 
well-circumscribed lesion typical 
for hemangioma. (d) The time-
intensity curve from the ROI of the 
lesion (green curve) reflects the 
steady enhancement of heman-
gioma (atypical Type I curve). The 
time-intensity curve from the ROI 
of the blue curve (line 3) shows 
normal liver parenchyma enhance-
ment, and line 2 represents the 
signal intensity within the aorta 
at the acquired vascular phase. 
Note: decremental value in color 
spectrum: red > orange > yellow 
> green > blue > indigo > violet.
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HCC is the most common primary malignancy of the 
liver and occurs most frequently in males1. HCC is soli-
tary in 50%, multifocal in 40%, and diffuse in 10% of 
the cases. Often, HCC will show a moderately high sig-
nal on T2-weighted images. HCC typically shows in-
tense enhancement of the tumor in the arterial phase 
(high wash-in rate) and looses much of its contrast in 
later phases (high washout rate). In later phases, most 
HCCs show enhancement of a tumor capsule. A com-
bination of high signal intensity on T2-weighted im-
ages and the enhancement pattern described above, 
particularly in a patient with pre-existing hepatitis or 
cirrhosis, is considered diagnostic for HCC. HCCs dem-
onstrate Type III enhancement curves, in which the 
delayed phase images show a lower signal intensity 
of the lesion compared to the lesion (washout) (Fig. 6-
8). Fibrolamellar HCC is an uncommon variety of HCC, 
which often occurs, in young female patients23. At MR 
imaging, fibrolamellar HCC may show some overlap 
with FNH, including arterial enhancement and pres-
ence of a fibrous central scar. Important differences 
between FNH and fibrolamellar HCC include: 1) a 
more pronounced and homogeneous enhancement 
in the arterial phase for FNH, and heterogeneous, less 
pronounced arterial enhancement for fibrolamel-
lar HCC; and 2) presence of washout in the delayed 
phase in fibrolamellar HCC and persistent higher sig-
nal intensity in the delayed 
phase after contrast admin-
istration in FNH.  Time-in-
tensity curves as well as the 
color-coded images may 
further facilitate the distinc-
tion between fibrolamellar 
HCC and FNH.
Liver metastases are the 
most common malignant 
tumors of the liver. Optimal 
evaluation with MR imag-
ing includes detection as 
well as characterization. 
Characterization is impor-
tant because patients with known primary malignan-
cies commonly have small hepatic lesions that are 
benign cysts or hemangiomas. In addition, accurate 
assessment of the segmental extent of the metastatic 
disease may have a substantial impact on patient 
management. Liver metastases are generally low 
on T1-and moderately high on T2-weighted images. 
Small hypervascular metastases may show intense 
enhancement in the arterial phase. Most commonly, 
liver metastases show a peripheral irregular ring of 
enhancement. The color-coded images may provide 
more information concerning the vascularity of the 
lesions. The time-intensity curves of liver metastases 
most closely fit into the Type II enhancement curves. 
The enhancement pattern is similar to the surround-
ing liver in the arterial phase, but with different be-
havior in the later phases, including the portal and 
delayed phases. In these phases, the intensity of en-
hancement is routinely lower than the surrounding 
liver, resulting in a Type II enhancement curve which 
is located below the enhancement curve of the sur-
rounding hepatic stroma (Fig. 9). 
Diffuse liver lesions
Diffuse liver parenchymal abnormalities may include 
a wide variety of disease entities, such as hepatitis, cir-
rhosis, hemochromatosis, steatosis, and diffuse malig-
Figure 6: Hepatocel-
lular carcinoma
62-year old male with hepa-
tocellular carcinoma (HCC) in 
the right liver lobe. (a-d) Four 
images illustrating the typical four 
phases of dynamic gadolinium 
enhanced sequence, including 
the pre-contrast phase (a), arterial 
phase (b), portal phase (c), and 
delayed phase (d). Note that the 
HCC is intensely enhancing in the 
arterial phase and shows washout 
in the delayed phases with late 
enhancement of a ptumor capsule.
Figure 5: Focal nodu-
lar hyperplasia
32-year old female, with large 
focal nodular hyperplasia (FNH) in 
the left liver lobe. (a) (Subtrac-
tion image from the arterial 
phase) Intense homogeneous 
enhancement of the lesion. (b) 
(Color-coded parameter image 
from the arterial phase, calculated 
by using relative enhancement) 
Homogeneous intense enhance-
ment of the lesion. (c) (Color-
coded parameter image from the 
portal phase, calculated by using 
relative enhancement) The lesion 
is almost isointense to the liver. (d) 
(Color-coded parameter image 
from the delayed phase, calcu-
lated by using relative enhance-
ment) Delayed enhancement of 
the central scar. (e) (Color-coded 
parameter image, calculated by 
using maximum enhancement) 
The absolute values of enhance-
ment of the lesions are higher 
than the liver. (f) (Color-coded 
parameter image, calculated by 
using washout rate) This lesion has 
a similar washout rate as the sur-
rounding liver. (g) (T2- weighted 
image (TR/TE=1500/80 msec) The 
lesion is only slightly hyperintense 
to the liver. (h) The time-intensity 
curve of the lesion (green curve) 
parallels the curve of the aorta 
in the arterial phase, indicating a 
very steep enhancement (Type III).  
In the delayed phases it parallels 
the curve of the liver, reflecting its 
benignity as well as its similarity 
to the normal liver tissue. Note: 
decremental value in color 
spectrum: red > orange > yellow 
> green > blue > indigo > violet.
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Figure 8: Hepatocel-
lular carcinoma
The same patient as in Figures 
6-7.  This figure shows various 
parameters as color-coded images. 
(a) (Color-coded parameter image, 
calculated by using T0) The lesion 
has a shorter T0 (i.e. enhances 
earlier) than the surrounding liver. 
(b) (Color-coded parameter image, 
calculated by using time-to-peak 
(TTP)) The center of this lesion 
has a shorter TTP as compared to 
the tumor capsule. This indicates 
that the peak of contrast reaches 
the center of the lesion in an 
earlier phase. (c) (Color-coded 
parameter image, calculated by 
using wash-in rate) The center of 
this lesion has a lower wash-in rate 
as compared to the tumor capsule. 
(d) (Color-coded parameter imag-
ing, calculated by using washout 
rate) The center of the lesion has 
a slightly higher washout rate 
than the surrounding liver. (e) 
(Color-coded parameter image, 
calculated by using brevity-of-
enhancement) The time between 
the wash-in rate and washout rate 
is longer in the center of this lesion 
as compared to the surrounding 
liver. (f) (Color-coded parameter 
image, calculated by using area-
under-curve) The tumor capsule 
of this lesion received a higher 
dosage of contrast agent than 
the center of the lesion. (g) (T2- 
weighted image (TR/TE=1500/80 
msec) Slightly hyperintensity in the 
center as well as the tumor capsule 
of the lesion. (h) The time-inten-
sity curve shows that the lesion 
(green curve) enhances more 
than the liver and less than aorta 
in the arterial phase, and loses 
contrast in the later phases (sign 
of washout). Please note that the 
curve, unlike the curve in the FNH 
(see Figure 5h), is not parallel to 
the curve of the liver in any phase. 
Note: decremental value in color 
spectrum: red > orange > yellow 
> green > blue > indigo > violet.
nancies1,23. Acute hepatitis may present with reversible 
heterogeneous patchy enhancement of the hepatic 
stroma in the arterial phase. In the portal and delayed 
phases, the abnormal enhancement pattern is occult. 
To illustrate the role of the subtraction images and 
the color-coded images in detection of diffuse liver 
parenchymal disease as well as monitoring of therapy, 
an example of acute hepatitis in a patient with pri-
mary sclerosing cholangitis before and after medical 
treatment with Prednisone is provided (Fig 10). 
Discussion 
Post-processing of dynamic gadolinium-enhanced 
MRI exams of the abdomen allows generation of the 
color-coded images and time-intensity curves46. The 
information may further improve the diagnostic capa-
bility of MRI at high temporal and spatial resolution. 
Unlike the original gadolinium-enhanced images, the 
color-coded images provide information concerning 
the intra-tumoral distribution of vessels (vascular den-
sity) as well as the nature of the vascular wall (intact or 
immature and leaky blood vessels). This may contrib-
ute to a better understanding of tumor enhancement 
patterns and angiogenesis, and hence may result in 
improved characterization of tumors. As described in 
literature47, tumors do not grow beyond 2 mm3 in size 
as a result of hypoxia unless angiogenesis, a process of 
the development of new capillaries derived from host 
tissues that allow tumors to grow exponentially. 
The enhancement mechanisms behind dynamic gad-
olinium-enhanced MRI 
Because of the unique dual blood supply of the liver 
(arterial and portal), hepatic lesions probably have 
different contrast kinetics as compared to lesions in 
other organs with only a single (arterial) blood sup-
ply. Therefore, the generated TICs of focal liver lesions 
should always be compared with the curves of the 
surrounding liver. 
The mechanisms behind the differential contrast en-
hancement are thought to include differences in tu-
mor perfusion and the levels of tumor capillary wall 
permeability and hydrostatic pressure. The growth 
of a tumor, and its associated angiogenesis, is often 
rapid and disordered, leading to: 1) a relatively high 
fraction of immature blood vessels; 2) abnormal basal 
membranes in the vessel wall with relative lack of peri-
cytes or smooth muscle associations with endothelial 
cells which render the vessels more “leaky” or perme-
able (providing an access point for contrast agents); 3) 
tumor vessels are tortuous, 
vary in diameter, and tend 
toward excessive branch-
ing and shunt formation; 
4) intermittent or unstable 
blood flow with acutely 
collapsing vessels; and 5) 
hydrostatic pressure dif-
ferences between tumors 
and normal tissue, partly re-
duced or absent lymphatics 
which may influence contrast agent uptake. 
Blood volume, blood flow, mean transit time and mi-
crovascular permeability–surface area product are all, 
in principle, quantifiable through analysis of dynamic 
Figure 7: Hepatocel-
lular carcinoma
The same patient as in Figure 6. (a-
b) (Two subtraction images from 
the arterial and portal phases, re-
spectively) Improved visualization 
of the HCC. (c-d) (Two color-coded 
parameter images from the arte-
rial and portal phases, respec-
tively, calculated by using relative 
enhancement) Heterogeneous 
enhancement of the lesion, i.e. the 
lesion is enhancing more intensely 
in the center than in the periphery 
(more red in the center) (c), and 
lost contrast in the center (sign of 
a high washout rate), with enhanc-
ing tumor capsule (more red in 
the periphery of the lesion) (d).
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Figure 10: Diffuse paren-
chymal liver disease 
Diffuse liver disease, before and 
after medical treatment. 59 year 
old male with primary sclerosing 
cholangitis with an acute hepatitis 
in the left and part of the right 
liver. Images A-D were performed 
prior to medical treatment, while 
images E-H were performed after a 
three-month treatment with Pred-
nison. (a) (Subtraction image from 
the arterial phase) Abnormally 
increased enhancement of the 
liver parenchyma in the left and 
part of the right liver. (b) (Color-
coded parameter image from the 
arterial phase, calculated by using 
relative enhancement) The het-
erogeneous increased enhance-
ment of the liver. (c) (Color-coded 
parameter image from the portal 
phase, calculated by using relative 
enhancement ) The abnormalities 
are less well depicted in this phase. 
(d) (Color-coded parameter image 
from the delayed phase, calculated 
by using relative enhancement) No 
abnormalities at all. (e) (Subtrac-
tion image from the arterial phase, 
after treatment) Substantially less 
abnormal enhancement of the 
liver parenchyma. (f) (color-coded 
parameter image from the arterial 
phase, after treatment, calculated 
by using relative enhancement)  
Decreased heterogeneous 
increased enhancement of the 
liver. (g and h) (Two color-coded 
parameter images from the portal 
and delayed phases calculated by 
using relative enhancement) The 
abnormalities have become occult. 
Note: decremental value in color 
spectrum: red > orange > yellow 
> green > blue > indigo > violet.
Figure 9: Liver metastasis  
56-year old female with a large 
hepatic metastasis from sigmoid 
carcinoma. a) (Substraction image 
from the portal phase) Irregular 
ring enhancement of the lesion 
as well as a faint enhancement 
in the center of the lesion. b) 
(Color-coded parameter image 
from the arterial phase, calculated 
by using relative enhancement) 
Faint enhancement of the lesion. 
c) (Color-coded parameter image 
from the portal phase, calculated 
by using relative enhancement) 
Irregular ring of enhancement 
in the periphery of the lesion, 
whereas the more central parts of 
the lesion are enhanced less than 
the surrounding liver. d) (Color-
coded parameter image from the 
delayed phase, calculated by using 
relative enhancement) The lesion 
has enhanced slightly more than 
in the previous phase, whereas the 
liver has lost some of its contrast. 
Therefore, the conspicuity of lesion 
has decreased. e) (Color-coded 
parameter image, calculated by 
using wash-in rate) The periphery 
of the lesion has a higher wash-in 
rate than the center of the lesion. 
f) (Color-coded parameter image, 
calculated by using the maximum 
relative enhancement) The central 
parts of the lesion enhance less 
than the surrounding liver. g) (T2- 
weighted image (TR/TE=1500/80 
msec) The periphery of the lesion 
is slightly hyperintense to the 
liver. h) The time-intensity curve 
of the lesion (green curve) shows 
that the lesion is enhancing 
similar to the liver in the arte-
rial phase. In the portal phase, 
there is the greatest difference 
in enhancement between the 
lesion and the surrounding liver. 
In the delayed phase, the lesion 
shows slight further increase in 
enhancement, whereas, the liver 
loss some contrast. Therefore, 
the conspicuity of the lesion 
decreases after the portal phase. 
Note: decremental value in color 
spectrum: red > orange > yellow 
> green > blue > indigo > violet.
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gadolinium-enhanced MRI by using pharmaco-ki-
netic models36. Tumor regions with dense neovascu-
lature may enhance more rapidly compared to other 
regions. The position of these regions is related to the 
distribution of viable blood supply within the tumor. 
In necrotic or cystic regions, vascular density can be 
extremely low, whereas in highly active regions, the 
vascular density can be high. 
Dynamic contrast-enhanced MR imaging proposed 
as an in-vivo marker of angiogenesis
Due to its high quality and reproducible measure-
ments, dynamic contrast-enhanced MR imaging is 
being proposed as an in-vivo marker of angiogen-
esis22,48 with the advantage over the “gold standard” 
of direct histologic quantification of angiogenesis 
with discrepancy between “true” functional and his-
tologic microvessel density: 20% to 85% of microves-
sels are perfused at any given time depending on the 
microenvironment22,39. Dynamic contrast-enhanced 
MR imaging may help define the pharmacological re-
sponse and dose of vascular endothelial growth fac-
tor (VEGF)-mediated angiogenesis inhibitors, such as 
PTK787/ZK 222584, an orally active inhibitor of VFGF 
receptor tyrosine kinases, for further clinical develop-
ment in patients with advanced colorectal cancer49. 
Functional CT versus dynamic contrast-enhanced 
MRI
Functional CT using multidetector row, as with dynam-
ic contrast-enhanced MRI, has also been proposed for 
evaluation of tumor vascularity. Both techniques are 
easily incorporated into routine examinations and 
provide reliable quantitative perfusion data, although 
for both imaging modalities, there remains a lack of 
consensus regarding optimal acquisition technique, 
type of analysis method, and surrogate measurement 
to use22. There are differences between the two imag-
ing modalities in acquisition techniques, mathemati-
cal analysis, measurement parameters, and propensity 
to artifacts22. The benefit of functional CT is the direct 
linear relationship between CT attenuation value and 
contrast agent concentration. The functional CT anal-
ysis technique includes deconvolution, distributed 
parameter model. Unfortunately, the risks of contrast 
agent reactions and potential biologic hazards from 
radiation exposure to the patients (especially onco-
logic patients that undergo repeated scans to moni-
tor therapy response) are associated with functional 
CT. The radiation burden associated with a functional 
CT acquisition protocol is determined by the number 
of images in the sequence and the tube current (mAs) 
used for each image.  Dynamic contrast-enhanced 
MRI does not involve the use of ionizing radiation, 
which is a particular advantage for serial examinations 
to monitor treatment response. The choice between 
functional CT and dynamic contrast-enhanced MRI 
depends on machine availability, doctor expertise, 
tumor location, desired parameters, and the require-
ment of decreased radiation burden22.
The benefits of the color-coded images and time- 
intensity curves 
Color-coded images can provide information con-
cerning focal as well as diffuse disease processes. This 
reduces the risk of creating ROIs containing more than 
one tissue type, and makes further ROI analysis more 
accurate. In addition, the color-coded images com-
bine both the enhancement pharmaco-kinetics of 
tissues and morphology, and visualize the enhance-
ment changes over time. 
The generation of TIC by placing ROIs has two bene-
fits over functional images: 1) sampling only a limited 
number of pixels at once increases the signal-to-noise 
ratio; and 2) small spatial misregistration between 
points only introduces small errors. However, there 
are also some drawbacks. The time-intensity curves 
are insensitive to regional variation in the parameter 
being examined, small foci of high or low signal inten-
sity may be missed as they are averaged out within an 
ROI, and diffuse disease may be difficult to analyze. Pa-
tient motion might lead to faulty time-signal intensity 
curves at each pixel, and hence to faulty functional 
images.
The parameters derived from the time-intensity 
curves, which is the basis of the color-coded im-
ages have contributions from MR imaging protocols. 
Therefore, it may be difficult to compare the results 
of studies from different institutions. Application of 
pharmaco-kinetic modeling has the potential to stan-
dardize these results22. 
In conclusion, the generation of color-coded images 
and time-intensity curves based on dynamic multi-
phasic gadolinium-enhanced MR imaging data sets 
provides new opportunities for research. Moreover, it 
facilitates the diagnostic work-up of hepatic disease 
for the detection, staging, therapeutic monitoring; 
and development of anti-tumor drugs.
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 DISCUSSION
chapter7.1
 general discussion
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important, to improve patient outcome and deci-
sion making in therapeutic strategies. Our studies 
have illustrated the potential value of MR imaging 
for improved detection of HCC in an early stage. 
Even though therapeutic possibilities for HCC have 
expanded greatly in the past two decades, poten-
tially curative surgical therapy for HCC is still limited 
to approximately 40% of patients only. This is partly 
caused by an often advanced stage of liver fibrosis, 
but also because of often advanced HCC at presenta-
tion. Therefore, improved patient outcome depends 
not only on extended therapeutic options, but also 
on improved imaging information5. 
MR imaging is the modality of choice in the assess-
ment of developing HCC. The MR imaging findings of 
developing HCC may vary, which is possibly related 
to the diversity in genetic pathways and a possible 
polygenic predisposition, but this remains to be de-
termined. As demonstrated in our study, in the transi-
tion of a DN to HCC, it is important to assess changes 
in T2-weighted signal intensity, which may show in-
creasing signal; and arterial enhancement patterns, 
which often show a transition of portal enhancement 
to true early arterial enhancement. In addition, detec-
tion of delayed phase washout in combination with 
delayed phase enhancement of a tumor capsule is 
diagnostic in many cases. However, as demonstrated 
in our study (chapter 4.2), it is important to realize that 
in the growth process of HCC, signal intensities may 
change, which reflects not only the intrinsic tissue 
characteristics, but also the changing blood supply, 
distribution and excretion expressed as dynamic en-
hancement patterns after administration of a gado-
linium-chelate5. 
In the development of high magnetic field MR imag-
ing scanners (3.0T), the increased signal-to-noise ratio 
(SNR, theoretically double as high) provides potential 
for improved hepatobiliary imaging. The doubled 
SNR can be utilized to significantly improve the spa-
tial resolution in the same acquisition time, or ½ slice 
thickness with identical coverage, or 4-fold faster scan 
time for identical resolution settings1. However, there 
are some associated challenges for imaging at high 
magnetic field strength (3.0T) as well. These include: 
1) the changed relaxation times at higher magnetic 
field strength, which translate in different signal inten-
sities; 2) increased inhomogeneity of the magnetic 
field which results in more pronounced B1-inhomoge-
neities and dielectric resonance effects that degrade 
image quality; and 3) increased energy deposition 
within the scanned subject, expressed as increased 
specific absorption rate levels (SAR)1. 
Nonetheless, the increased SNR was soon success-
fully used for markedly improved dynamic MR imag-
ing after contrast administration, with high resolution 
three-dimensional T1-weighted sequences acquired 
with parallel imaging. T2-weighted sequences how-
ever, in particular the fast spin-echo (FSE) sequences, 
were limited in anatomic coverage by increased SAR 
levels. As demonstrated in our studies, the application 
of a special shape radiofrequency pulse for excitation 
and refocussing, the “variable-rate selective excitation 
(VERSE)” provides a solution for this problem, as FSE 
sequences obtained with VERSE provide markedly 
increased slice coverage. This is important for patient 
comfort, as it shortens total scan duration consider-
ably. In this respect, black-blood echo-planar imaging 
(BBEPI) should be considered as well, as this sequence 
provides full volume liver coverage within a single 
breath-hold, with low SAR levels at 3.0T. In addition, 
this sequence enables improved thin-slice imaging, 
and high contrast of the lesion compared to the liver 
which will improve confident lesion detection. 
In the future, semi-automated analysis of computed 
tomography (CT) and MR imaging exams may play 
an increasingly important role, as the amount of data 
acquired with these imaging modalities have vastly 
increased in the past decade and will certainly con-
tinue to rise even further. In this respect it is impor-
tant to aim at acquiring near-isotropic datasets for im-
proved automated analysis. Even though this remains 
challenging, the implementation of 3.0T MR imaging 
scanners has provided potential development in this 
area. Additionally, semi-automated analysis of dynam-
ic contrast-enhanced imaging of the liver by means 
of color-coded techniques and generation of time-in-
tensity curves facilitates the analysis of often very large 
datasets. Since hepatic perfusion is essential for analy-
sis and differential diagnosis of either focal or diffuse 
liver abnormalities, quantification of these parameters 
may facilitate the evaluation of hepatic diseases, as is 
demonstrated in chapter 6. The improved visualiza-
tion of the abnormality within the liver by means of 
color-coded images provides easy-to-interpret color 
images for either the less experienced radiologist or 
involved clinician. 
 
Conclusions and recommendations for future 
research
It may be concluded that MR imaging is a highly ac-
curate method for the detection and characterization 
of focal liver lesions. In the near future, spectroscopy, 
perfusion imaging including high resolution slice im-
aging and perfusion imaging with tagging, diffusion-
weighted imaging and MR elastography will most 
likely be added to the routine work-up and follow-up 
of patients with suspected or proven focal liver dis-
ease, or for follow-up of treatment including chemo-
embolization, radiofrequency ablation therapy (RFA), 
or radiotherapy8. 
Therefore, it is to be expected that MR imaging will 
continue to expand its possibilities for versatile ab-
This has resulted in the development of new se-
quences that have allowed improved visualisation of 
neoplastic processes, including fat-suppressed T2- 
weighted sequences and black-blood echo-planar 
imaging2. In addition, improved multiphasic dynamic 
imaging after intravenous administration of con-
trast media became feasible, which has resulted in 
improved timing of the arterial peak enhancement. 
Since analysis of peak arterial enhancement is essen-
tial for diagnosis of especially malignant lesions, time-
resolved dynamic MR imaging provided improved 
tumor characterization possibilities3. 
The radiologic imaging work-up of primary hepatic 
tumors improved considerably as a result of the de-
velopments in MR imaging techniques. MR imaging 
is an imaging modality that is highly valuable for the 
differentiation of these tumors, since the combination 
of several T1- and T2-weighted sequences before and 
after administration of a gadolinium-chelate allows 
determination of intrinsic tissue characteristics of the 
lesion, with possibility to detect neovasculature in an 
early stage. In addition, liver-specific contrast media 
may provide additional information on the origin of 
the tumor. These characteristics make MR imaging an 
ideal modality for detection and differentiation of fo-
cal liver lesions3. 
Primary liver tumors are categorized according to the 
regenerative or dysplastic nature of the lesion in com-
bination with the anatomic characteristics of adjacent 
hepatic stroma. Most common lesions are focal nodu-
lar hyperplasia (FNH), hepatocellular adenoma (HCA) 
and hepatocellular carcinoma (HCC)4. 
FNH and HCA most frequently occur in young wom-
en, in whom differentiation between FNH and HCA 
is important, in view of the risk of bleeding and po-
tential malignant transformation in larger HCA5. Even 
though it is rare, malignant transformation has been 
reported repeatedly in literature. In this context, liver 
cell dysplasia (LCD) has been proposed as missing link 
between HCA and HCC, in which HCA is not pre-ma-
lignant, whilst LCD is potentially malignant and may 
proceed to HCC5 (see chapter 3.1). In the diagnosis of 
HCA versus FNH, our studies illustrated that HCA has 
intratumoral fatty infiltration in most lesions whilst 
this is rare in FNH; HCA has less pronounced arterial 
enhancement than FNH, and the liver may show co-
existing liver abnormalities in case of HCA. In addition, 
the use of liver-specific iron-oxide contrast agents 
(SPIO) facilitate the diagnosis of FNH, since the uptake 
of SPIO within the lesion improves the conspicuity of 
the central scar and septa which is a characteristic fea-
ture of FNH. 
 In routine clinical care, typically, classic FNH does not 
require follow-up examinations, whilst in HCA, follow-
up imaging is advised every 6-12 months. MR imaging 
is the modality of choice for imaging of these lesions, 
since it provides extensive information on the tumor 
characteristics, has no radiation exposure and enables 
confident diagnosis of the lesion, including confident 
assessment of potential complications including hem-
orrhage or development of HCC3. 
HCC is the most common primary hepatocellular 
malignancy, and develops in at least 1-2% of patients 
with longstanding cirrhosis. The incidence is highest 
in patients with hepatitis B or C related cirrhosis or cir-
rhosis related to alcohol abuse, hemochromatosis or 
biliary abnormalities such as primary biliary cirrhosis. 
Men older than 50 years of age with longstanding 
cirrhosis and liver cell dysplasia, may develop HCC 
in as many as 10% of the cases. Recently, the insulin 
resistance syndrome (obesity, diabetes) has been de-
scribed as a possible risk factor for development of 
HCC, but the exact relation to the rising incidence of 
HCC remains unclear6. In cirrhosis, HCC typically oc-
curs in a step-wise fashion, which can be visualized 
with MR imaging5 (see chapter 4.1). In this sequence, 
a regenerative nodule (RN) develops into low grade 
dysplastic nodule (DN I) – high grade dysplastic nod-
ule (DN II) – small HCC – large HCC, respectively. On 
the other hand, HCC occurring in a non-cirrhotic liver 
is typically very large7. 
Early detection of HCC in patients with cirrhosis is 
Magnetic reso-
nance  imaging is a 
diagnostic modality 
THAT HAS BEEN 
EVOLVING RAPIDLY  
IN THE PAST TWO 
DECADES. 
The development of advanced software, improved 
coil technology, and higher magnetic field strength 
has allowed faster imaging, with increased temporal 
and spatial resolution1.
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dominal imaging. In this context, it should be kept in 
mind that even though the development of current 
high-quality multi-slice CT scanners is very promising 
for the evaluation of the vasculature of the upper ab-
domen; it is limited for the interpretation of focal liver 
lesions. Potential health effects from increased radia-
tion exposure resulting from routinely implemented 
multiphasic CT exams of the liver should therefore not 
be underestimated9. 
From this thesis, it is concluded that MR imaging can 
provide a non-invasive differentiation of FNH and 
HCA in the work-up of young women with focal liver 
lesions. Even though a predilection was suggested for 
diffuse liver abnormalities in patients with HCA, this 
could not be firmly established. To further address 
this matter, a study including both patient groups is 
recommended. 
In the diagnostic work-up of patients with cirrhosis 
that are at high risk for development of HCC, MR im-
aging should be considered as the modality of choice. 
The results of this thesis show that development and 
evolution of HCC can be followed safely and non-inva-
sively by means of MR imaging, as the gradual chang-
es within the lesion can be evaluated and monitored 
by means of a combination of T1- and T2-weighted 
sequences before and after administration of an intra-
venous contrast agent. The accurate timing of these 
follow-up examinations remains to be determined. 
In order to address this, accurate determination of le-
sions at low, intermediate, or high risk for malignant 
transformation is recommended to allow justified fol-
low-up criteria for improved patient care. A large mul-
ticenter trial evaluating all lesions that developed in 
HCC may potentially answer this question.  
The main goal for further development and expan-
sion of the potential of MR imaging should be aimed 
at development of fast, easy-to-apply, one-stop-shop 
imaging protocols for hepatobiliary imaging. In this 
perspective, it is possible that further development of 
imaging at high magnetic field strength will enable 
this development. Such imaging protocols should aim 
at prescribing a maximum duration of 5-15 minutes 
scan time for full work-up of patients with known or 
suspected liver disease, or for work-up of potential 
living-related donors for liver transplantation candi-
dates. 
In addition, further development and implementa-
tion of liver-specific contrast media will most likely 
add to facilitated diagnosis of primary liver tumors 
and tumors of biliary origin, or for the follow-up after 
focal treatment strategies, including chemo-emboli-
zation or RFA. 
In conclusion, implementation of MR imaging as the 
primary imaging modality in clinical follow-up pro-
tocols for patients with abnormalities of the liver or 
biliary tree should be considered, aiming at accurate, 
non-invasive, patient-friendly diagnosis of hepatobili-
ary diseases. 
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lesions, including focal nodular hyperplasia, hepato-
cellular adenoma and hepatocellular carcinoma; 2) 
the step-wise carcinogenesis of hepatocellular carci-
noma in cirrhosis on MR imaging; and 3) the typical 
imaging findings of primary hepatocellular lesions on 
MR imaging and differential diagnoses. 
Current terminology and classification
In 1995, an International Working party established a 
classification system for the evaluation of primary he-
patocellular nodules5. In this classification, nodular le-
sions within the liver are classified according to the re-
generative or neoplastic nature of the lesions; and the 
characteristics of adjacent hepatocellular 
stroma. This results in 1) regenerative; 
and 2) dysplastic or neoplastic nodules. 
Regenerative nodules
The regenerative nodules consist of a lo-
calized proliferation of hepatocytes and 
supporting hepatic stroma, resulting in 
the following lesions: monoacinar nod-
ules; multiacinar nodules; lobar or seg-
mental hyperplasia; focal nodular hyperplasia (FNH); 
and cirrhotic nodules5. 
A monoacinar or multiacinar regenerative nodule 
contains either only one (monoacinar) or multiple 
(multiacinar) portal tracts, and are assumed to have 
developed in response to altered circulation, necro-
sis, or other stimuli6. Lobar or segmental hyperplasia 
entails a more diffuse hyperplastic reaction, in which 
a complete or part of the 
liver lobe has enlarged. This 
is usually accompanied by 
atrophy, necrosis, or fibrosis 
of other areas of the liver5. 
In FNH, the gross appear-
ance consists of multiple nodules composed of he-
patocytes, which are surrounded by radiating septa 
originating in a central fibrous scar7 (Fig. 1). In cirrhotic 
regenerative nodules, diffuse nodular changes with 
micro- (<3 mm) and/or macrodules (>3 mm) are ob-
served within the liver, surrounded by thin fibrous 
septa. As a rule, within regenerative nod-
ules, no dysplastic or neoplastic patho-
logic features such as increased cellularity, 
atypical nuclei and/or chaotic distribution 
are present.  
Dysplastic or neoplastic nodules
The dysplastic and neoplastic hepato-
cellular nodules consist of hepatocytes 
that show histological characteristics of 
abnormal growth caused by genetic al-
teration. These lesions in-
clude: hepatocellular ad-
enoma (HCA), dysplastic 
foci, dysplastic nodules 
with or without a focus of 
HCC, and hepatocellular 
carcinoma (HCC). 
Even though the growth pattern of HCA is relatively 
Figure 1: Focal nodular hyperpla-
sia (FNH), illustrating the multinod-
ular appearance of these lesions. 
(a) Macroscopic image of a subcap-
sular FNH, with multiple nodules 
within the lesions. (b) detailed 
view of the FNH, illustrating fibrous 
septa surrounding the nodules. 
Figure 2: Multiple regenera-
tive cirrhotic nodules in a pa-
tient with longstanding cirrho-
sis, photomicrograph x40, H&E 
staining. This illustrates the 
presence of multiple regenera-
tive nodules surrounded by 
fibrous bands, and a focus of 
HCC (<1 mm), with high grade 
atypia, increased nuclear den-
sity with mitoses, and hepato-
cytes organized in >3 plates. 
Figure 3: Photomicrograph 
(x100, H&E stain) of HCC in long-
standing cirrhosis, showing a 
profoundly chaotic organization 
of the hepatocytes, increased 
cellular and nuclear density, and 
atypical nulei with mitoses. 
ABSTRACT
MR imaging is routinely used for the work-up of pa-
tients with focal or diffuse liver disease, including pri-
mary hepatocellular lesions, storage diseases, meta-
static liver disease and diseases of the hepatobiliary 
tree. The most important MR imaging sequences 
used for diagnostic imaging of the liver consist of T1-
weighted sequences, T2-weighted sequences, and 
at least the arterial and delayed phases of dynamic 
gadolinium-enhanced imaging. This paper provides 
an overview of MR imaging of primary hepatocellu-
lar lesions, and will describe: 1) the classification and 
etiology of primary hepatocellular lesions, including 
focal nodular hyperplasia, hepatocellular adenoma 
and hepatocellular carcinoma; 2) the step-wise car-
cinogenesis of hepatocellular carcinoma in cirrhosis 
on MR imaging; and 3) the typical imaging findings 
of primary hepatocellular lesions on MR imaging, with 
differential diagnoses. 
 
INTRODUCTION
Annually, thousands of patients worldwide undergo 
an imaging work-up for the evaluation of proven or 
suspected diffuse or focal liver disease. In most cen-
ters, a combination of different imaging modalities 
is used for detection and characterization, including 
one or more of the following: ultrasonography (US), 
computed tomography (CT), positron emission to-
mography (PET) and magnetic resonance (MR) im-
aging. These imaging modalities have fundamental 
differences in the data acquisition, which translates in 
different accuracy in detecting and characterizing the 
type of liver disease that they interrogate. Currently, 
no strict consensus for the optimal imaging work-up 
for evaluation of the liver exists. Therefore, the choice 
of the applied imaging modality often depends of 
the referring physician and the expertise of the local 
radiologist1. MR imaging is often used as a problem-
solving modality, and valued for its potency for the 
evaluation of intrinsic tissue characteristics, the pos-
sibility for multiphasic dynamic contrast-enhanced 
imaging, the possibility to use liver-specific contrast 
agents, and all without radiation exposure1.  
Current state-of-the-art MR imaging protocols consist 
of a set of T1-weighted and T2-weighted sequences; 
and dynamic contrast-enhanced imaging in multiple 
phases after intravenous administration of a gadolini-
um-chelate2. In our institute, the routine liver imaging 
protocol consists of single-shot fast spin-echo (SSFSE) 
images with varying echo-times (TE) in the axial and 
coronal planes; in- and opposed phase T1-weighted 
gradient-echo (GRE); either 3D fat-suppressed or 2D 
non-fat-suppressed dynamic multiphasic gadolini-
um-enhanced sequences in at least the arterial, por-
tal, venous and delayed phases; and a T2-weighted 
fast spin-echo (FSE) sequence with fat suppression. 
The coronal and axial SSFSE sequences can be used 
for a quick overview of the abdominal anatomy as 
well as localizers for planning of the other sequences. 
Our liver protocol contains axial shorter and longer TE 
SSFSE sequences that are  used to make distinction 
between lesions with high-fluid content and solid le-
sions2. Chemical shift imaging (in- and opposed phase 
T1-weighted GRE) are essential for the detection of 
the fatty infiltration of the liver (steatosis) and lesions. 
Dynamic time-resolved multiphasic imaging gives 
valuable information on the dual-blood supply of the 
liver, which consists of inflowing blood from both the 
hepatic artery (25%) and the portal vein (75%) as well 
as the enhancement patterns of focal liver lesions3. 
Last, the fat-suppressed T2-weighted FSE sequence 
with moderate T2-weighting which is routinely per-
formed only after the dynamic gadolinium-enhanced 
sequence has been performed4, provides valuable in-
formation for the detection of focal liver lesions, since 
most lesions will be depicted  with high liver-to-lesion 
contrast on this sequence. 
This paper provides an overview of MR imaging of pri-
mary hepatocellular lesions, and will describe: 1) the 
classification and etiology of primary hepatocellular 
Primary hepatocel-
lular lesions:  
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of HCC is regenerative nodule (RN) – low grade dys-
plastic nodule (DN I)) – high grade dysplastic nodule 
(DN II) – small HCC – large HCC12. In this sequence, the 
nodule shows gradually increasing cellularity, nuclear 
atypia, and changing vascularity surrounding the le-
sion, which can be observed as a slow transition from 
portal vein to hepatic artery inflow13. The appearance 
of these tumor arteries is essential for development 
and sustained growth of the HCC. When a focus of 
HCC develops within a dysplastic nodule, this may be 
observed as a “nodule-within-nodule” appearance 
on MR imaging, as was described by Mitchell et al in 
199514. 
As demonstrated in a recent 
study15, the step-wise develop-
ment of HCC in cirrhosis may show 
a spectrum of MR imaging findings, 
including: 1) localized fatty infiltra-
tion within a developing dysplastic 
nodule that gradually evolved into 
HCC; 2) development of a focus of 
HCC with high T2-signal intensity 
in a dysplastic nodule; 3) promi-
nent neovasculature as initial sign 
of fast growing HCC. Therefore, on 
MR imaging, developing HCC in 
the step-wise carcinogenesis may 
be associated with fat accumulation; gradual increase 
in size; increasing signal intensity on T2-weighted im-
ages; progressive enhancement in the arterial phase 
with a nodule-within-nodule appearance (Fig 5); and 
progressive washout of contrast material in the de-
layed phase15.
MR imaging of hepato-
cellular carcinoma
Hepatocellular carcinoma 
(HCC) is the most com-
mon primary neoplasm 
of the liver. The incidence 
is highest in patients with 
hepatitis B or C related cir-
rhosis and cirrhosis related 
to alcohol abuse, metabolic 
liver diseases and others16, 17. 
The tumor marker for HCC is alpha-fetoprotein (AFP). 
Even though AFP is not specific for HCC, and can give 
false-positive results in hepatitis, fibrosis, and cirrhosis, 
it is useful in monitoring the disease process in com-
bination with imaging results18. Currently, treatment 
of HCC includes liver transplantation, segmental liver 
resection, percutaneous minimal invasive therapies, 
such as radiofrequency abla-
tion (RFA), stereotactic radiation 
therapy19, transarterial (chemo)-
embolization procedures and 
gene or immune therapies20. 
Curative therapy of HCC is still 
limited to approximately 40% 
of cases only, which is partly 
Figure 6: HCC in a patient with 
hepatitis-B related cirrhosis, show-
ing classical MR imaging findings 
of HCC. (a) In-phase T1-weighted 
gradient-echo (GRE), showing a 
hypointense signal of HCC in seg-
ment 1 (caudate lobe). (b) Fat-sup-
pressed T2-weighted FSE, showing 
hyperintense signal intensity of 
the HCC. (c) Arterial-phase 3D 
fat-suppressed T1-weighted 
GRE, showing marked arte-
rial enhancement of the HCC. (d) 
Delayed-phase image of the same 
sequence, illustrating washout 
of contrast material and delayed 
enhancement of a fibrous tumor 
capsule surrounding the HCC. 
Figure 7: Macroscopic image of a 
subcapsular HCC in a patient with 
cirrhosis, illustrating intratumoral 
multinodularity and a fibrous tumor 
capsule surrounding the lesion. 
benign, the International Working Party classified this 
lesion as neoplastic due to rare reports of malignant 
transformation into HCC8. Dysplasia is defined as pres-
ence of cytoplasmic and/or nuclear changes within 
a cluster of hepatocytes, without definite histologic 
criteria of malignancy2. A dysplastic focus consists 
of a localized cluster of hepatocytes with dysplastic 
features, measuring <1 mm in diameter. Dysplas-
tic nodules are often found in cirrhotic liver disease, 
and can show either low- or high-grade dysplasia. In 
high-grade dysplastic nodules, the atypia is at least 
moderate, but insufficient for the diagnosis of malig-
nancy. In addition, microscopic evaluation of these 
nodules shows increased number of cells, increased 
nuclei-to-cytoplasm ratios, and increased layers of he-
patocytes5. HCC is a malignant neoplasm composed 
of cells with hepatocellular differentiation, and may 
occur as a focus of HCC in a highly dysplastic nodule 
(Fig. 2). A small HCC is defined as <2 cm. The differen-
tiation of a highly dysplastic nodule from a small HCC 
can be challenging, but the following criteria favor 
malignancy: 1) increased cellularity; 2) loss of normal 
reticulin structure; 3) plates three or more cells thick; 
and 4) invasion of stroma or surrounding portal tracts2 
(Fig. 3). 
Step-wise carcinogenesis of HCC in cirrhosis
Even though the gold standard for diagnosis of liver 
cirrhosis is histologic, the following MR imaging cri-
teria are routinely used for the assessment of either 
presence or absence of cirrhosis9, 10:  
1) undulating liver surface with nodularity;
2) changed segmental distribution, consisting of 
 hypertrophy of Couinaud’s segment 1 (caudate 
 lobe), atrophy of segment 4, enlargement of the 
 periportal spaces and expansion of the gallblad- 
 der fossa;  
3) secondary signs of portal hypertension, including 
 splenomegaly, collateral formation and/or ascites 
 (Fig. 4). 
In cirrhotic livers, HCC typically develops in a step-
wise fashion, as described by Sakamoto et al in 199111. 
According to their findings, the step-wise carcinogen-
esis of HCC is based on increasing cellularity, changing 
vascularity and increasing lesion size. The currently 
accepted nomenclature in step-wise carcinogenesis 
Figure 4: Histology proven 
cirrhosis in a patient with 
longstanding hepatitis-B related 
cirrhosis. (a) Coronal T2-weighted 
single-shot fast spin-echo (FSE), 
showing an undulating liver 
surface, and portal hypertension 
with splenomegaly and ascites. 
(b) Axial T2-weighted single-shot 
FSE, showing a macronodular 
cirrhotic liver with changed 
segmental distribution, with a 
hypertrophic segment 1 (caudate 
lobe) and an atrophic segment 4. 
Figure 5: Developing HCC in a patient with hepatitis-B related cirrhosis, in which in developing HCC is visible on arterial phase 3D 
fat-suppressed T1-weighted gradient-echo. Three months after the initial MRI, HCC with a nodule-within-nodule appearance is vis-
ible within a dysplastic nodule. Because patient refused to undergo treatment and regular follow-up, unfortunately, seven month after 
the second MRI, full-blown HCC had developed, with washout and tumor capsule enhancement in the delayed phase (not shown).
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as anabolic steroid use by body 
builders, pregnancy or hor-
mone production by a (gyne-
cological) neoplastic lesion26. 
Diagnosis of HCA is important, 
since HCA is associated with a 
risk of (potentially life-threaten-
ing) hemorrhage or rarely, ma-
lignant transformation26, 27. For 
differentiation with FNH, it is 
helpful to realize that HCA: has 
intratumoral fatty infiltration 
in up to >70%28; has homoge-
neous, less pronounced, arte-
rial enhancement compared to 
FNH; may occur with single or multiple lesions (some-
times with liver steatosis); and is associated with hem-
orrhage. HCA with malignant degeneration into HCC 
may show more heterogeneity, delayed phase wash-
out and capsule enhancement. Often, HCA occurs 
with multiple lesions, which is recognized as hepatic 
adenomatosis. However, it should be kept in mind 
that these two entities show identical characteristics 
on histopathology, therefore, presumably, both enti-
ties represent the same ongoing disease process29. 
At histology, HCA consists solely of hepatocytes which 
are organized in plates that are one or three cell lay-
ers thick. Typically, HCA lacks bile 
ductules, which facilitates the dis-
tinction from FNH29. Intratumoral 
fatty infiltration is present in >70%, 
and microscopic areas of previous 
hemorrhage are often detected 
(Fig. 9). 
On MR imaging, HCA typically does 
not differ much from the surround-
ing liver on in-phase T1-weighted 
GRE and T2-weighted sequences, 
confirming in fact its primary nature (Fig. 10). Since 
underlying liver abnormalities are frequent, with ste-
atosis in a majority of cases, most HCA become hyper-
intense to the surrounding liver on opposed-phase 
T1-weighted images30 (unpublished data). In case of 
intratumoral fatty infiltration, the opposed-phase 
T1-weighted GRE shows 
decreased signal intensity 
of the lesion compared to 
the signal intensity on the 
in-phase T1-weighted GRE 
(Fig. 11). On T2-weighted se-
quences, the signal intensity 
may vary from hyperinten-
sity to, rarely, hypointensity, 
related to the degree of fat-
ty infiltration either within 
the lesion and/or the sur-
rounding liver26. In the arterial phase after gadolinium, 
HCA typically enhances with a faint blush, typically 
less intense than FNH, with fading to isointensity in 
the delayed phase without washout or enhance-
ment of a fibrous tumor capsule (Fig. 10). HCA may 
be surrounded by a complete or partial pseudocap-
Figure 9: Macroscopic image of resected 
HCA, showing focal fatty infiltratin and 
small areas of hemorrhage within the lesion. 
Figure 10: HCA in young female 
patient. (a) In-phase T1-weighted 
gradient-echo (GRE), show-
ing isointensity of the HCA. (b) 
Fat-suppressed T2-weighted fast 
spin-echo, showing slight hyper-
intensity of the lesion. Note the 
hyperintensity of the surrounding 
pseudocapsule. (c) Arterial-phase 
2D T1-weighted GRE, showing a 
faint blush enhancement pattern. 
(d) Delayed-phase 2D T1-weighted 
GRE, showing persistent enhance-
ment with isointensity with the sur-
rounding liver. Note the persistent 
enhancement of the surrounding 
pseudocapsule (open arrow).  
related to often advanced HCC at presentation21. This 
makes early detection and characterization of HCC of 
paramount importance.
Classic MR imaging findings of HCC include a slightly 
hypointense signal on in-phase T1-weighted se-
quences; hyperintense signal intensity on T2-weight-
ed sequences; increased heterogeneous arterial en-
hancement; and washout with fibrous tumor capsule 
enhancement in the delayed phase12 (Fig. 6). However, 
since the introduction of current state-of-the-art MR 
imaging sequences, HCC can be detected when le-
sions are still small. According to a recent study, the 
imaging finding of HCC are related to the size of the 
tumor22 (unpublished data). In this study, it is shown 
that 1) smaller HCC have tendency for hypo- or isoin-
tensity on fat-suppressed T2-weighted sequences; 2) 
smaller HCC show more pronounced arterial enhance-
ment compared to larger HCC; and 3) smaller HCC 
show less pronounced washout in the delayed phase. 
Multinodularity or mosaic pattern within the lesion 
can be observed in especially larger HCC, including 
intratumoral fatty infiltration. At histology, HCC is of-
ten composed of multiple intratumoral nodules with 
different tissue characteristics (including fatty infiltra-
tion, accumulation of iron), surrounded by a fibrous 
tumor capsule (Fig. 7). 
HCC in non-cirrhotic liver 
HCC occurring in non-cirrhotic liver is typically very 
large (mean size 9 cm), and has a better prognosis 
compared to HCC occurring in cirrhosis23. Often, the 
lesion has striking heterogeneity, with extensive mul-
tinodularity within the lesion. A central scar may occur 
within the lesion, and a thick fibrous tumor capsule 
is virtually always present6. If the surrounding tumor 
capsule ruptures, satellite lesions may be observed 
in proximity to the main tumor. Tumor invasion may 
be observed in the adjacent venous vessels (most fre-
quently the portal vein) (Fig. 8). 
On MR imaging, typically, a hypointense signal in-
tensity is observed on T1-weighted sequences, and 
intratumoral fatty infiltration may be present (with 
decrease in signal intensity on the opposed-phase T1-
weighted images). On T2-weighted sequences, the 
lesions are typically hyper-
intense, with marked het-
erogeneity. In the arterial 
phase, the enhancement 
pattern is usually hyper-
vascular, with marked het-
erogeneity; whilst delayed 
phase imaging typically 
shows marked washout, 
heterogeneity and enhancement of a thick fibrous 
tumor capsule6 (Fig. 8). 
Hepatocellular adenoma
HCA occurs mainly in young women, and is strongly 
related to use of oral contraceptives (OC)24. In fact, 
the incidence of HCA strongly increased since the 
introduction of OC in the 1960s25. Non-OC-related 
causes of HCA include (glycogen) storage disease, 
and hormonal stimulation from other sources, such 
Figure 8: large HCC in a patient 
with a non-cirrhotic liver. (a) In-
phase T1-weighted gradient-echo 
(GRE), showing a heterogeneous, 
predominantly hypointense 
signal intensity of the HCC. (b) 
Fat-suppressed T2-weighted fast 
spin-echo, showing a heteroge-
neous hyperintense signal intensity 
of the HCC. Note a thin layer of 
ascites surrounding the liver. (c) 
Arterial phase 2D T1-weighted GRE, 
showing heterogeneous arterial 
enhancement of intratumoral 
vessels. (d) Delayed phase 3D 
fat-suppressed T1-weighted 
GRE, showing washout, marked 
heterogeneity and enhance-
ment of a fibrous tumor capsule. 
Note invasion of the tumor in 
the main portal vein (asterisk). 
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hypointense to the surrounding liver. In a recent 
study, intratumoral fatty infiltration within FNH was 
observed in approximately 6%, with decreased signal 
intensity on the opposed-phase T1-weighted GRE im-
ages33. On T2-weighted sequences, FNH is typically 
slightly hyperintense. In the arterial phase after ad-
ministration of gadolinium, FNH typically enhances 
strongly hypervascular, with persistent enhancement 
or fading to isointensity with the liver in the delayed 
phase (Fig. 9). The typical morphology of FNH is a 
lobulated lesion which consists of multiple nodules, 
with a central scar and radiating septa that surround 
these nodules. Typically, the central scar has low sig-
nal intensity on T1- and slightly higher signal on the 
T2-weighted sequences, with delayed enhancement 
after gadolinium (Fig. 9). In a recent study it was 
shown that additional administration of a liver-specif-
ic iron containing contrast agent (superparamagnetic 
iron-oxide particles, SPIO), facilitates the visualization 
of a central scar, since this area within the lesion does 
not contain any Kupffer cells33. Last, FNH is typically 
surrounded by a thin pseudocapsule, which consists 
of compressed surrounding hepatic stroma and com-
pressed surrounding blood vessels. This pseudocap-
sule is typically very thin, with low T1-signal, slightly 
higher T2-signal and may show persistent enhance-
ment in the delayed phase after gadolinium32 (Fig. 9). 
Differential diagnosis
For improved differential diagnosis of liver lesions, it 
is important to consider the appearance of the sur-
rounding liver parenchyma. Fibrosis or cirrhosis of 
the liver can be caused by a variety of exogeneous 
and endogeneous causes, including: toxic agents (in-
cluding aftatoxin), obesity, alcoholism, viral infections 
(hepatitis B and C being the most common infectious 
agents), and metabolic or genetic disorders, including 
hemochromatosis2. 
The International Working Party (1995) has advised 
not to diagnose HCA and FNH in the setting of cirrho-
sis5. Therefore, the differential diagnosis of a nodule 
or multiple nodules in case of a cirrhotic liver should 
always include regenerative nodule, dysplastic nod-
ule (low or high grade), or HCC. A hypervascular le-
sion within a cirrhotic liver will be likely a HCC or high 
grade dysplastic nodule unless proven otherwise.
Differential diagnoses in case of a non-cirrhotic liver 
Figure 13: Medium-sized hemangioma in the right liver lobe. (a) In-phase T1-weighted gradient-echo (GRE), showing hypointensity of the  
lesion. Note that the signal intensity is lower compared to primary liver lesions. (b) Single-shot T2-weighted fast spin-echo (TE 80msec), 
illustrating very high fluid-like signal intensity of the hemangioma. (c) Single-shot T2-weighted fast spin-echo (TE 120msec), showing  
persistent high signal of the hemangioma, whilst the liver (a solid organ) has dropped in signal intensity. (d) Arterial-phase 2D T1-weighted 
GRE, showing peripheral nodular enhancement in a discontinuous ring. (e) Portal-phase 2D T1-weighted GRE, showing progressive filling-in  
of contrast towards the center of the hemangioma over time l. (f) Delayed-phase fat-suppressed 3D T1-weighed GRE, showing  
persistent enhancement of the hemangioma. 
sule, which consists of compressed hepatic paren-
chyma and compressed vessels, which typically has 
high signal intensity on T2-weighted sequences and 
persistent delayed-phase enhancement (Fig. 10). A 
relatively thick capsule with low signal intensity on 
T2-weighted images and delayed enhancement may 
suggest malignant nature of the lesion.
Focal nodular hyperplasia
FNH is the second most common benign liver tumor 
after hemangioma, the incidence is 0.9%31. Underly-
ing vascular malformations have been suggested to 
explain the underlying pathogenesis, but this is not 
well understood7. FNH oc-
curs mainly in young wom-
en (man:women ratio 1:8), 
and there is no relation with 
oral contraception use31. In 
approximately 20%, mul-
tiple FNHs are found. The 
combination of multiple FNHs and hemangiomas is 
considered as multiple FNH syndrome32. Since FNH 
is usually observed in young to middle-aged women 
and is usually asymptomatic, the distinction between 
FNH and other hypervascular liver lesions such as 
HCA, HCC, and hypervas-
cular metastases is essential 
to ensure proper treatment. 
In patients with symptoms 
related to the lesion or in 
ambiguous cases, trans-
arterial embolization or 
surgical resection may be 
considered32. At histology, 
FNH is composed of multiple nodules surrounded by 
fibrous bands (Fig. 1), and typically, malformed vascu-
lar structures are found within the central scar.  
On MR imaging, typically, the signal intensity of FNH 
does not differ much from the surrounding liver on 
T1- and T2-weighted sequences before the admin-
istration of a gadolinium-chelate33. Therefore, on T1-
weighted sequences, the signal is often only slightly 
Figure 12: FNH in a young female 
patient. (a) Opposed-phase 
T1-weighted gradient-echo (GRE) 
shows only slight hypointensity 
compared to the surrounding 
liver. (b) Fat-suppressed T2-
weighted fast spin-echo (FSE) 
shows isointensity – to slight 
hyperintensity – of the FNH, with 
a slightly hyperintense central scar 
(open arrow). (c) Arterial-phase 
2D T1-weighted GRE shows very 
strong enhancement of the FNH. 
Note the lobulated contours, 
and less enhancement of the 
central scar. (d) Delayed-phase 3D 
fat-suppressed T1-weighted GRE 
shows persistent enhancement 
of the FNH, and enhancement 
of the central scar, radiating 
septa and pseudocapsule.
Figure 11: HCA in a female 
patient. (a) In-phase T1-weighted 
gradient-echo (GRE) shows 
isointensity of the HCA. (b) 
Opposed-phase T1-weighted 
GRE shows profound decrease 
in signal of the HCA, indicating 
intratumoral fatty infiltration. 
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should include the following entities:  1) FNH (no 
washout in the delayed phase, presence of a central 
scar); 2) HCA (no washout in the delayed phase, often 
intratumoral fatty infiltration present); 3) HCC (large 
single lesion, striking heterogeneity in especially 
larger lesions, washout in the delayed phase, delayed 
enhancement of a fibrous tumor capsule (note that 
intratumoral fatty infiltration or central scar may rarely 
be present)); 4) hypervascular metastasis (ring-like 
enhancement with target-like appearance); 5) intra-
hepatic cholangiocarcinoma; 6) vascular abnormali-
ties, such as arterio-portal or porto-venous shunts; 7) 
flash-filling hemangiomas. 
The MR imaging features of these lesions include the 
following: 
Hemangioma: typically shows very high T2-signal in-
tensity, indicating the non-solid nature. In addition, on 
T2-weighted single-shot FSE images with shorter and 
longer TE, the T2-signal shows only minimal signal 
decay indicating the high fluid-content of the lesion. 
In dynamic gadolinium-enhanced imaging, heman-
gioma shows a peripheral nodular enhancement in 
a discontinuous ring in the arterial phase, with fill-
ing-in towards the center of the lesion over time (Fig. 
13). Large hemangioma may contain a central fibrous 
scar12. Flash-filling hemangioma may show some 
atypical findings which include rapid (or flash-filling) 
enhancement, with or without perilesional enhance-
ment or shunting. The appearance in the delayed 
phase12 on the other hand, is the same as the classi-
cal hemangioma with persistent enhancement in the 
delayed phase. 
Colorectal metastasis: typically shows low signal in-
tensity on T1-weighted sequences, never with intra-
tumoral fatty infiltration. On T2-weighted sequences, 
the signal is slightly hyperintense compared to the sur-
rounding liver. After gadolinium, the colorectal metas-
tasis shows a progressive ringlike (onion-ringlike) en-
hancement towards the center of the lesion over time, 
with hypointense areas in the delayed phase (Fig. 14). 
Hypervascular metastases, including neuroendocrine 
tumors (or carcinoids) and islet cell tumors; typically 
show very high signal intensity on the T2-weighted 
sequences, which nearly equals the signal intensity 
of fluid. After gadolinium, the lesions show irregular 
ring-shaped or heterogeneous enhancement in the 
arterial phase, with delayed phase washout. 
Intrahepatic peripheral cholangiocarcinoma: on T1-
weighted sequences, the signal intensity usually is 
slightly lower, with heterogeneity. On T2-weighted 
sequences, signal intensity is heterogeneously hyper-
intense, and typically, dilated bile ducts may be ob-
served both within and in the periphery of the lesion. 
After gadolinium, the enhancement pattern is usually 
slow and progressive over time. Pooling of contrast 
may occur in the delayed phase as a large amount of 
fibrosis is usually present within the tumor34 (Fig. 15). 
Differential diagnosis with HCC may be challenging, 
but the most important features to consider are: 1) 
there is usually no liver cirrhosis (although this may 
rarely occur, such as in underlying primary sclerosing 
cholangitis); 2) the enhancement is very slow; and 3) 
there is no fibrous tumor capsule surrounding the le-
sion34.
CONCLUSION
Primary hepatocellular tumors are classified according 
to the nature of the lesion and the characteristics of 
the surrounding liver. Currently, no strict consensus 
for the optimal imaging work-up for evaluation of the 
liver exists, but MR imaging is often used as a prob-
lem-solving modality, and is valued for its potency 
for the evaluation of intrinsic tissue characteristics, 
and the possibility for multiphasic dynamic contrast-
enhanced imaging. The most important MR imaging 
sequences used for diagnostic imaging of the liver 
consist of T1-weighted sequences, T2-weighted se-
quences, and at least the arterial and venous phases 
of dynamic gadolinium-enhanced imaging. In this 
review article, the imaging findings of the most im-
portant primary liver lesions are discussed, including 
focal nodular hyperplasia, hepatocellular adenoma 
and hepatocellular carcinoma; with a variety of other 
lesions that must be considered in the differential di-
agnosis of these lesions. This article will enable the 
reader to understand the classification of primary 
hepatocellular lesions, to understand the step-wise 
carcinogenesis of hepatocellular carcinoma, and to 
evaluate the typical MR imaging findings of the most 
common lesions. 
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nodule; 3) prominent neovasculature as the initial sign 
of developing, fast growing HCC, confirmed at histol-
ogy after liver explantation. These findings provide in-
sight in various pathways of step-wise carcinogenesis 
of developing hepatocellular carcinoma in cirrhosis, 
which may facilitate early detection, improve patient 
outcome, provide better identification of patients for 
follow-up and further explain the genetic heteroge-
neity of hepatocellular carcinoma. In chapter 4.2, 
the relationship between the size of hepatocellular 
carcinoma and specific MR imaging findings is stud-
ied. Related to the improved MR imaging hardware, 
coils and software, accelerated imaging sequences 
have become available which allow detection and 
characterization of smaller (malignant) primary liver 
lesions. These developments have had their influence 
on the MR imaging findings, both because of differ-
ent magnetization properties of the tissues related to 
changed pulse techniques, but also because lesions 
are detected when they are still small. In this study it is 
shown that smaller HCCs often show lower signal on 
fat-suppressed T2-weighted sequences, more intense 
enhancement and less pronounced washout com-
pared to larger tumors (typically >2 cm). In chapter 
4.3, MR imaging findings are described in a young 
patient, who underwent Kasai portoenterostomy for 
biliary atresia as a neonate, and developed HCC as a 
rare complication. Kasai surgery has substantially in-
creased the survival rates of this young patient group 
since its introduction in 1959, and consequently post-
pones subsequential liver transplantation. However, 
almost all patients develop features of end-stage liver 
disease and biliary cirrhosis. Since they are at risk for 
development of HCC, repeated sequential MR imag-
ing exams of the native liver is necessary to monitor 
possible malignant transformation of liver nodules 
that may develop as a result of chronic cholestatic 
disease. Chapter 4.4 illustrates the MR imaging find-
ings of a large gallbladder tumor in a patient with no 
known liver disease and strongly elevated AFP. Given 
the combination of tumor morphology and location 
in the gallbladder, signal intensity, contrast enhance-
ment, high AFP and histology, hepatoid adenocarci-
noma (HAC) of the gallbladder was the most likely 
diagnosis. This is a rare form of adenocarcinoma with 
hepatoid differentiation of the tumor cells, which be-
haves and acts like HCC, but occurs in a multitude of 
organs outside the liver. Knowledge of these tumors 
is important, since HCC and HAC require a different 
therapeutic approach, especially in patients with non-
cirrhotic liver disease.
Chapter 5 presents two optimization studies which 
were performed to improve hepatobiliary imaging at 
higher magnetic field strength. The introduction of 
3.0T MRI systems has provided a number of poten-
tial advantages for abdominal MR imaging, related 
to doubled signal-to-noise ratio (SNR) which allows 
faster imaging and improved resolution. However, 
imaging at 3.0T posed some challenges as well, in-
cluding increased inhomogeneity of the magnetic 
field, changed magnetic tissue characteristics and 
increased specific absorption rate (SAR) levels, which 
potentially result in heating effects within the scanned 
subject. This is most pronounced for SAR-intensive se-
quences such as T2-weighted fast spin-echo imaging. 
Since this sequence is essential for detection of focal 
liver lesions, the following two studies were designed 
to relieve some of the limitations for imaging at 3.0T 
whilst making use of the advantages of imaging at 
higher magnetic field strength. 
In chapter 5.1, variable-rate-selective excitation 
(VERSE) radiofrequency (RF) pulses were assessed and 
compared to standard RF pulses, for fat-suppressed 
T2-weighted fast spin-echo (FSE) liver MR imaging 
at 3.0T. The results of this study indicate that the use 
of VERSE RF pulses provided significantly increased 
slice coverage with lower SAR. Compared to 1.5T, the 
increased SNR on 3.0T enabled thin-slice volumetric 
imaging of the liver within a single breath-hold, with 
multiplanar reformatting possibilities as post-pro-
cessing tool. In chapter 5.2, breath-hold diffusion-
weighted black-blood echo-planar-imaging (BBEPI) 
was evaluated as potential alternative for SAR-inten-
sive spin-echo sequences at 3.0T. The results of this 
study indicate that BBEPI can be used for ultrafast, low 
SAR, thin-slice morphologic imaging of the entire liver 
in a single breath-hold at 3.0T.  
Chapter 6 illustrates the current status of automat-
ed and color-coded post-processing techniques for 
analysis of dynamic multiphasic contrast-enhanced 
MR imaging of the liver. Post-processing of these im-
ages on dedicated workstations allows generation 
of time-intensity curves (TIC) as well as color-coded 
images, which provides useful information on (neo-) 
angiogenesis within a liver lesion, if necessary com-
bined with information on enhancement patterns of 
surrounding liver parenchyma. Analysis of these im-
ages provides an easy to interpret schematic presen-
tation of tumor behavior, providing additional charac-
teristics for adequate differential diagnosis. Inclusion 
of TIC and color-coded images as part of the routine 
abdominal MR imaging work-up protocol may help to 
further improve the specificity of MR imaging findings 
and may facilitate the diagnostic work-up of disease 
for detection, staging, and monitoring of anti-tumor 
therapy. 
 in chapter 7.1; and an overview article discussing the 
MR imaging findings of primary hepatocellular lesions 
in chapter 7.2.
Chapter 1 provides an overview of the anatomy of 
the liver and the fundamentals of MR imaging in chap-
ter 1.1.; and an outline of the study in chapter 1.2. 
Chapter 2 presents the results of a prospective study, 
which was designed to assess the MR imaging fea-
tures of focal nodular hyperplasia (FNH) before and 
after administration of two contrast agents, including 
gadolinium-chelate and superparamagnetic iron-ox-
ide particles (SPIO). This study indicates that the com-
bination of dynamic gadolinium-enhanced imaging 
with T1- and T2-weighted imaging after administra-
tion of SPIO facilitates detection and characterization 
of FNH in a large majority of patients. It is shown that 
signal intensity of FNH prior to contrast differs only 
slightly from the surrounding liver; accumulation of 
fat is present in a minority of FNH; dynamic enhance-
ment with a gadolinium-chelate is intense and ho-
mogeneous in the arterial phase with fading to near 
isointensity in the delayed phase; and uptake of SPIO 
in FNH is pronounced with improved conspicuity of 
central scar and septa. 
Chapter 3 addresses the imaging findings of hepa-
tocellular adenoma (HCA). In chapter 3.1, the most 
recent concepts on HCA are reviewed: the clinical 
presentation of HCA; the findings at pathology; recent 
literature on pathogenesis and transformation into 
HCC; and imaging findings at ultrasonography (US), 
computed tomography (CT), and MR imaging are dis-
cussed. The full spectrum of imaging findings using 
state-of-the-art MR imaging is shown, in comparison 
with US and CT. Chapter 3.2 presents the results of a 
retrospective study which was designed to assess the 
spectrum of MR imaging findings of both HCA and 
the surrounding liver. It is shown that HCA has intratu-
moral fat in >70%; hyperintense signal intensity on T2-
weighted fat-suppressed sequences and early arte-
rial enhancement. The surrounding liver parenchyma 
shows changed segmental distribution; steatosis and 
inhomogeneous patchy arterial enhancement. These 
results indicate that in patients with HCA, both lesions 
as well as surrounding liver parenchyma show similar 
soft tissue and vascular abnormalities.
Chapter 4 illustrates three studies addressing the MR 
imaging findings of hepatocellular carcinoma (HCC), 
and a report of a rare hepatoid adenocarcinoma of 
the gallbladder as a mimicker of HCC. In chapter 4.1, 
the detailed imaging findings of developing hepato-
cellular carcinoma in cirrhosis at sequential MR imag-
ing are described. In this study, state-of-the-art MR 
imaging displayed a spectrum of findings in the initial 
detection of developing HCC, including 1) localized 
fatty infiltration within a developing dysplastic nodule 
that gradually evolved into HCC in combination with a 
slowly increasing alpha-fetoprotein (AFP); 2) develop-
ment of a focus of pathology-proven HCC with high 
signal intensity at T2-weighted imaging in a dysplastic 
The purpose of this 
research project 
was 1) to improve 
insight in magnetic 
resonance (MR) 
imaging findings 
of primary hepa-
tocellular lesions; 
2) TO INCREASE 
AWARENESS IN 
SPECIFIC TUMOR 
FEATURES ON 
DIFFERENT MR 
IMAGING SEQUENCES  
INCLUDING CON-
TRAST-ENHANCED 
IMAGING;
 3) to improve non-invasive diagnosis for these lesions 
through increased diagnostic confidence by the read-
ing radiologist; 
and 4) to develop hepatobiliary imaging at high mag-
netic field strength. 
chapter8.2
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onderzochten, en een rapportage van het zeldzame 
hepatoid adenocarcinoom van de galblaas als imita-
tor van HCC. In hoofdstuk 4.1 worden gedetailleerd 
de kenmerken van HCC in ontwikkeling bij onderlig-
gende levercirrose beschreven, op opeenvolgende 
MRI onderzoeken. In dit onderzoek werd met behulp 
van MRI een spectrum van kenmerken van een zich 
ontwikkelend HCC gevisualiseerd: 1) focale vetinfiltra-
tie in een dysplastische nodule, die langzaam in een 
HCC ontwikkelde terwijl het alfa-foetoproteine (AFP) 
gehalte in het bloed langzaam steeg; 2) ontwikkeling 
van een focus van HCC in een dysplastische nodule, 
met een hoge signaal intensiteit op de T2-gewogen 
sequentie; en 3) prominente neovascularisatie als 
initieel teken van een zich ontwikkelend, zeer snel 
groeiend HCC (histologisch bevestigd na levertrans-
plantatie). Al deze bevindingen bieden verder inzicht 
in de verschillende reeksen van stapsgewijze ontwik-
keling van HCC in een cirrotische lever. Dit bevordert 
de vroege diagnostiek van deze tumoren, kan dien-
tengevolge de prognose voor de patiënt verbeteren 
en maakt het mogelijk om patiënten voor wie korte 
termijn follow-up noodzakelijk is, beter te herken-
nen. Verder wordt de genetische heterogeniteit die 
ten grondslag ligt aan de ontwikkeling van HCC door 
deze studie bevestigd. In hoofdstuk 4.2 wordt de re-
latie tussen de grootte van een HCC en specifieke MRI 
bevindingen bestudeerd. Door de verbeteringen in 
MRI hardware, coils en software zijn zeer snelle beeld-
vormende sequenties ontwikkeld die de detectie en 
karakterisatie van kleinere (maligne) primaire levertu-
moren duidelijk hebben verbeterd. Deze ontwikkelin-
gen hebben invloed gehad op de MRI kenmerken van 
deze tumoren, zowel doordat de magnetische karak-
teristieken van weefsels kunnen verschillen door het 
gebruik van andere puls sequentie technieken; maar 
ook omdat lesies worden ontdekt als ze nog klein zijn. 
In deze studie wordt aangetoond dat kleinere hepato-
cellulaire carcinomen (typisch kleiner dan 2 cm) in ver-
gelijking met grotere tumoren vaak een lagere signaal 
intensiteit hebben op vetonderdrukte T2-gewogen 
sequenties, een sterkere aankleuring in de arteriële 
fase, en een minder sterk verlies van contrast in de 
late fase. In hoofdstuk 4.3 worden de MRI bevindin-
gen beschreven van een patiënt die als zuigeling een 
Kasai portoenterostomie voor een aangeboren afslui-
ting van de galwegen onderging, en die later een HCC 
ontwikkelde als zeldzame complicatie. Kasai chirurgie 
heeft sinds de introductie van deze techniek in 1959 
de overleving van deze patiënten groep sterk verbe-
terd, mede doordat de noodzakelijke levertransplan-
tatie vaak lang kan worden uitgesteld. Echter, bijna 
alle patiënten ontwikkelen eindstadium leverfalen en 
biliaire cirrose, waarbij ze een verhoogd risico op de 
ontwikkeling van HCC hebben. Herhaalde MRI ver-
volg onderzoeken lijken geïndiceerd in deze patiën-
ten groep, om mogelijke kwaadaardige degeneratie 
binnen de nodules, die zich in de lever ontwikkelen als 
gevolg van de chronische galstuwing, zo vroeg mo-
gelijk op het spoor te komen. In hoofdstuk 4.4 wor-
den de MRI bevindingen van een grote galblaastumor 
bij een patiënt met een blanco voorgeschiedenis en 
een sterk verhoogd serum AFP gehalte beschreven. 
De diagnose hepatoid adenocarcinoom (HAC) van de 
galblaas was in deze patiënt de meest waarschijnlijke 
diagnose, gezien de combinatie van tumor morfo-
logie, lokalisatie, signaal intensiteit, aankleuring na 
contrast, AFP gehalte en histologische bevindingen. 
HAC is een zeldzaam adenocarcinoom met hepatoïde 
differentiatie van de tumor cellen, dat zich gedraagt 
als een HCC, maar kan voorkomen op meerdere plaat-
sen buiten de lever. Kennis van dergelijke tumoren is 
belangrijk, omdat HCC en HAC een verschillende the-
rapeutische benadering vereisen, vooral in patiënten 
die een niet-cirrotische lever hebben. 
Hoofdstuk 5 beschrijft twee optimalisatie studies die 
werden uitgevoerd met het doel de beeldvorming 
van de lever op hogere magnetische veldsterkte (3.0 
Tesla (3.0T)) te verbeteren. De introductie van 3.0T MRI 
systemen heeft een aantal voordelen voor MRI van 
het abdomen, welke zijn gerelateerd aan een verdub-
belde signaal-ruis verhouding (SNR). Deze hogere SNR 
maakt het mogelijk om in kortere tijd afbeeldingen 
te maken, met een hogere resolutie. Echter, beeld-
vorming op 3.0T bracht een aantal uitdagingen met 
zich mee, waaronder een verhoogde inhomogeniteit 
van het magnetisch veld, veranderde magnetische 
karakteristieken van de weefsels en toegenomen SAR 
(specific absorption rate levels), die mogelijk kunnen 
resulteren in gevaarlijke temperatuursstijging in weef-
sels. Het SAR effect is het meest uitgesproken voor T2-
gewogen FSE (fast spin-echo) sequenties, welke juist 
zeer belangrijk zijn voor detectie van focale leveraf-
wijkingen. Om dit probleem verder te bestuderen en 
oplossingen te genereren, werden de volgende twee 
studies verricht. In hoofdstuk 5.1 wordt de VERSE 
(variable-rate-selective excitation) radiofrequentie 
(RF) puls techniek geëvalueerd en vergeleken met 
standaard RF pulsen, en toegepast in vetonderdrukte 
T2-gewogen FSE voor afbeelding van de lever op 
3.0T. De resultaten van deze studie geven aan dat het 
gebruik van VERSE RF pulsen in een duidelijk verbe-
terd anatomisch bereik resulteert, en tegelijk in een 
een lager SAR gehalte. Ook maakte de verhoogde 
SNR op 3.0T het mogelijk om met gebruik van VERSE 
RF pulsen afbeeldingen van de lever te maken met 
zeer dunne coupes, die in verschillende richtingen 
konden worden gereconstrueerd. In hoofdstuk 5.2 
wordt een andere techniek geëvalueerd als potenti-
eel alternatief voor sequenties met hoog SAR gehalte, 
voor beeldvorming met een 3.0T magneet, name-
Hoofdstuk 1 behandelt de anatomie van de lever en 
basis principes van MRI in hoofdstuk 1.1, en geeft 
een overzicht van de verrichte studies in hoofdstuk 
1.2. 
Hoofdstuk 2 beschrijft de resultaten van een pros-
pectieve studie, waarbij het doel was de MRI kenmer-
ken van focale nodulaire hyperplasie (FNH) in beeld 
te brengen, voor en na toediening van twee verschil-
lende contrast middelen. In deze studie werd gebruik 
gemaakt van een gadolinium-verbinding en een ijzer-
houdend contrast middel (SPIO). De resultaten van dit 
onderzoek tonen dat de detectie en karakterisatie 
van FNH bevorderd wordt door een dynamisch MRI 
onderzoek met gadolinium te combineren met T1- 
en T2-gewogen sequenties na toediening van SPIO. 
Er wordt aangetoond dat FNH vóór contrast toedie-
ning nauwelijks te onderscheiden is van de rest van 
de lever; dat vetstapeling in FNH slechts in een klein 
percentage van de lesies aanwezig is; dat de aankleu-
ring na gadolinium toediening in de arteriële fase in-
tens en homogeen is; en dat er een sterke opname 
van SPIO contrast in FNH is, waarbij het karakteristieke 
centrale bindweefselschot en de verschillende bind-
weefselsepta duidelijker in beeld komen. 
Hoofdstuk 3 beschrijft de karakteristieken van le-
vercel adenomen (hepatocellular adenoma, HCA) bij 
beeldvorming. In hoofdstuk 3.1 wordt een overzicht 
gegeven van de huidige denkbeelden wat betreft de 
histologische kenmerken van HCA, de onderliggende 
pathogenese en maligne degeneratie van HCA in he-
patocellulair carcinoom (HCC); en het volledige spec-
trum van radiologische bevindingen van HCA op basis 
van de huidige literatuur, inclusief echografie, compu-
ter tomografie (CT) en MRI. Hoofdstuk 3.2 beschrijft 
de resultaten van een retrospectieve studie die werd 
opgezet om de kenmerken op MRI van zowel HCA 
als de omgevende lever te bestuderen. Hierin wordt 
aangetoond dat  vetstapeling aanwezig is in meer 
dan 70% van de HCA lesies; dat de signaal intensiteit 
van HCA op vetonderdrukte T2-gewogen sequenties 
hoog is; en de aankleuring in de arteriële fase vroeg 
is. Het omgevende leverparenchym vertoont vaak 
vetstapeling, een inhomogene vlekkige aankleuring 
in de arteriële fase, en een veranderde morfologie 
van de verschillende segmenten. Deze bevindingen 
tonen aan dat in patiënten met HCA zowel de lesies 
als de omgevende lever gelijksoortige veranderingen 
vertonen. 
Hoofdstuk 4 beschrijft drie studies die de MRI ka-
rakteristieken van hepatocellulair carcinoom (HCC) 
Het doel van het 
in dit proefschrift 
beschreven 
onderzoek was om: 
1) het inzicht in het 
aspect van primai-
re levertumoren 
bij beeldvorming 
met magnetische 
kernspinresonan-
tie (magnetic 
resonance imaging, 
MRI) te verdiepen;
 2) DE SPECIFIEKE 
MORFOLOGISCHE 
KENMERKEN VAN 
DEZE LESIES OP MRI 
TE VERDUIDELIJKEN;
3) de non-invasieve diagnostiek van primaire lever-
tumoren met MRI verder te verbeteren door het ver-
trouwen in de diagnostische waarde van MRI te ver-
groten; 
en 4) beeldvorming van de lever op hogere magneti-
sche veldsterkte verder te ontwikkelen. 
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lijk de breath-hold diffusion-weighted black-blood 
echo-planar-imaging (BBEPI). De resultaten van dit 
onderzoek geven aan dat BBEPI gebruikt kan worden 
voor het maken van ultrasnelle afbeeldingen van de 
gehele lever in een enkele adempauze, waarbij zeer 
dunne coupes vervaardigd kunnen worden en de SAR 
laag blijft. 
Hoofdstuk 6 illustreert de huidige stand van zaken 
omtrent de geautomatiseerde en kleur-gecodeerde 
post-processing technieken voor analyse van dyna-
mische multifasische contrast-versterkte MRI van de 
lever. Post-processing van deze MRI beelden maakt 
het mogelijk om zogenaamde “time-intensity curves” 
(TIC) en kleur-gecodeerde afbeeldingen te vervaardi-
gen op speciale werkstations. Dergelijke afbeeldingen 
verschaffen aanvullend inzicht in het aankleuringspa-
troon van een leverlesie, alsmede informatie over het 
aankleuringspatroon van de omgevende lever. Op 
deze wijze kunnen makkelijk te interpreteren, sche-
matische representaties worden gegeven van het 
tumor gedrag, hetgeen verder kan bijdragen aan de 
differentiële diagnostiek. De routine toepassing van 
deze post-processing technieken in MRI protocollen 
kan de MRI diagnostiek van focale leverafwijkingen 
verbeteren, en de werkwijze omtrent lesie-detectie, 
tumor stagering en therapie-monitoring vergemak-
kelijken.
 
In hoofdstuk 7.1; en een overzichtsartikel over de 
MRI kenmerken van primaire hepatocellulaire tumo-
ren in hoofdstuk 7.2.
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Prof.dr. J.N.M. IJzermans; beste Jan, als chirurg en voorzit-
ter van de Lever Tumor Werkgroep ben je van grote impor-
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Drs. R.S. Dwarkasing; beste Roy, ik 
ontmoette je als ouderejaars assistent 
in opleiding, en had toen al de bewon-
dering voor je die ik nu nog steeds heb. 
De precisie en toegewijdheid waarmee 
je je aan studies van diverse aard wijdt 
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en dat maakt je tot een ra-
dioloog van bijzonder ni-
veau. Dank voor alles wat 
ik van je heb geleerd in de 
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spreking voorbereidden, 
dank voor je vertrouwen 
en dank voor je deelname 
aan enkele van onze stu-
dies. Ik wens je heel veel succes 
toe met de afronding van je ei-
gen promotie; 
De leden van de Lever Tu-
mor Werkgroep, voor de 
steun en prettige samen-
werking in de afgelopen 
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Mijn paranimfen Marion en Meike, 
voor het naast mij staan tijdens de 
verdediging van dit proefschrift 
en voor de vele uren die wij 
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onschatbare waarde geweest 
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Mijn vader Antonie, mijn moeder Merel, 
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Jouw liefde voor de wetenschap en 
drang naar verbetering van de pa-
tiëntenzorg heeft velen weten te 
inspireren! Zonder jouw 
bezielende begeleiding 
was dit proefschrift niet 
in deze vorm tot stand 
gekomen. Dank voor 
de vele uren brainstor-
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het altijd beschikbaar 
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mijn promotor, een man met vele 
hoeden op. Dank u voor al uw 
tijd, alles wat ik van u heb mo-
gen leren, en dank u voor de im-
mer openstaande deur en dat ik u 
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het bedenken van oplossingen voor afbeeldend 
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Dr. R.A. de Man; beste Rob, jouw immers 
vriendelijke en bescheiden opstelling heeft 
al velen voor mij geinspireerd. Dank voor 
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